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sexuality, in sickness and in health
It is nowadays increasingly recognized that sexual health is important to overall health 
and well-being (1). For both men and women, satisfaction with the sexual life is strongly 
associated with quality of life in many aspects. It is associated with a positive outlook on 
life in general, family life, financial wellbeing and better physical health. Furthermore, it is 
a very important factor for a loving relationship (1;2).
But, as with all good things in life, it can also be harmed. The other, dark side of sexuality 
is that it can lead people (mostly men) to commit sexual offences such as rape, child 
pornography and incest. In contrast to the positive effects a healthy sexual life can have 
for peoples’ mental and physical health, sexual abuse highly impacts victim’s mental and 
physical condition, often affecting them for the rest of their lives (3;4). It is commonly 
known that sexual abuse, especially childhood sexual abuse, often results in sexual 
dysfunction in later life too (5).
Women have been documented to experience sexual abuse more frequently than men (6) 
and subsequently experience lower levels of sexual interest and frequent anorgasmia, 
especially after abuse that involved penetration and force or recurrent sexual victimization (7). 
Sexual abuse in men is recently more reported, especially since this topic got a lot of 
attention due to the reports concerning abuse in the Roman-Catholic church. However, 
due to the negative feelings associated with being overpowered by a woman or the fear of 
being labeled homosexual when the abuse is perpetrated by a male, sexual abuse remains 
underreported in men. Associated sexual difficulties in men that experienced sexual 
abuse are erectile dysfunction (ED, also known as impotence), premature ejaculation and 
low sexual desire (8).
Sexual dysfunctions in itself have been shown to negatively impact quality of life, 
psychological well-being and marital/partnership satisfaction (9;10).
Life time prevalence of adult sexual abuse, in the broadest sense of the term, in modern 
western societies is estimated up to 10% for males and up to 25% for females (11-13). 
According to the British national survey of sexual attitudes and lifestyle among individuals 
in a sexual relationship for the past year, 18% of men and 17% of women reported that 
their partner had sexual difficulties. Of men and women in the oldest age group (65-74 
years), 43% of women and 31% of men reported sexual dysfunction in the past year (14). 
But, in spite of these high prevalence rates, we know from the literature that sexual abuse 
and sexual dysfunction are frequently underdiagnosed, and untreated (15-18). Multiple 
factors are accountable for the fact that these subjects are not routinely discussed 
in clinical practice. On the one hand, patients seldom dare to initiate discussion about 
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sexual abuse or ‘even’ sexual dysfunction spontaneously in clinical settings (14;19). On 
the other hand, physicians may feel several barriers raising either of these subjects. Due 
to the fact that physicians still seem to trust in the concept that disease has something 
to do with survival and self-preservation and that sexuality comes in the second instance, 
when the disease problem is resolved. However, both dimensions go together as integral 
parts of patients’ lives. In a patient-centered approach the global dimension of health and 
sexuality both have to be taken into account (20).
sexual health in disease
Improvements in medical care have allowed individuals with chronic disease to survive 
and live longer. This greater life expectancy with disease has led healthcare providers to 
change their focus from ‘survival’ to improving ‘quality of life’.
Sexuality is a phenomenon in which biological and psychological factors interact; therefore, 
both physical condition and psychological well-being are cornerstones of sexual health.
Figure 1 presents a basic conceptual framework about the association of chronic disease 
and sexuality.
As shown in Figure 1, physical condition and psychological functioning are interrelated. 
For example, the prevalence of pain in patients with a depressive disorder and, vice versa, 
the prevalence of depression in patients with pain are much higher compared to the 
prevalence’s of patients without a depression and without pain respectively (21).
As well, the relationship with a sexual partner should be taken into account because this 
relationship plays an important role in adaptation to the disease state, thereby impacting 
psychological well-being and sexuality. 
Furthermore, to control the symptoms of the disease or to prevent further progress, 
patients should comply with the prescribed treatment regimen. Noncompliance to 
(drug) treatment is nonetheless a well-known problem in medical practice, which often 
contributes to the burden of disease. 
As shown in Figure 1, compliance may be affected by changes in the physical condition. 
On the one hand, the conviction of the patient that a condition is ‘asymptomatic’ may 
lead to non-compliance with therapy, whereas insight about the necessity of treatment 
or the feeling of control may promote compliance (22). On the other hand, experience 
of medication induced adverse effects (such as sexual dysfunction) often leads to non-
compliance with therapy (21;23).
At last, disease activity may have a direct or indirect influence on sexual functioning. Apart 
from this, short term and long term complications may affect sexuality independent from 
the primary disease activity.
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This framework displayed in Figure 1 is applicable in both physical and mental disease and 
provides insight into the process by which disease-related psychological and relational 
factors impact sexual functioning and well-being of patients, necessary to place this thesis 
in the right context.
this thesis
In this thesis two seemingly different subjects will be discussed, however, both can 
be placed in the categories quality of life, quality of care, sexual health and patient 
centeredness. In part I, care for sexual dysfunction in cardiovascular disease is evaluated 
and in part II, care for sexual abuse in the gastroenterology practice is assessed. Both parts 
can be read separately and are not interrelated. But as mentioned before, both comprise 
clinical problems that are commonly seen and both are written with the same goals in 
mind: improvements for quality of life and quality of care. 
figure 1. A conceptual framework about the impact of disease on sexual functioning and sexual well-being
Source: Verschuren, J.E.A. et al. Journal of Sex Research, 47:2-3,153-170
General Introduction 11
1
sexual health in cardiovascular disease
The age-adjusted mortality rates of cardiovascular disease (CVD) in Western Europe lay 
between 170 and 240 per 100.000 (24).  Men and women in countries with higher 
development status (measured in terms of gross domestic product per capita) experience 
CVD events at an older age and die much later than in less developed countries. For 
example, in Australia, France, and Sweden, the median age at death from ischemic 
heart disease averages 85 years in women and 77 years in men. Men in these countries 
experience an acute myocardial infarction (MI) more than a decade before their median 
age at death (25).
CVD causes mass disability: within the coming decades the disability-adjusted life years 
(DALYs) estimate is expected to rise from a loss of 85 million DALYs in 1990 to a loss of 
~150 million DALYs globally in 2020, thereby remaining the leading somatic cause of loss 
of productivity (26). 
A less obvious problem which often comes hand in hand with CVD is sexual dysfunction. 
Sexual dysfunctions are very prevalent among both men (prevalence 50-75%) and women 
(prevalence 43-87%) with CVD compared to those without CVD (27-29). Reasons for 
this association include the vascular causes, the use of antihypertensive agents and the 
psychological problems such as depression, anxiety for cardiac events and changes in the 
relationship due to the disease (30).
Especially erectile dysfunction (ED), defined as the persistent inability to achieve and 
maintain an erection to permit satisfactory sexual intercourse, is commonly associated 
with cardiovascular disease, with prevalence rates ranging between 47 and 75% in studies 
(31-33). Due to the prolonged life expectancy of patients with CVD and the aging of the 
population, the projected prevalence of ED for the year 2025 is expected to rise to 322 
million men worldwide (34).
ED and CVD share the same risk factors such as age, dyslipidemia, hypertension, 
diabetes, smoking etc. Endothelial dysfunction is believed to be the pathophysiologic 
link. Frequently, the clinical consequences of ED frequently manifest 2-3 years before the 
consequences of coronary atherosclerosis. The last years mounting research has been 
investigating this link and ED was shown to be an independent marker of increased CVD 
risk (32;35-37), commonly preceding clinical coronary artery disease (38), and peripheral 
arterial disease and stroke (39). 
The artery-size hypothesis (40) is the proposed mechanism explaining why patients 
frequently report ED before coronary artery disease is detected. The lumen of the penile 
arteries (1–2 mm) is considerably smaller than that of the coronary (3–4 mm), carotid 
(5–7 mm), and femoral (6–8 mm) arteries, endothelial dysfunction or plaque burden that 
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significantly impairs circulation in the penile arteries may be associated with sub clinical 
plaque disease of the larger vessels. Thus, atherosclerosis sufficient to trigger ED may not 
be sufficient yet to cause ischaemic symptoms in other vascular beds (see Table 1). 
A very important finding, which may be extrapolated to female sexual dysfunction 
such as vaginal dryness and dyspareunia as well (41). However, research in this context 
has focused predominantly on ED and has almost completely neglected female sexual 
dysfunction (FSD) and other male sexual dysfunctions. In fact, the patients’ side of the 
story did not receive much attention at all. For patients the fact that ED may predict 
cardiovascular disease is obviously not the only relevant aspect of it. Obviously, the ED in 
itself is important for most patients as well. This side of care for patients with CVD remains 
understudied and FSD in CVD from the female patients’ point of view has virtually not 
been highlighted at all. 
Still, both care for ED, FSD, other sexual difficulties, such as counseling about safely 
restarting sexual activity after a cardiac event, and counseling about adverse effects of 
antihypertensive agents are all very important issues to address in the cardiac clinic. 
figure 2. The ‘artery size’ hypothesis
Source: Vlachopoulos C et al. Eur Heart J 2013;34:2034-2046
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Sexual abuse and gastrointestinal disease 
Many studies have documented that striking numbers of patients presenting with 
functional gastrointestinal complaints have endured sexual abuse. In 1990, Drossman et 
al. found that 38.5% of patients who presented to a university-based gastroenterology 
practice reported a history of sexual abuse (13). Only 17% of patients with an SA history 
had previously informed their physicians about the abuse, and almost one third had never 
discussed it with anyone. Patients that reported a history of SA were more likely to report 
chronic pelvic pain (odds ratio, 4.0) and multiple other somatic symptoms (odds ratio, 
7.1). Furthermore, they had more lifetime surgeries (odds ratio, 2.8) compared to patients 
who did not report SA (42). The high prevalence of sexual abuse in patients with irritable 
bowel syndrome (IBS) and other gastrointestinal symptoms (GI) was shown repeatedly (43-
50). Significantly higher levels of sexual abuse have been reported in patients with pelvic 
floor disorders (51-53). Patients with chronic pelvic pain were found to have experienced 
significantly higher levels of sexual abuse; this was often accompanied by significant levels 
of psychiatric dysfunction (46;54). Furthermore, it has clearly been shown that sexual 
abuse is a common concomitant of functional gastrointestinal disorders. 
The exact relationship between functional gastrointestinal disorders and a positive abuse 
history remains to be defined completely; however, several studies have found evidence 
of physiologic disturbance outside the gastrointestinal tract. For example, in women with 
chronic pelvic pain, chronic dysfunction of the hypothalamic-pituitary-adrenal axis, a 
positive abuse history, and a diagnosis of posttraumatic stress disorder was correlated 
(55;56). Severity of abuse has been correlated positively with deteriorating health status, 
as measured by significantly more days in bed, greater pain severity, and psychological 
problems as well as poorer functioning in activities of daily life (48). 
Research comparing the brains of abused children and control subjects, showed that 
abuse seems to induce a cascade of molecular and neurobiological effects that alter 
the development of specific areas in the brain. These areas include the limbic system, 
left hemisphere, corpus callosum and cerebellar vermis. The limbic system is the brain’s 
emotional processing center and includes the amygdala and hippocampus. MRI scans also 
revealed an association between early maltreatment and the reduction in the size of the 
adult left hippocampus or amygdala (57).
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In Figure 3, a bio psychological model was laid out to conceptualize the pathogenesis 
and clinical expression of (functional) gastrointestinal symptoms. This model proposes 
that early-life factors (e.g. genetic factors, GI infection and family environment) may 
be factors associated with susceptibility towards functional gastrointestinal symptoms. 
Abuse history has an amplifying effect on the experience and clinical expression of these 
symptoms, which may be associated with greater ‘body awareness’ due to earlier trauma. 
Psychosocial factors as noted may further amplify the symptom experience and clinical 
state, leading to adverse health outcomes, including increased physician visits, referral to 
gastroenterologists, specialized centers and, when severe, disability (58).
figure 3. Conceptual relationship of abuse history and other psychosocial co-morbidities on 
gastrointestinal symptoms and adverse health outcomes
CNS= central nervous system, ENS= enteric nervous system; MD= medical doctor
Adapted from Drossman D, Am J Gastroenterol. 2011 Jan; 106(1): 14-25 in combination with Tanaka 
Y, J Neurogastroenterol Motil. 2011 Apr; 17(2): 131-139.
General Introduction 15
1
Sexual abuse is of course a highly sensitive topic and therefore patients may find it 
difficult to start talking about it. Thus, the importance of taking an abuse history cannot 
be overstated for patients presenting with chronic gastrointestinal or any other chronic 
unexplained medical complaint. To aid general practitioners and gastroenterologists in 
inquiring about sexual abuse, reviews of the literature and guidelines how to approach this 
topic have been published (4;59;60) as well as an instrument to measure abuse severity 
(49). However, these recommendations have never been tested in normal outpatient 
settings. Until now, we are even unaware whether attention is paid to SA in the day to day 
gastroenterology practice. But without attention for sexual abuse, no one will ever put the 
knowledge about its impact for patients with gastrointestinal symptoms or the valuable 
recommendations from the literature actually into practice.
Outline of the thesis
The aim of this thesis was to evaluate to what extend cardiologists and gastroenterologists 
succeed in the provision of patient-centered healthcare with regard to sexual health.
To be more specific: this investigation was aimed to identify the lacunas in the cardiology 
practice regarding attention and care for sexual health and in the gastroenterology 
practice regarding attention and care for victims of sexual abuse. In order to obtain the 
required information to meet these aims, the problem was approached from two sides: 
the specialists’ point of view and the patients’ point of view.
In part I, the cardiologist and the cardiac patient are evaluated regarding the omissions in 
care for sexual health in cardiology.
In part II, the gastroenterologist and the colonoscopy patient are surveyed regarding the 
omissions in care for sexual abuse victims in gastrointestinal disease. 
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DISCuSSING SExuAl 





Sexuality is one of the core dimensions of the human experience and an important 
determinant of well-being [1]. With the current high life expectancy in the Western world, 
people have higher expectations of being able to achieve and sustain satisfying sexual 
relationships into older age [2]. Next to the urologist and the gynecologist, of all medical 
specialists especially the cardiologist will be confronted with sexual problems in their patient 
population. There is a large body of evidence supporting the concept that, of the physical 
causes, erectile dysfunction (ED) is predominantly a vascular disease, with the same risk 
factors as coronary artery disease (CAD). Consequently, men with ED have a higher incidence 
of CAD and peripheral vascular disease than is present in the general population, and men 
with CAD have a similarly increased incidence of ED (50-75%) [3]. In women, the processes 
of vascular endothelial dysfunction may lead to impairment of the genital blood flow which 
is essential for appropriate female sexual function, especially sexual arousal [4]. In a survey 
among 2,763 postmenopausal women with Coronary Heart disease (CHD), 65% of the 39% 
sexual active women complained of at least one sexual problem (5). Furthermore, in heart 
failure patients, between 47% and 73% reported a marked loss in sexual interest and 48% to 
76% a marked decrease in frequency of sexual activity caused by their illness [5;6].
Sexual problems in patients with heart disease and their partners may as well arise from the 
fear of a cardiovascular event or sudden death during sexual activity[7] and due to loss of 
self-esteem, anxiety and depression, commonly seen after cardiac events [8].  Furthermore, 
cardiovascular drugs such as digoxin, diuretics, and β-blockers may negatively affect sexual 
function [9]. It must not be understated that sexual dysfunction is an important cause of 
relationships problems, effecting partners’ sexual life as well [10].   
Open and frank discussion about sexuality between physicians and patients is fundamental 
for addressing treatable causes of sexual dysfunction [11]. Sexual advice is an essential part 
of cardiac rehabilitation since sex is a normal part of life’s activities. Already thirty years ago 
Jackson postulated: “It should now be routine policy to advise the patient and spouse on 
sexual activity, whether they be post infarction or regularly attending with angina pectoris. 
The vast majority of patients with ischaemic heart disease can enjoy normal sexual relations 
without risk” [12]. Current guidelines state that cardiologists need to raise the subject pro-
actively, pointing out that it is a problem within the vascular arena [13]. Yet, still little is 
known about the attitude of cardiologists towards the discussion of sexual function with 
patients. This knowledge is crucial to optimise strategies to increase sexual health and 
well-being in cardiac patients. Therefore, we performed a study to evaluate cardiologists’ 
attitudes and practice patterns with regard to their inquiry about sexual function in men 
and women of all ages in day-to-day practice.




A national cross-sectional questionnaire survey on cardiologists set in the Netherlands.
Participants
The sampling frame was all active Dutch cardiologists and residents in cardiology (1,054) 
who were members of the Netherlands Society of Cardiology in the autumn of 2011. 
Because some addresses were out of date, a total of 980 questionnaires were sent to their 
work addresses. 
survey and Procedure
The questionnaire was designed by the authors, based on a concise review of the 
literature in the area. A pilot study was performed at the Cardiology department of the 
Leiden University Medical Center; 40 anonymous pilot questionnaires were distributed 
and 23 were completed and returned (response rate 57.5%). The questionnaire was 
adjusted according to the comments of these cardiologists and residents. A copy of the 
questionnaire can be viewed in the appendix. 
The questionnaire comprised 31 questions focusing on:
1. Level of knowledge and awareness of sexual problems in cardiac patients
2. Current practice in addressing sexual problems in patients
3. Presumed responsibility for sexual healthcare
4. Perceived barriers to address sexual issues. Twenty barriers were listed and 
cardiologists were asked to rate their agreement with each barrier.
The questionnaire was accompanied by a letter explaining the objectives of the study. 
A free post return envelope was added, as well as an opt-out possibility. Cardiologists 
who were not interested in participation could answer the first question of the survey 
regarding the reason(s) not to participate and return the questionnaire empty. Reminder 
letters were sent to non-responders 2, 5 and 7 month after the initial mailing.
data analysis
Quantitative data were analyzed by SPSS release 18 (SPSS Inc., Chicago, IL, USA). 
The internal consistency of the questionnaire was measured using Cronbach’s coefficient 
α. Means of numerical demographic values and the answers to the questions were 
analyzed with frequencies. Bivariate associations between demographic information 
and the categorical data were calculated using the Pearson chi-square procedure; for 
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ordinal variables Armitages’ trend test was used. Associations between numerical data 
and demographics of the respondents were analyzed with the independent sample t 
tests. Two-sided p values < 0.05 were considered statistically significant. Some questions 




Total scores for items regarding cardiologists knowledge about sexual matters 
demonstrated high internal consistency (Cronbach’s α= 0.84). Cronbach’s alpha for the 
subscales regarding counseling about sexual activity ranged from 0.64 to 0.81. 
The Likert scale measuring cardiologists’ frequency of asking about sexual health (item 6) 
had an alpha of 0.5 when compared to item 8 (estimated percentage of discussing sexual 
health), this is due to the different scales used; ordinal scales cannot be compared to 
continues scales. The internal consistency between the items concerning cardiologists’ 
barriers for asking about sexual health were acceptable to good (Cronbach’s α ranging 
from 0.68 to 0.75).  
demographics
Of the 980 eligible participants, 528 surveys were returned, yielding an unweighted 
response rate of 53.9%. Seven participants were eliminated because they were not 
participating in a clinical setting or because they were physician assistants. A total 
of 98 questionnaires were eliminated because they were empty and 16 because they 
were incomplete (>10% missing data). The reasons mentioned for the inability to fill 
in the questionnaire (n=114) were: not interested (n=4), no time (n=2), or not enough 
experience in the field (n=2). Others indicated they were only working with specific 
patient groups such as children or pregnant women and therefore were not able to fill in 
the questionnaire (n=5), some respondents gave no reason (n=101). In total 78.4% of the 
returned surveys were analyzed (n=414). Mean age of the respondents was 45.5 years old 
(SD 9.6) and 75.8% was male. Of these respondents 80.9% were cardiologists and 19.1% 
were residents. The female respondents were significantly younger then male respondents 
[mean 42.31 (SD 8.37) resp. mean 46.56 (SD 9.75); p<0.001], consequently significantly 
more female respondents were residents (p<0.001). Demographic characteristics of non-
respondents were not available for analysis due to the anonymous design of the survey. 
The personal and practice characteristics of respondents are summarized in Table 1.
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Asking about sexuality and responsibility
To the question: “how often do you discuss sexual health with your patients?” 2.9% of 
the cardiologists answered ‘never’, 29.6% said ‘rarely’, 48.7% said ‘sometimes’, 16.9% 
said ‘regularly’ and 2.0% said ‘often’. Cardiologists inquired significantly more often about 
sexuality than residents (linear-by linear association, p<0.001). No significant differences 
were seen between male and female physicians. To the question ‘In how many patients 
do you think sexual life changes due to their cardiac condition?’ the mean estimated 
percentage of the respondents was 32.2% (SD 19.7). In an estimated 10.8% (SD 13.0) 
of the patients sexuality was discussed in the past year. An estimated 2.2% (SD 4.2) was 
referred to another healthcare professional for treatment of sexual problems (Figure 1). 
According to 38.5% of the respondents, cardiologists do have the responsibility to discuss 
sexual matters with their patients; 20% did not know who is responsible. In contrast, 41.5% 
stated that the care for patients’ sexual quality of life is somebody else’s responsibility: 
almost seventy percent (69.4%) of the respondents answered that the general practitioner 
table 1. Respondent characteristics (n=414)
Age, years n(%)
≤ 45 208 (50.2)
> 45 206 (49.8)
sexa
Male 314 (76.0)
Female, 99  (24.0)
functiona
Cardiologist 335 (80.9)
Resident 79  (19.1)
Type of clinic/practice
Tertiary referral center (or university hospital) 90 (21.8)
District general teaching hospital 174 (42.2)
District general hospital 148 (35.9)
Time of practice in cardiology
0-11 month 18 (4.3)
1-2 years 30 (7.2)
3-5 years 80 (19.3)
6-10 years 106 (25.6)
11-15 years 49 (11.8)
15 years or more 131 (31.6)
a n differs because the questions were not answered consistently, some were skipped or forgotten.
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is responsible for this part of patient care and 51.6% stated that the patient must initiate 
conversation about it (multiple answers were possible). Furthermore, 16.9% pointed to the 
psychologist, 9.3% to the rehabilitation doctor, 8% to the nurse and 5.8% to the social 
worker. 
Knowledge
When it comes to knowledge, 27.5% of the respondents thought they have ‘not much’ of 
the knowledge necessary to discuss sexual function with patients, 2% stated to have no 
knowledge about this at all. The majority of the cardiologists (65.1%) stated to have ‘some’ 
and 5.4% to have ‘a lot’ of the necessary knowledge to discuss sexual problems with their 
patients. Experienced doctors were significantly more confident about their knowledge 
on sexual function (linear-by-linear association, p=0.015). Twenty-eight percent of the 
respondents stated that a lack of knowledge is a reason not to inquire about sexual 
problems and 35.2% stated that a lack of training is one of the reasons they do not ask 
(Table 3). Almost 27% (~26.6%) of the respondents did not know if there was a specialist 
in their own medical center where they could refer patients with sexual dysfunction to.
To the question: “Do you need training to increase your knowledge, so you will be able 
to discuss sexual matters with your patients?” 41.9% of the respondents answered 
affirmative. Sixty-three percent indicated that it would be helpful to have a directory of the 
healthcare professionals where they can refer patients with sexual problems to. Regarding 
the need for training, no significant difference between male and female physicians or 
between cardiologists and residents was observed. However, the more experienced the 
cardiologist was the less he/she stated the need for training or for a referral directory 














































figure 1. Frequency of discussing sexual health versus years in practice as cardiologist
Discussing sexual function in the cardiology practice 31
2
Counseling and informing
Half of the responding cardiologists stated to counsel their patients regularly about the 
sexual side effects of cardiac medication. Fifteen percent stated to inquire about sexual 
problems when a patient recently started with cardiac medication; in 74.4% when a 
patient recently started with a β-blocker. On the contrary, only 19.5% of the respondents 
inquired regularly or often about the use of PDE5 inhibitors. More than two third of the 
respondents seldom (49.4%) or never (20.1%) advised patients about when to resume 
sexual activity after myocardial infarction or heart failure. In patients between the age of 
20 and 35 year and in patient older than 76 year, cardiologists asked about sexual function 
less often than in patients between the age of 36 and 75 year. Cardiologists informed 
about sexuality significantly more often in case of male patients than in female patients 
(p=0.0001). For more data about sexual counseling, see Table 2. 
table 2. Counseling and informing of patients about sexuality, n(%)
how often do you counsel patients 
after MI or with heart failure 
about
Never seldom regularly often
na 
(total)
When to resume sexual activity 82 (20.1) 201 (49.4) 95 (23.3) 29 (7.1) 407
Warning signals to report during 
sexual activity
80 (20.0) 175  (43.6) 90 (22.4) 56 (14) 401
Effects of cardiac medication on 
sexual function
15 (3.7) 80 (19.7) 201 (49.5) 110 (27.1) 406
The use of PDE5-inhibitors 27 (6.7) 201 (49.6) 154 (38.0) 23 (5.7) 405
how often do you inform about
Sexuality in male patient after a 
myocardial infarct or heart failure
27 (6.7) 221 (54.4) 139 (34.2) 19 (4.7) 406
Sexuality in female patient after a 
myocardial infarct or heart failure
147 (36.2) 221 (54.4) 34 (8.4) 4 (1.0) 406
The use of PDE-5 inhibitors in 
males in the outpatient clinic
94 (23.1) 234 (57.4) 59 (14.5) 20 (4.9) 407
how often do you inform about 
sexuality in the follow  
age-categories
20-35 years 107 (27.1) 200 (50.6) 71 (18.0) 17 (4.3) 395
36-50 years 38 (9.6) 227 (57.2)  112 (28.2) 20 (5.0) 397
51-65 years 33 (8.2) 231 (57.7) 120 (29.9) 17 (4.2) 401
66-75 years 80 (19.9) 232 (57.7) 77 (19.2) 13 (3.2) 402
≥76 years 168 (41.7) 202 (50.1) 26 (6.5) 7 (1.7) 403
a
 n differs because the questions were not answered consistently, some were skipped or forgotten. 
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reasons not to inquire about sexual function
The respondents were asked to indicate to what extent they agreed with a list of reasons 
for retaining from asking about sexuality (Table 3). The reason most respondents agreed 
with (53.7%) was: “the patient does not ask about it”. A difference was seen between 
younger physicians (≤ 45 years old) and older ones; younger physicians agreed with this 
statement significantly more often (linear-by-linear association, p=0.036).
The second reason not to discuss sexual function was: “I do not have an angle or motive 
to start about it”, 45.9% agreed. A time constraint was mentioned by 42.9%. Furthermore 
35.2% agreed with ‘a lack of training on dealing with sexual problems’ and 33.8% with 
“reasons related to language and ethnicity”. The reasons agreed with the least were 
“feelings of shame”(5.7%), “no connection with the patient”(6.2%), “age difference 
between me and the patient”(6.4%) and “fear of offending the patients”(7.4%) (Table 
3). Significantly more female physicians mentioned a lack of time to be the reason not to 
discuss sexual function, compared to their male colleagues (linear-by-linear association 
p=0.034). Furthermore, significantly more female than male physicians agreed that the 
fear of offending a patient is a reason not to ask (linear-by-linear association, p=0.009). 



















































































































































































































































































































































































































































































































































































































































































































































































































































The key findings of this study were that cardiologists did not routinely discussed sexuality 
with their patients and the majority did not feel responsible for this part of patient care. 
Forty-two percent of the respondents, however, indicated that they would benefit from 
training regarding sexual dysfunction in the cardiology practice. 
This survey was one of the first to evaluate cardiologists’ attitudes and practice patterns 
regarding the assessment of sexual health. A limitation of the study was that physician 
responses were self-reported which may have resulted in overestimation of physician 
history-taking practices. Attempts were made to reduce this bias by making the survey 
anonymous. A non-validated questionnaire was used in which cultural and religious 
components were not taken into account. Test-retest reproducibility of the questionnaire 
was not tested; therefore nothing can be said about the stability of the used instrument. 
Nevertheless, the internal consistency of the important items of the questionnaire was 
tested adequate to good. Our response rate was comparable to that of other postal 
questionnaires [14] and the demographics found were comparable with the national 
figures. However, non-respondents may have different beliefs and practice patterns than 
respondents which may have caused a non-response bias. In the real situation therefore, 
cardiologists may pay even less attention to patients’ sexual health. The lack of interest 
in responding to the questionnaire may itself indicate the low priority assigned to sexual 
history taking by many physicians, this may have caused a selection bias.
The results of this study revealed that a large group of cardiologists did not feel responsible 
for their patients’ sexual health. More than half of the respondents expected the patient 
to take the lead in discussing sexual function; and almost 70% percent pointed to the 
general practitioner as the responsible physician. Literature supports this finding, showing 
that more than 65% of hypertensive men with ED remain undiagnosed even though the 
majority states a wish for treatment [15;16].
Seventy percent of the respondents informed patients after a myocardial infarction or 
heart failure never or seldom about when to resume sexual activity. Yet, especially these 
patients should receive adequate information, since many have groundless fear for a 
cardiovascular event or sudden death during sexual intercourse [17;18]. 
Less than 20% of the cardiologists’ informed about PDE5-inhibitor use in their patients. 
However, the guidelines recommend assessing PDE5-inhibitor use in all cardiac patients 
since these drugs are widely used nowadays and abundantly available on the internet. Its 
combined use with nitrates is absolutely contraindicated as it can lead to unpredictable 
falls in blood pressure[19].
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The findings of this study are disappointing because already in 1981 it was postulated 
that cardiologists should routinely advise their patients on sexual activity[12]. The first 
Princeton Consensus Conference convened in June 1999 to develop recommendations for 
the clinical management of sexual function in men and women with known cardiovascular 
disease [20]. A second and third conference in 2004 and 2010 followed to update and 
deepen these recommendations [21;22]. In 2001 the role of the cardiologist in assessing 
sexual function was already reviewed [23] and in 2002 the British consensus identified 
the questions to ask to smooth the consultation when assessing erectile dysfunction [24]. 
Last year Circulation published the American Heart Association Scientific Statement to 
synthesize and summarize data relevant to sexual activity and heart disease in order to 
provide recommendations to foster physician communication with patients about sexual 
activity [25]. Regrettably, our study showed that cardiologists are still not alert to the fact 
that assessing sexual function is part of their remit. 
Several factors can be indicated to cause cardiologists’ lack of routine in assessing sexual 
health. Firstly, almost 30% of the cardiologists stated to lack the necessary knowledge and 
35% stated to have missed adequate training in dealing with sexual dysfunction. Almost 
half of the respondents indicated the absence of an angle to raise the subject as a reason 
not to raise it. Experienced cardiologists discussed sexual function significantly more 
often than their younger colleagues. Accordingly, literatures showed that physicians’ 
previous training in communication is the strongest predictor for sexual history taking 
[26]. Unfortunately, a recent review showed that sexual medicine education for medical 
students, residents, physicians and other healthcare professionals is still non standardized 
and inadequate in most centers [27]. 
Second, time constraints of the consultation were cited by 43% of the cardiologists as the 
barrier for inquiring about sex. These constraints may be overcome by the organization 
of nurse- or physician assistant office hours. And patients can always be referred to a 
specialist in sexual healthcare, such as the gynecologist, the sexologist or the urologist. 
Sixty-three percent of the respondents stated they would be helped with a list of sexual 
healthcare professionals where they can refer their patients to.  
Finally, multiple other reasons for avoiding the discussion about sex were indicated. 
Some were related to the cardiologists’ perception of patients’ feelings and others gave 
arguments which were related to their own feelings concerning sexuality. However, 
none of these reasons can be considered as valid, since physicians’ personal feelings and 
attitudes should never get into the way of patient care. 
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CoNCluSIoN
Over the last 30 years, recommendations and guidelines have been pointing out the 
importance of assessing sexual function in patients with cardiovascular disease. In spite 
of this, cardiologists still do not routinely discuss patient’s sexual function in their daily 
practices. This study suggests that physicians’ experience in the field plays an important 
role in discussing sexual matters and that sexual healthcare can be improved with more 
education on the subject. A directory of the available healthcare professionals for the 
referral of patients with sexual dysfunction was indicated as mandatory. 
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Since the late 1980s a rapid increase in the number of prescriptions for the treatment and 
prevention of cardiovascular disease (CVD) began. 
The class of antihypertensive agents is the second most commonly prescribed classed of 
medication, exceeded only by antidepressants [1]. In this time of high life expectancies, 
this therapy will be received during a substantial part of patients’ lives [2]. The side effects 
induced by cardiovascular drugs are strongly associated with an impaired quality of life 
[3], affecting both patients and their partners [4]. Some classes of cardiovascular drugs 
have been described to cause sexual dysfunction. Diuretics and β-blockers can give rise 
to a decrease in libido, difficulty attaining or maintaining an erection and ejaculation 
problems [5-7]. However, recent literature describes beneficial effects on sexual health 
for third generation β-blockers [8], Angiotensin II Receptor Blockers (ARBs) [9-12] and 
statins [13].  Existing data of experimental, observational and clinical studies consistently 
point towards similar effects of antihypertensive drugs in male and female sexual function 
[14-16]. As many as 70% of hypertensive patients who experience side effects are non-
compliant with their antihypertensive medication and have a 40%-60% higher rate of 
therapy discontinuation, compared to patients whose quality of life is unaffected [17;18]. 
Since non-adherence with antihypertensive therapy can be life threatening, it is of great 
importance for cardiologists to be aware of side effects that may be caused by drugs they 
prescribe, including effects on patients’ sexual function (SF). Of course, cardiovascular 
drugs improving symptoms and survival should not be withheld due to concerns about 
their potential impact on SF [19]. But whenever possible, multiple alternative options 
are available in order to provide patient-centered care (these options are described in 
Chapter 3). Information about cardiologists’ practice patterns concerning switches 
in medication in order to improve patients’ SF is not yet available. Neither is it known 
whether cardiologists are aware of the different effects of cardiac drugs on SF. However, 
cardiologists will only be able to provide medicinal therapy with an optimum balance 
between efficacy and quality of life and to provide patients with sufficient information 
regarding the prescribed therapy if they have knowledge about these effects. 
A recent report from our group revealed that Dutch cardiologists did not routinely discuss 
SF and a considerable number (41.9%) of the respondents indicated a need for training 
to increase their knowledge to be able to discuss sexual matters with patients [20]. 
Accordingly, we hypothesised that information about the several effects of cardiovascular 
agents on SF has not yet permeated the cardiology practice. Therefore, aim of this study 
was to evaluate to what extend cardiologists are aware of the potential negative, neutral or 
beneficial effects that cardiovascular drugs can have on SF and whether this knowledge is 
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actively used in patient care. We made use of additional data obtained during the National 
survey among cardiologists assessing their awareness, knowledge and practice patterns 
regarding sexual dysfunction in cardiac patients. Results of this survey, in combination 
with the review (chapter 4), will provide cardiologists and residents in cardiology with the 
necessary information to be able to provide holistic healthcare. 
methOds 
study design and sample
A national cross-sectional questionnaire survey was set among all active Dutch 
cardiologists and residents in cardiology (1054) who were members of the Netherlands 
Society of Cardiology (NVVC) in the autumn of 2011. However, some addresses from the 
society were out of date, leading to a total of 980 questionnaires which could be sent to 
the work addresses of NVVC members. 
survey and Procedure
The study methodology was identical to previously reported evaluation of Dutch 
cardiologists, evaluating their inquiry into patients’ SF [20]. The questionnaire was 
designed by the authors, based on a review of the literature in the area. A multidisciplinary 
expert panel, with experience in developing surveys, checked the questionnaire for 
comprehensiveness and quality. The survey was pilot tested with 40 anonymous pilot 
questionnaires which were distributed to cardiologists and residents in cardiology from 
the LUMC. Of the pilot questionnaires, 23 were completed and returned (response 
rate 57.5%). To improve the suitability and comprehensiveness of the questionnaire, 
it was adjusted according to the remarks made by the responding cardiologists. The 
questionnaire comprised 31 questions focusing on current practice in addressing sexual 
health and knowledge about (side) effects of the eight main classes of cardiovascular 
drugs. Questionnaires were accompanied by a letter explaining the nature, scope, 
objectives and contents of the questionnaire and total anonymity was ensured. A free post 
return envelope was added, as well as an opt-out possibility. Cardiologists not interested 
in participation could answer a question regarding the reason(s) not to participate and 
return the questionnaire empty. Reminder letters were sent to non respondents 2, 5 and 
7 month after the initial mailing.
Results about cardiologists daily practice patterns regarding assessment of SF can be 
found in chapter 2. 
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data analysis
Means of numerical demographic values and answers to the questions were analysed with 
frequencies. Bivariate associations between demographic information and the categorical 
data were calculated using the Pearson chi-square procedure, for ordinal variables 
Armitages’ trend test was used. Associations between numerical data and demographics 
of the respondents were analysed with the independent sample t-tests. Two-sided P 
values < 0.05 were considered statistically significant. Some questions with more than 
one possible answer and with open answers were grouped together for analysis. Data 
were analyzed by SPSS release 20 (SPSS Inc., Chicago, IL, USA). 
resuLts
demographics
Of the 980 eligible participants, 528 surveys were returned, yielding an unweighted 
response rate of 53.9%. Seven participants were eliminated because they were not 
participating in a clinical setting or because they were physician assistants. A total of 98 
questionnaires were eliminated because they were empty or incomplete for more than 
60% and 16 because they lacked answers to the most important questions. Reasons 
mentioned for the inability to fill in the questionnaire (n=114) were: not interested 
(n=4), no time (n=2), or not enough experience in the field (n=2). Others indicated they 
were only working with specific patient groups such as children or pregnant women and 
therefore were not able to fill in the questionnaire (n=5). However, most cardiologists that 
indicated unwilling to participate, gave no reason for this (n=101). In total 78.4% of the 
returned surveys were analyzed (n=414). Mean age of the respondents was 45.5 years 
old (± 9.60), 75.8% was male, 80.9% was cardiologists and 19.1% was resident. Female 
respondents were significantly younger then male respondents (mean 42.3 ± 8.37 resp. 
46.6 ± 9.75; p<0.001), consequently more female respondents were residents (p<0.001). 
Demographic characteristics of non-respondents were not available for analysis due to the 
anonymous design of the survey. The personal and practice characteristics of respondents 
are summarized in Table 1 of chapter 2.
knowledge about sexual side effects
More than one fourth (27.5%) of respondents stated they have ‘not much’ of the 
knowledge necessary to discuss SF with patients, 2.0% said to have no knowledge about 
this at all. The majority of cardiologists reported to have ‘some’ (65.1%) and only 5.4% 
said to have ‘a lot’ of the necessary knowledge to discuss sexual problems with patients. 
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Respondents were asked to note which effect on SF they thought was caused by each 
class of cardiovascular drugs (positive, neutral or negative). For β-blockers 93.1% of the 
cardiologists believed that it has negative effects on SF. Significant more female physicians 
thought that β-blockers have a positive effect on SF compared to male physicians (9.1% 
resp. 1.6%; p<0.001). Regarding diuretics, respondents gave more diverse answers; 57.7% 
said it has a neutral effect and 40.5% knew it has a negative effect on SF. The majority 
(64%) indicated ARBs to have a neutral effect on SF, only 9.2% knew this class can 
have beneficial effects on SF. Cardiologists’ answers regarding the presumed effects of 
cardiovascular drugs on SF were illustrated in Figure 1. No significant differences between 
male and female physicians were seen.
figure 1. Effects of eight classes of cardiovascular medication on the sexual function as presumed by 
the responding cardiologists, shown in percentages
Based on answers of at least 400 cardiologists (in training) per category
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Counseling about sexual side effects
The majority of the responding cardiologists (76.6%) stated to counsel their patients 
regularly or often about sexual side effects of cardiovascular drugs. Fifteen percent said 
to inquire about sexual problems when a patient recently started with cardiac medication 
and 74.4% when a patient recently started using a β-blocker. On the contrary, only 19.3% of 
the respondents inquired regularly or often about PDE-5 inhibitor use, while 43.6% said to 
inform patients about the possibility to use a PDE-5 inhibitor after a myocardial infarction 
(MI) or in patients with heart failure. Furthermore, 48.2% of the respondents said to 
change medications regularly or often in an attempt to improve SF (Table 2). Significant 
differences were seen regarding this statement; cardiologists stated to do this significantly 
more often then residents (p<0.001). Finally, the more knowledge about SF a cardiologist 
thought they had, the more often they changed medication in an attempt to improve SF 
(linear-by-linear association, p=0.002), and the more often they counseled patients about 
effects and use of erection potentiating medication (linear-by-linear association, p=0.032 
and p<0.001, respectively).
table 2. Counseling and informing of male patients with erectile dysfunction 
how often do you counsel 
patients regarding erectile 
function (Ef) after MI or with 











The use of nitrates with pain 42 (10.4) 112 (27.1) 145 (35.1) 104 (25.8) 403
Effects of medication on EF 15 (3.7) 80 (19.7) 292 (49.6) 110 (27.0) 407
The use of PDE5-inhibitors 27 (6.7) 202 (49.8) 154 (37.9) 23 (5.7) 406











Inform about erection 
potentiating agents
93 (22.9) 234 (57.6) 59 (14.5) 20 (4.8) 406
Change medication to improve 
sexual function
17 (4.2) 193 (47.7) 176 (43.5) 19 (4.7) 405
*n differs because the questions were not answered consistently, some were skipped or forgotten. 
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DISCuSSIoN
This study indicates that cardiologists are not fully aware of the effects cardiovascular 
drugs can have on SF. Although the majority of responding cardiologists stated to inform 
patients about sexual side effects from the medication they prescribe, their knowledge 
of these effects seems incomplete. Most cardiologists designated negative effects on SF 
to β-blockers, although third-generation β-1 blockers have been shown to have beneficial 
effects on SF. Furthermore, the lion’s share of respondents thought no effects on SF were 
to be expected from most other classes of cardiovascular drug, underestimating that 
most classes of cardiovascular drugs either have a beneficial or a negative effect on SF. 
Interestingly, more experience as a cardiologist was positively associated with informing 
about SF and counseling about side effects, suggesting that more education about sexual 
health in cardiologists’ training could improve awareness and thus quality of patient care 
on this point. 
This was the first survey among cardiologists assessing their knowledge about (side) effects 
of cardiovascular agents and their practice patterns regarding switching of medication in 
order to resolve or avoid sexual dysfunction. Findings should be considered in the light 
of potential study limitations. First, the self-reported character may have let to response 
and selection bias although the response rate was sufficient and the demographics found 
were comparable with the national figures. Second, we made use of a non-validated 
questionnaire, since validated questionnaires about this subject are not available. Third, 
the questionnaire was designed to obtain information about cardiologists’ knowledge and 
practice patterns concerning both male and female SF. Most trials investigating effects 
of cardiovascular drugs on SF are specifically designed to measure effects on erectile 
function since this is a common problem which is easy to measure with one of the available 
validated questionnaires [21]. And, because Erectile dysfunction has been shown to be a 
sentinel marker for risk of cardiovascular disease [22] is has received full attention in the 
past years, while very little attention was paid to female sexual dysfunction. Respondents 
may therefore answered the questionnaire with erectile dysfunction in mind which may 
have led to an upward distortion of the results. 
Our data still indicate that there is room for improvement regarding cardiologists’ 
knowledge about the sexual (side) effects of cardiovascular drugs. To improve compliance 
of therapy in cardiology, patients should be properly informed about the side effects that 
can be expected from a drug and equally important, patients should have the possibility 
to discuss a switch in medication with their physician when sexual dysfunction occurs. 
Large clinical trials about the effects of switching are lacking and have to be conducted 
in the near future. However, available data from observational studies and clinical trials 
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point consistently towards significant benefits for SF when prior antihypertensive therapy 
is switched to either Nebivolol or an ARB (Chapter 3) as significant improvements were 
observed in orgasmic function and intercourse satisfaction, along with benefits in sexual 
desire and frequency of sexual intercourse [23;24].  From an different angle, the American 
Heart Guideline [25] states that sexual dysfunction has not been associated with the use 
of ACE inhibitors, ARBs and calcium channel blockers. Cardiologists should be aware that 
these drugs classes can be prescribed safely.  
Obviously, patients’ health and cardiac condition take precedence above SF. In 
young patients with chronic heart failure for example, especially those awaiting heart 
transplantation, the use of β-blockers is of the utmost importance to improve survival 
and should not be withheld in order to preserve SF. In addition, without even taking 
the co-morbidities into account, heart failure itself often leads to deterioration in the 
physical condition of a lack of condition and to erectile dysfunction independent of 
the medication used [26]. Choices for medicinal treatment should always be balanced 
between cardiologists’ expert judgments and patients’ wishes. But while guidelines highly 
recommend routine assessment of SF before initiation of antihypertensive treatment 
[27], our results showed that inquiry about SF is not yet routine in the cardiology practice. 
A significant number of Dutch cardiologists lacked the knowledge to be able to provide 
accurate information about the effects cardiovascular agents can have on SF. Experience 
and sufficient self-perceived knowledge about sexual health appeared to be crucial factors 
for inquiring and dealing with medicinal effects on SF. Therefore, education about these 
(side) effects in cardiologists training could be useful to enable cardiologists to deal with 
patients presenting with sexual dysfunction during treatment with cardiovascular agents. 
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In the US, the class ‘lipid regulators’ was the most prescribed drugs class in 2010 with 
255.5 million prescriptions, beta blockers (plain and in combinations) and ACE inhibitors 
followed on the second and third place with 191.5 million and 168.7 million prescriptions, 
respectively [1]. In this era of high life expectancies, this therapy will be received during 
a substantial part of patients’ life [2]. The side effects induced by antihypertensive drugs, 
including sexual dysfunctions, are strongly associated with an impaired quality of life [3].
As many as 70% of hypertensive patients who experience side effects are non-compliant 
with their antihypertensive medication and have a 40%-60% higher rate of therapy 
discontinuation, compared to patients whose quality of life is unaffected [4]. Some classes 
of antihypertensive drugs have shown to cause sexual dysfunction, but others have been 
described to have beneficial effects on sexual health. Physicians and especially cardiologist 
and general practitioners should be aware of these possible effects of the medication 
they prescribe, because it makes them able to minimise sexual side effects and maximise 
quality of life and compliance with therapy. However, previous data obtained by our 
research group (part I) showed that cardiologists seem to lack the sufficient knowledge 
about the effects cardiac medication can have on sexual function [5]. 
With this review we aimed to provide a practical overview of the available literature 
regarding the effects of eight widely used classes of cardiovascular agents on sexual 
function. A clear overview table applicable for both male and female patients was 
provided for use in clinical settings. 




A review of the literature was assessed using PubMed and MEDLINE, searching for articles 
from 1970 to 2012. The search strategy involved the (MeSH) terms ‘sexual dysfunction’, 
‘erectile dysfunction’, ‘sexual side effects’, ’side effects’, ‘sexual adverse effects’ and ‘adverse 
effects’ consecutively in combination with the MeSH terms: Adrenergic Beta Antagonists, 
Angiotensin-Converting Enzyme Inhibitors, Angiotensine Receptor Antagonists, diuretics, 
Calcium Channel Blockers, hydroxymethylglutaryl-CoA Reductase inhibitors, Digoxine and 
more general terms: ‘antihypertensive agents’, ‘beta blocker’, ‘beta receptor antagonist’, 
‘diuretic’ , ‘α1-adrenoceptor antagonist’, ‘Angiotensin Converting Enzyme inhibitor’, 
‘Angiotensin Receptor blocker’, ‘calcium channel blocker’, ‘digoxin’, ‘heart glycosides’, 
‘statins’ and ‘nitrates’. The last search was conducted in March 2013. The reference list 
was hand-searched and all relevant studies and reviews were read and reviewed. 
Study selection
All clinical studies reporting about effects on male or female sexual function in relation 
to a cardiovascular agent were included. These included: animal studies, observational 
studies, small clinical studies, meta-analyses and randomized controlled trials. Studies not 
published as full-text articles, single case reports and opinion articles were excluded, as 
well as articles not written in English. Hard copies of all relevant articles were obtained 
and read in full. Since the purpose of this review was to provide a positive overview table 
listing the effects of the eight most widely used cardiac drugs classes for use in clinical 
practice, we used randomized controlled trials (RCT), double-blind cross-over studies and 
questionnaire based prospective and retrospective studies in human males and females 
for the overview tables (Tables 1 and  2).
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table 1. Overview of studies* showing effects of antihypertensive agents on sexual function in (human 
men and women
Effect on sexual 
function
 Beneficial Neutral Negative
β-blockers Nebivolol:
Doumas et al., 2006
Brixius et al., 2007
Medical Research Council, 1981
Wassertheil-Smoller et al., 1991
Rosen et al., 1994
Neaton et al., 1995
Grimm et al., 1997
Perez-Stable et al., 2000 
Franzen et al., 2001 
Bauer et al., 1978 
Hogan et al., 1980 
Suzuki et al., 1988 
Fogari et al., 1998
Buchardt et al,. 2000
Fogari  et al., 2001 
Llisteri et al., 2001
Fogari et al., 2002 
Ko et al., 2002 
Fogari et al., 2004 (♀)
Doumas et al., 2006 (♀)
Cordero et al., 2010 
Ma et al., 2012  (♀)
Diuretics Croog et al.,1988 
Prisant et al. 1999
Doumas et al., 2006 (♀)
Bulpitt et al., 1973 
Hogan et al., 1980 
Medical Research 
Council,1981
Curb et al., 1985
Wassertheil-Smoller et 
al., 1991
Chang et al;, 1991
Duncan et al., 1993
Rosen et al., 1999
Grimm et al., 1997
Ogihara et al., 2000
Epstein et al., 2011 
α-blockers Grimm et al., 1997 Lowe et al., 1994 
Fawzy et al., 1995
Lepor et al., 1997 
Buchardt et al,. 2000
Llisteri et al., 2001 
McConnell et al., 2003 
Kirby et al., 2003 
De Rijke et al., 2004 
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Effect on sexual 
function
 Beneficial Neutral Negative
ACE inhibitors Croog et al.,1986 
DiBianco et al., 1991 
Gupta et al., 1995 
Mancini et al., 1996 
Gupta et al., 1998 
Croog et al.,1988 
Suzuki et al., 1988
Fletcher et al., 1990
Steiner et al., 1990 
Pelmer et al., 1992
Grimm et al., 1997
Fogari et al., 1998
Doumas et al., 2006 (♀)
Llisteri et al., 2001 
ARBs Fogari  et al., 2001
Llisteri et al., 2001
Dusing et al., 2003 
Yamamoto et al., 2003 
Della Chiesa et al., 2003 
Fogari et al., 2004 (♀)
Ma et al., 2012  (♀)
Chen et al., 2012 
Segal et al., 2012 
Suzuki et al., 1988 
Rosen et al., 1994 
Fogari et al., 1998 
Fogari et al., 2002 
Bohm et al., 2010 
Doumas et al., 2006 (♀)
Calcium channel 
blocker
Suzuki et al., 1988 
Morrisette et al., 1993 
Omvik et al., 1993 
Kroner et al., 1993 
Grimm et al., 1997 
Ogihara et al., 2000 
Burnier et al., 2007 
Doumas et al., 2006 (♀)
Tanner et al., 1988 
Statins Saltzman et al., 2004 
Herrmann et al., 2006 
Dogru et al., 2008 
Gokkaya et al., 2008 
Dadkhah et al., 2010 
Mastalir et al., 2011 
Trivedi et al., 2012 
Cardiac 
glycosides
Kley et al., 1982 
Kley et al., 1984 
Bellman et al., 1984 
Stoffer et al., 1973 
Neri et al., 1987 
Gupta et al., 1995 





Several reports have shown serious side effects on sexual function due to the use of (centrally 
acting) β-blockers; in particular erectile dysfunction (ED) and loss of desire have been 
reported [12;14;16;44]. One of the proposed mechanisms by which β-blockers may induce 
sexual dysfunction is inhibition of the sympathic nervous system, which is involved in the 
integration of erection, emission and ejaculation, in the regulation of luteinizing-hormone 
secretion and in the stimulation of testosterone release [45]. Indeed, several studies showed 
a depression in testosterone level in patients receiving a β-blocker [18]. In contrast, in other 
more recent trials no significant adverse effects on sexual function were found with metoprolol 
[46], propranolol [47], acebutulol [18] and atenolol [8]. In the few studies concerning sexual 
function in female patients with antihypertensive treatment, metoprolol seems to negatively 
affect female sexual function index scores (FSFI) [20], especially in comparison with ARBs 
which seem to ameliorate FSFI scores [48;49]. After reviewing 15 trials involving 35.000 
subjects, Ko et al. reported that the frequency of sexual dysfunction with β-blockers was 
21.6% and 17.5% in the placebo group. In addition, β-blockers were associated with an 
increased risk of reported impotence in men (RR, 1.22; 95% CI, 1.05-1.41). Risk of withdrawal 
due to a sexual dysfunction was substantially increased (RR, 4.89; 95% CI, 2.98-8.03); 
however, the annual absolute increase in risk of withdrawal was only 2 per 1000 patients 
(95% CI, 0-5) [19]. Silvestri et al. showed that knowledge and prejudice about side effects of 
beta-blockers can produce anxiety, which may cause erectile function [50]. A critical review 
used this study to underpin their doubts about the sexual side effects of β-blockers [51]. All in 
all, the final word has not been said about the effect of β-blockers on sexual function, yet the 
majority of studies about regarding this topic point to negative effects of first- and second-
generation β-blockers. The guidelines regarding management of ED published by The British 
Society for Sexual Medicine highly recommend routine assessment of sexual function prior 
to initiation of antihypertensive treatment [52]. Furthermore, if patients present with sexual 
dysfunction during treatment with β-blockers a switch to Nebivolol, a novel third-generation 
β-1 blocker with a greater degree of selectivity for β-1 adrenergic receptors, might be a 
solution. Nebivolol appears to have a very low risk of sexual side effects compared to other 
agents in its class [6;53;54]. In a study designed to compare the effects of metoprolol and 
Nebivolol in erectile tissue (MR-NOED), Nebivolol was even shown to significantly improve 
erectile function of hypertensive patients due to nitric oxide modulation [7]. In concordance 
with the recent review by Baumhakel et al., we can conclude that selective β-blockers might 
impair erectile function. However, considering the strong correlation and pathophysiological 
link between endothelial and erectile function, beta-blockers with beneficial effects on 
nitric oxide synthase and oxidative stress can improve erectile function [55].
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2. Diuretics: 
Diuretics are considered one of the most implicated classes regarding sexual dysfunction. 
Although the mechanism remains ill defined [56], striking results with respect of drug 
treatment in male hypertensive patients were obtained in the Medical Research Council 
Trial [57], a single blind study on the basis of 
23,582 patients-years. In this trial the prevalence of impotence was measured by 
questionnaires after 2 years of treatment with propranolol, bendroflumethiazide or 
placebo. Impotence was mentioned in 10.1% of the placebo group, in 13.2% of the 
propranolol group and in 22.6% of the bendroflumethiazide group. Incidence of withdrawal 
from randomized treatment because of impotence (rates per 1000 patient-years) was 0.89 
in the placebo group, 5.48 in the propranolol group and 19.58 in the bendroflumethiazide 
group. The TOMHS trail (The Treatment Of Mild Hypertension Study) a 4-year follow up, 
double-blind RTC in 557 men and 345 women, showed that chlortalidone at a dose of 15 
mg/day may also be suspected to negatively affect sexual function in men [11]. In the Trail 
of Antihypertensive Interventions and Management (TAIM), erection-related problems 
worsened in 28% of patients receiving chlortalidone, in 11% of patients receiving atenolol 
and in 3% of patients receiving placebo [8]. 
Smaller studies pointed to hydrochlorothiazide and chlortalidone causing loss of 
libido and ED [58;59]. However, sex-life satisfaction was similar for treatment with 
hydrochlorothiazide (alone or in combination with atenolol) and the more modern 
treatment with candesartan alone or in combination with the calcium antagonist felodipine 
[60]. In one of few studies addressing sexual function in women thiazide diuretics may be 
associated with decrease in vaginal lubrication [61]. In addition, although an effective anti-
aldosterone agent, spironolactone has a tendency to produce undesirable sexual adverse 
events; at standard dose, breast tenderness, gynaecomastia and erectile dysfunction can 
occur in men, whereas menstrual abnormalities may occur in premenopausal women 
[62]. These adverse effects are due to binding of spironolactone to progesterone and 
androgen receptors and represent a substantial reason for drug discontinuation [63]. In 
the treatment of hypertension, when compared with spironolactone, the selective mineral 
corticoid receptor antagonist eplerenone provides a reduced incidence of gynecomastia 
[64]. The potassium-sparing diuretics amiloride and triamterene do not seem to affect 
sexual function [62]. 
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3. α-adrenergic antagonists:
Since α-adrenergic antagonists are first-line therapy for benign prostate hyperplasia (BPH) 
but only second line agents for the treatment of hypertension (doxazosine and terazosin), 
most knowledge regarding sexual adverse effects α-adrenergic antagonists comes from 
BPH-studies. A recent systematic review on the effect of α1-adrenoceptor antagonists 
on male sexual function was performed by van Dijk et al.[65]. They showed α-adrenergic 
antagonists used as treatment for hypertension does not seem to adversely effect sexual 
desire. The net effect of α-adrenergic antagonists on erectile function is likely to depend 
on the balance between pro-erectile effects in the brain and the penis and anti-erectile 
effects as a result of blood pressure lowering mechanisms. A 4-year RCT comparing 
doxazosine in the treatment of hypertension showed that α-adrenergic antagonists were 
not associated with ED; it may even improve pre-existing sexual dysfunction [11]. 
Ejaculatory dysfunction, predominantly an ejaculation and decreased ejaculate volume, is 
associated with tamsulosin and silodosin, which are superselective α1A-adrenergic receptor 
antagonists. Ejaculatory dysfunction is rare with α1-adrenergic receptor antagonists that 
are not selective for the α1A-adrenergic receptor subtype, namely alfuzosin, doxazosin, 
and terazosin [66;67]. In conclusion, the α-adrenergic antagonists prescribed as second-
line antihypertensive treatment does not seem to affect erectile function or ejaculatory 
function.
4. Cardiac glycosides
In a community-based epidemiologic study of 1709 men, analysis of data on multiple 
cardiovascular medications, digoxin use had the highest association with complete ED 
[68]. The mechanism of action is not completely understood. Early studies linked sexual 
dysfunctions to hormonal alterations observed with digoxin use [69;70]. Later studies 
failed to confirm a relationship with digoxin use and changes in serum hormone levels 
[71-73]. Another theory proposed is the digoxin-associated inhibition of the corpus 
cavernosum smooth muscle sodium pump activity, which promotes corporeal contraction 
and impedes nitric oxide induced relaxation, leading to ED [68].
5. ACe inhibitors
Angiotensin-converting enzyme (ACE) inhibitors, particularly captopril, have been 
associated with improved sexual function [46;51,52]. It has been suggested that potential 
favorable sexual side effects of captopril were secondary to improved cardiac function; 
however, sufficient data to support this hypothesis do not exist [74]. The TOMHS trail 
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showed a significant decrease of sexual activity rate through 24 month in men taking 
enalapril, compared to placebo [11]. But, in a comparing study between the ACE inhibitor 
lisinopril and the β-blocker atenolol, lisinopril only caused a temporary decline in sexual 
activity. After 4 weeks of treatment the sexual intercourse rate was reduced but tended to 
recover with ongoing treatment. Atenolol on the other hand caused a chronic worsening 
of sexual function [17]. The fact that ACE inhibitors work through other channels than the 
sympathic nervous system in lowering blood pressure might in part explain their reduced 
impact on sexual function. Furthermore, ACE inhibitors have been reported to reverse 
endothelial dysfunction by preventing the effects of angiotensin II, prolonging the half life 
of nitric oxide and decreasing degradation of bradykinin. This latter is a potent stimulator 
of nitric oxide and prostacyclin release and may therefore benefit erectile function [34]. It 
can be concluded that ACE inhibitors have no effect, or may even have a positive effect on 
sexual function, but its precise role remains to be elucidated. 
6. Angiotensin ii receptor antagonists (ArBs)
Multiple studies showed beneficial effects of ARBs on sexual function. In a cross-over 
study comparing atenolol with valsartan, valsartan increased sexual activity significantly 
compared with atenolol (which significantly reduced sexual activity); however, these 
changes were not significant compared with placebo [18]. Compared with carvedilol, 
long-term therapy with valsartan was significantly associated with improved sexual 
activity [16]. Dusing et al. reported reduction in ED with improved orgasmic function, 
intercourse and overal sexual satisfaction in a group of 2550 hypertensive patients treated 
with valsartan [75].
Angiotensin II is synthesized in the corpus cavernosum, it is involved in detumescence of 
the corpus cavernosum, and produces oxidative stress in the penile endothelium, thereby 
possibly promoting the development of ED [76]. In hypercholesterolemic apolipoprotein 
E knockout mice, endothelial function of the corpus cavernosum as a surrogate for ED 
was improved in tandem with a reduction in aortic plaque load by ARB treatment [77]. 
Observational studies showed an increase in sexual activity in hypertensive subjects or 
patients with metabolic syndrome, treated with an ACE inhibitor or ARB compared to 
patients with other therapies such as β-blockers [15;76;78]. No differences were seen 
between use of ramipril, telmisartan or a combination of the two and there was no 
evidence for adverse effects of both treatments on erectile function [61]. The beneficial 
effects on sexual function were confirmed in a study among 2202 hypertensive patients, 
reporting an increase of sexual intercourse per week when treated with Valsartan. A 
recent double-blind randomized study among 1549 patients in which 400 participants 
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received ramipril, 395 telmisartan and 381 a combination of the two, no benefits of 
ARBs on erectile dysfunction has been proven [79]. It has to be marked however that 
ARBs were added on top of previous multidrug regime in high-risk patients and thus 
conclusions regarding the effects of ARBs monotherapy cannot be drawn [80]. In recent 
randomized trials, Irbesartan use after nerve-sparing prostatectomy in patients with 
normal preoperative erectile function was shown to improve erectile function recovery 
[81]. Losartan seemed to have positive effects on erectile function as well [82]. Concerning 
female sexual function, Valsartan has been shown to improve sexual desire and sexual 
fantasies, while atenolol significantly worsened these items [49]. Likewise, women treated 
with the combination Irbesartan-Felodipine showed significant higher 
FSFI scores than those treated with the Metoprolol-Felodipine combination [48].
 Overall, ARBs seems to have beneficial effects on sexual function and, if possible, should 
be used in treatment of patients complaining of sexual side effects of other cardiovascular 
agents, or in men with pre-existent ED. 
7. Calcium Channel Antagonists
These agents increase dilatation and lower blood pressure by reducing calcium entry into 
the smooth muscle of the blood vessels [83]. Due to this mechanism of action, calcium 
antagonists are not expected to cause sexual dysfunction [44]. Indeed, in the TOMHS trail, 
amlodipine did not appear to affect sexual function [11], neither did nicardipine [84], 
nifedipine or diltiazem in other studies [85;86]. In two early studies, gynecomastia and 
problems with ejaculation occurred in patients who received calcium channel blocker 
therapy, probably related to hyperprolactinemia [14;87]; this was never investigated in 
later studies. In a double blind comparative study in 451 patients of both sexes, patients 
were allocated either to treatment with the calcium channel blocker amlodipine or with 
the ACE inhibitor enalapril for 50 weeks after a 4 week placebo run-in. Sexual function was 
not different between the two groups [85]. Taken together, the available data suggest that 
calcium channel antagonists do not a detrimental effect on sexual function.
8. Statins (3-hydroxy-3-methylglaryl-coenzym A reductase inhibitors)
Cholesterol is the biochemical precursor for testosterone. An experimental study and 
a RCT showed reduced testosterone in men using a statin although the average effect 
is modest [88;89]. Studies in small samples or with lower statin doses did not show 
significant changes in average testosterone levels [90]. An In vitro study demonstrated 
statin effects on human testicular testosterone synthesis [91] and in animals effects on the 
morphology and function of Leydig cells have been seen after statin administration [92]. In 
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a prospective observational study among 93 men it was suggested that ED following statin 
therapy is more likely in patients with severe endothelial dysfunction due to established 
cardiovascular risk factors including age, smoking and diabetes [93]. On the other hand, 
statins have been reported to improve erectile function when the cohorts had no other 
cardiovascular risk factors accept for untreated ED [94-96]. Furthermore, statins seem 
to increase the beneficial effects of sildenafil through endothelial function benefits [97-
100]. These endothelial function benefits may rely on the antioxidant effects of statins 
[[101;102], which clearly predominate over the pro-oxidant effects [103]. On the whole, 
evidence shows that statins can have a beneficial effect on erectile function because the 
beneficial effects seem to be more powerful than the negative effects on the testosterone 
level [104].








Calcium channel blockers ±
Angiotensin Receptor Blockers +
Statins +
Information from randomized controlled trials, reviews, double-blind cross-over studies and 
prospective questionnaire studies in men and women;
* Except for Nebivolol, this seems to have positive effects;
† Except for potassium sparing diuretics, which do not appear to cause sexual adverse effects;
- = negative effect, ± = no effect, += positive effect
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DISCuSSIoN
Based on absence of hard data coming from randomized controlled studies, the Second 
Princeton Consensus Management Recommendation state that ‘a change in class of 
antihypertensive medication rarely results in the restoration off sexual function’ [105]. 
However, the available data point towards significant benefits in sexual function when 
switching prior antihypertensive therapy [4;75;78;106]. This review demonstrated that 
significant improvements in male and female sexual function can be achieved when 
cardiovascular drug treatment is switched to either Nebivolol or an ARB and that use of 
statins can improve sexual function. Also, several lines of evidence indicate that older-
generation beta blockers, digoxin and diuretics can indeed deteriorate sexual function. 
This knowledge should become incorporated in cardiologists and general practitioners 
practices, because it is necessary to be able to offer patients a tailor–made medical 
treatment, to avoid or diminish side effects and therewith improve compliance with 
therapy.
For this review we used RCTs next to double blind crossover studies, observational- 
and questionnaire studies. The impact of the studies was not scored or indexed for; 
consequently, definite conclusions can not be inferred from this review. It should be kept in 
mind that more than two-third of the hypertensive patients require combination therapy 
of at least two drugs to reach their blood pressure goals. Therefore, combination therapy 
or therapeutic strategies will have to be compared in the future with respect to their 
effects on sexual function [56]. Nevertheless, hard data from large randomized controlled 
trials regarding the switch of cardiovascular drugs in monotherapy or multidrug regimens 
for the benefit of sexual function are lacking. This review can be helpful for cardiologists, 
urologists, general practitioners and other healthcare professionals who deal with patients 
complaining from sexual dysfunction during treatment with cardiovascular agents. The 
overview table shows clearly which effects were found in the numerous studies that were 
performed until now. 
Poor adherence in antihypertensive drug therapy is a critical contributor to unsatisfactory 
blood pressure control rates and erectile dysfunction has been shown to contribute 
to poor adherence [4]. Management of sexual dysfunction induced by hypertension 
and its related medication represents a challenge in the everyday clinical practice. For 
patients presenting with sexual dysfunction during cardiovascular drug therapy, lifestyle 
modification and switching medication according to the information conveyed above 
should be the first line of action unless the current treatment is absolutely indicated [107]. 
Since ARBs are now generic, it should be considered to use them as first line therapy in 
men in which erectile function is important (most men); rather then relying on switching 
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in the case they are brave enough to mention ED. If there is no advantage for treatment 
of ACE-inhibitors above ARBs, we suggest ARBs should be considered as fist line therapy, 
instead of allowing sexual dysfunction to happen and then prescribe a (self-funded) 
PDE-5 inhibitor, because this is not a satisfactory solution for most patients. However, in 
males with persisting erectile dysfunction (and despite the use of ARBs) PDE-5 inhibitors 
should be offered as the next step, since they exert beneficial effects through improved 
adherence. It was shown that hypertensive men with erectile dysfunction are more likely 
to initiate rather than discontinue, and add rather than reject antihypertensive medication 
when receiving PDE-5 inhibitors [108].  
Literature about effects of antihypertensive drugs in female sexual function is limited, 
but findings from small observational and clinical studies point towards similar effects 
of antihypertensive drugs in male and female sexual function [4;20;109]. Female cardiac 
patients presenting with sexual dysfunction, should receive the same treatment and 
advice as male patients concerning lifestyle modifications. And, if not contraindicated 
ARBs should be considered as first line therapy in females too, as literature points to 
benefits of ARBs compared to beta-blockers in female sexual function. If these measures 
are insufficient, a referral to a sexologist or a gynaecologist can be the considered.
As was seen in the evaluation of cardiologists concerning their knowledge and practice 
patterns in regard to sexual dysfunction [110] and the sexual side effects of cardiovascular 
medication [5]. Cardiologists lack sufficient knowledge and training to provide solutions 
and advises necessary to ameliorate patients sexual function and with that, to ensure 
adherence to cardiovascular treatment. In our opinion, appropriate education of 
cardiologists and other involved healthcare professionals is needed to overcome this 
problem. Furthermore, sexual effects of cardiovascular medication in both male and 
female dysfunction are a broad area for future research; in the meanwhile the proposed 
overview table can be of help in the clinical setting.
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Erectile dysfunction (ED) and cardiovascular disease (CVD) share common risk factors 
including age, hypertension, metabolic syndrome and atherosclerosis. Consequently, ED 
has been shown to be a powerful predictor of future cardiovascular events, myocardial 
infarction (MI), cerebrovascular events and all-cause mortality. And it shows a trend to 
increase risk for cardiovascular mortality. The predictive ability of ED is higher in younger 
ED patients despite the fact that probability of ED increases with age and it most likely 
identifies a group of patients with early and aggressive vascular disease [1-3]. These 
findings support implementation of ED assessment into clinical practice and stress the need 
to establish standardized methods to diagnose ED. Back and Forth, ED is very common in 
patients with CVDs; prevalence rates up to 75% in men with chronic stable coronary artery 
disease (CAD) have been shown [4]. Furthermore, a number of medications have been 
associated with an increased risk for ED, including first- and second generation β-receptor 
blockers, and thiazide diuretics [5]. Knowing that sexual activity is considered an important 
component of patients’ and their partners’ quality of life, independent of age [6;7]. A 
large body of research in the past decades has led to recommendations and guidelines 
for safe management of cardiac patients regarding sexual activity and the treatment of ED 
[8-11]. Recently a consensus document from the American Heart Association and the ESC 
Council on Cardiovascular Nursing and Allied Professions was published to synthesize and 
summarize current evidence related to sexual counseling in CVD and to provide direction 
to health care professionals is sexual counseling [12]. However, despite the abundance 
of evidence and guidelines, application of this knowledge in clinical practice has been 
limited[5;13-15]. This appears to be due to a lack of training in raising and discussing the 
subject sexual dysfunction [15]. Furthermore, it is unknown whether male patients have 
specific needs and wishes concerning sexual health counseling. Various interventions may 
improve management of ED in cardiology, some more timely and costly than others. We 
aimed to assess the burden of ED in a multi centered cross-sectional cohort of males 
visiting outpatient cardiology clinics in the Netherlands and to assess patients’ attitude 
towards sexual health care in cardiology. We sought to identify male patients’ view of 
possible improvements in sexual healthcare and the preferred forms of sexual counseling 
in the cardiology practice. Presenting a range of easy-to-use options, our results may 
contribute to the improvement of patient centered healthcare in cardiology.




In February 2013, a total of 650 surveys were mailed to a cross sectional cohort of adult 
male patients that consulted a cardiologists in one of two participating ‘Cardiology 
Centers of the Netherlands’ (CCN) (G.A.S, I.I.T., CCN location Amsterdam or G. J. d. G., 
CNN location Voorschoten) between January 2011 and January 2012. Furthermore 200 
questionnaires were randomly distributed to adult male patients visiting the outpatient 
cardiology department of the Leiden University Medical Center (academic hospital) or the 
Diaconessen Hospital Leiden (local general hospital) between May 2012 and January 2013. 
The questionnaires were accompanied by a letter explaining the nature, scope, objectives 
and contents of the questionnaire and ensuring total anonymity. An information sheet 
indicating participation was voluntary and ensuring confidentiality was provided with 
each survey. People unwilling to participate could mark the consent form stating their 
unwillingness; a question was added to obtain their reason(s) not to participate. In the 
two other outpatient clinics, the questionnaires were distributed by the secretary in 
closed envelopes. Patients were asked to fill out the questionnaire at home and return it 
by mail in the provided freepost envelope. 
Two independent researchers (M.P.J.N and J.v.B.) were responsible for the processing of 
the questionnaires. The returned questionnaires could not be traced back to patients’ 
records. Because of this anonymous design, reminders could not be sent out to non-
respondents. The protocol was approved by the institutional Committee for Medical 
Ethics (MEC) at the Leiden University Medical Center and the boards of the three other 
participating centers. No extramural funding was used to support this work.
All patient presenting with chest pain, hypertension, arrhythmias, dyspnea, dizziness and 
vascular problems, aged older than 18 years and the ability to understand the Dutch or 
English language (appendix) were included. While aiming to obtain information about 
a cross sectional cohort of male patients visiting the outpatient cardiac clinic; patients 
visiting for a regular check up or medical inspection in which no cardiac problems were 
found were also included. Because of this design, data from both sexual active and sexually 
inactive men were obtained. Study flow chart is displayed in Figure 1 to accurately indicate 
sources and methods of selection of participants. 
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survey instrument
Established, validated questionnaires about sexual function and quality of life were used 
to develop a 25-item gender-specific survey directed towards male patients with all 
possible indications for consulting a cardiologist. The survey consisted of three sections 
and was developed to address several aspects of ED, ED-related distress and to gain 
insight into patients needs regarding availability of sexual health care. The first part was 
designed to obtain demographic information including the reason(s) for consultation. 
To obtain information about erectile function, the validated Sexual Health Inventory for 
Men (SHIM) was used for the second part of the questionnaire. Of the SHIM, we used 
the abbreviated international index of erectile function (IIEF-5) which is a widely used 
scale for screening and diagnosis of ED and severity of ED in clinical practice and research 
[16]. Several questions from the validated Female Sexual Function Index were added 
to obtain information about sexual dysfunction- related distress in life and relationship 
[17]. Furthermore, information about use of phosphodiesterase inhibitors was obtained. 
The last part of the questionnaire was designed by our research group in order to assess 
patients’ opinion about discussing sexual health in the cardiology practice, to identify if 
more attention to ED would be welcomed and, if so, in which form this would preferably 
be. A multidisciplinary expert panel with experience in developing surveys checked the 
questionnaire for comprehensiveness and quality. Furthermore, the survey was pilot 
tested with 10 males consulting one of the participating centers to assess its suitability 
and comprehensiveness and was adjusted according to the remarks made. 
data Analysis
Results were summarized by reporting responses on all survey items. Frequencies of 
demographic characteristics, health behaviors, chronic conditions, and aspects of sexual 
function were presented. Prevalence of ED was based on IIEF-5 score of ˂21, and severity 
of ED was assessed following the guidelines [18] with mild 17-21; mild to moderate 12-16; 
moderate 8-11 and severe 1-7. Numerical demographic values were summarized as mean 
(SD). Differences in numerical data between demographic groups were analysed with 
independent sample t-tests, χ2 tests were used to assess association between categorical 
respondents’ characteristics and categorical responses. Bivariate correlations were used 
to correlate IIEF-5 scores with bother-scores. Statistical significance was defined as 
p<0.05, all tests were 2 sided, and confidence intervals were defined as 95%. Analyses 
were conducted using SPSS release 20 (SPSS Inc., Chicago, IL, USA).
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Mean age of the 296 respondents was 62.9 years (±11.1). For 86.1% of these men, a 
cardiac diagnose was made. The other 13.9% came for cardiac screening or check-up, and 
no cardiovascular problems were found. Of the respondents, 16.1% used one, 26.5% used 
two, and 29.9% used 3≥cardiac agents (see Table 1).
Erectile function and sexual activity
ED, as defined by an IIEF-5 score of ˂21, was prevalent in 165 (65%) of the 255 men that 
completed the IIEF-5 questionnaire. Of these, 240 had been sexually active in the past 
year and 15 had been sexual inactive. An IIEF-5 score ˂ 21 was significantly associated with 
current and former smoking (linear-by-linear association, p=0.001) and body mass index 
(BMI) ˃25 kg/m3 (p=0.007). The prevalence of ED increased with age starting from age 40 
(Figure 2). 
Almost three quarters of patients with CAD had ED (74.3%, p=0.049) and the majority of 
patients which had a myocardial infarction (MI) (83%) or heart failure (86%) scored ˂21 
points on the IIEF-5 scale (p=0.031). In contrast, patients in which no cardiac diagnosis was 
made, ED was seen significantly less often (39%, p=<0.001); for more details see Figure 3.
Of the respondents 81% had been sexually active in the past 12 months. The number of 
respondents that was sexual active diminished with age, of men ˃80 years 22% had been 
sexual active. The men who had not engaged in sexual activity (n=86) were prompted 
to state one or multiple reasons. Lack of interest was reported by 15% (n=13) and 23% 
(n=20) mentioned physical problems or insufficient condition. The most stated reason not 
to be sexually active was ED (43%; n=37).
To the question “Did you reckon the cardiac medication you take influences your sexual 
life?” 53% of the respondents that used one or more cardiovascular agents (n=202) 
answered with “no influence”, 4% noticed a positive influence, 36% noticed a negative 
influence of the medication and 7% did not know.
Respondents were asked to score discomfort experienced due to sexual dysfunction on 
a scale from 0 to 10. The mean bother score was 5.9 (±2.6). This bother was negatively 
correlated to the IIEF-5 scores (r=-0.63; p<0.001; figure 4). Mean influence of sexual 
dysfunction on respondents’ marriages/relationships was 3.3 (±3.3) on a 0 to 10 scale. 
The IIEF-5 score was weakly negative correlated with experienced influence on the 
relationship (r= -0.30, p=0.003).
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table 1. Characteristics of study sample 
Patients Characteristics n=296 a
Age, mean (range), years 62.9 (20-94)
Weight, mean (SD), kg 85.9 (±13.7)
Height, mean (SD), cm 180.3 (±6.9)
BMI, mean, (SD), kg/m3 26.4 (±3.6)
Nationality n (%)
Dutch 268 (91.5)
Other western country 10 (3.4)
Non-western country 13 (4.4)
Cardiovascular agents b n (%)
α-receptor blocker 13 (4.4)
ACE inhibitor 95 (32.4)
ARB 57 (19.5)
β-receptor blocker 103 (35.2)
Calcium-antagonists 44 (15.0)
Digoxin 11 (3.8)
Loop diuretic 11 (3.8)
Thiazide diuretic 33 (11.3)
Nitrate 20 (6.8)
Statin 112 (38.2)
Other 16  (5.4)
Co-medicationb n (%)
Coumarin derivatives 37 (12.5)
Platelet Aggregation Inhibitors 90 (30.5)





Quited < 1 year ago 10 (3.4)
Quited >1-5 years ago 13 (4.3)
Quited>5-10 years ago 15 (5.1)
Quited>10-20 years ago 27 (9.2)
Quited>20 years ago 59 (20.0)
Cardiac diagnoseb n (%)
Coronary Artery Disease 86 (29.2)
Hypertension 90 (30.5)
Arrhythmias 87 (29.5)
Myocardial infarction 34 (11.5)
Heartfailure 10 (3.4)
Valvular Heart Disease 25 (8.5)
Primary Myocardial Disease 5 (1.7)
Congenital Heart Disease 4 (1.4)
No cardiac diagnose 41 (13.9)
Abbreviations: ARB, angiotensin receptor blocker; ACE, Angiotensine converting enzyme; BMI, body 
mass index. a Columns may not add to 296 due to missing value. b Multiple answers were possible, 
total exceeds 296
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figure 2. Prevalence of erectile dysfunction (ED) by age group
figure 3. Cardiac diagnose made and distribution of erectile dysfunction
Abbreviations: CAD = coronary artery disease; MI, Myocardial infaction; HD = Heart Disease; No ED, 
No erectile dysfunction; ED +, Erectile dysfunction; 
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figure 4. Bother experienced due to sexual dysfunction versus IIEF-5 score
Based on data from 212 men. Bother was expressed on a scale from 0 to 10
Patients’ perception: care for ED in the cardiology practice
None of the respondents stated it would annoy them if the cardiologist would ask 
about sexual function; 1 patient said this question would offend him. Most respondents 
considered a question about sexual health as something positive (Table 2). Respondents’ 
opinions regarding several possibilities for the improvement of sexual healthcare in 
cardiology were summarized in Table 3. Of men with ED (n=165), 46% (n=75) would like to 
have a conversation with the cardiologist about possibilities to improve sexual function, 
55% (n=90) would be helped if questions could be asked during consultation with a nurse 
and 58% (n=95) with written information. Of those that stated cardiologists do not have 
to ask about sexual health (n=55), 27% (n=15) said not to believe the cardiologists could 
help and 24% said sex was not important for them (n=13). Five men (9%) felt too old 
to have sex; all of them were older than 80 years. Other reasons for not being willing 
to discuss sexual function were: “Sex is a private matter” (5%; n=3), “I do not want to 
claim my doctors’ time for something like that” (5%) and “there is no relationship with my 
complaints” (18%; n=10).
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table 2. Patients’ opinion about discussing sexual function with the cardiologist
If the cardiologist would ask you about your sexual function  




Offended (sex is a private matter) 1 (0.3%)
I do not think the cardiologist can help me with sexual problems 19 (6.6%)
I would not mind 132 (45.5%)
It seems logical to ask 90 (31%)
I would be happy if the cardiologist started about it 45 (15.5%)
Relieved 17 (5.9%)
I think it is necessary for a complete consultation 95 (32.9%)
a Multiple answers were possible.
Of the 296 participants, 50% (n=149) considered themselves to have a sexual dysfunction, 
62 would like to try treatment for it (42%), see Table 3. No significant differences were seen 
regarding questions about sexual health care between the different age categories. But 
the older the patients, the lower was his wish for treatment (linear-by-linear-association 
p=0.001). 
Phosphodiesterase 5 inhibitors
Of all respondents (n=296), 28% (n=83) tried a PDE5 inhibitor at least once. Of the sexual 
active men with ED (n=152), 37% tried or used it and of the sexual active men without ED 
(n=89), 11% did. Of patients that indicated not to have been sexual active the past year, 
32% (n=53) tried a PDE5 inhibitor. 
Most (65%; n=56) of the respondents that used a PDE-5 inhibitor, got it prescribed by 
the general practitioner, 8% (n=7) obtained it from a friend or family member and 2% 
(n=2) ordered it on the internet. Almost a quarter (24%) obtained the prescription from a 
medical specialist, of which 4% from the cardiologist.
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table 3. Wish for treatment of ED and preferred forms of care as can be offered in the cardiology 
practice
If there would be a treatment option for your sexual problem (ED), would 
you be willing to try this? 





Not applicable (no sexual dysfunction) 147 (49.7)
would be helped with written information about sexual dysfunction and 
its possible solutions?




Not applicable (I do not have a sexual problem) 100 (33.8)
would you be helped if you could ask questions about sexual dysfunction 
during consultation with a specialized nurse?




Not applicable (no sexual dysfunction) 118 (39.9)
would you like to have a conversation with the cardiologist about 
possibilities to improve your sexual life?




Not applicable (no sexual dysfunction) 99 (33.4)




Just listen to me 5 (4.5)
Give me some advise how to deal with it  37 (33.6)
Give me explanation about how it works   25 (22.7)
Refer me to an urologist      15 (13.6)
Refer me to a sexologist 15 (13.6)
Refer me to a psychologist    9 (8.2)
Give me information so I can read about it 30 (27.3)
Give me some information and let me think
about treatment options at home  
34 (30.9)
Change my medication if possible 10 (9.1)
Based on answers of 110 patients which stated to have a wish for treatment (yes or maybe), data 
from two respondents are missing. Multiple answers were possible.
Chapter 588
DISCuSSIoN
This study characterized male patients visiting general cardiac outpatient clinics in 
terms of demographics, cardiac diagnosis, erectile function and attitudes towards sexual 
counseling. It adds to the literature as it is the first study to describe views and preferences 
of sexual health care in a cross-sectional cohort of males visiting an outpatient cardiology 
practice. ED was prevalent in more than half of men in this cohort and the most stated 
reason not to be sexual active. Patients experienced significant bother due to the ED. Half 
of men with ED would feel helped discussing it with the cardiologist and the majority 
indicated both written information about treatment options and consultation with a 
nurse would be helpful options.
In 1980, the Massachusetts Male Aging Study (MMAS) reported prevalence’s for complete 
ED ranging from five percent at age 40 years to fifteen percent at age 70 years. For mild 
and moderate ED, prevalence estimates were 17% and 25%, respectively [19]. In men 
with CVD, prevalence rates of ED are much higher ranging from 42 to 75% [4;20]. In 
accordance with our results, in literature ED was found in up to three quarters of patients 
with established CAD [4] and in as much as 84% of men with heart failure [21]. In a study 
evaluating the view of patients with chronic CAD regarding the discussion of sexuality with 
the cardiologist, 73% of responding men indicated they were comfortable with that. Our 
results were similar, showing that most respondents would feel comfortable and would 
appreciate discussion about sexual function [13]. 
Findings should be considered in the light of potential study limitations. On the one hand, 
the sensitive nature of the topic explored may have led to non-response bias. Especially 
widowers, singles and patients in poor mental or physical health may have elected 
not to participate. On the other hand, non-respondents may have been content with 
their erectile function and considered their participation irrelevant. Our findings were 
consistent with prior research and the demographic data were comparable with statistics 
from general cardiological clinics [22;23]. However, non-respondents have been shown to 
have worse health status than the population average and to be less satisfied with medical 
care [24]. To minimize potential biases, we provided detailed assurances of confidentiality, 
pilot tested and refined the instrument and used balanced keying. 
Time after a cardiac event and the New York Heart Association classification for heart 
failure have been shown to be important factors in sexual function [12;25], our data 
would have been more complete if we could have included that information. However, 
because of restrictions imposed by the Committee for Medical Ethics, we could not link 
questionnaires with patient files and therefore were unable to obtain these data.
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In the past years, since ED has been shown to be an important sentinel marker for CVD, 
several reviews and guidelines for the management of ED in patients with CVD have been 
proposed [5;9;11;26]. Consequently, cardiologists should be aware that ED is part of their 
responsibility. As ED is predominantly a vascular disease and associated with an increase 
in cardiovascular events, CVD and all-cause mortality, cardiologists have to recognize ED 
within their remit and must routinely ask about it. If followed by appropriate preventive 
action, this can improve and may save lives [11]. Vice versa, this study showed that ED is 
highly prevalent in patients with a variety of cardiovascular diagnosis, and it influences 
quality of life. Indicating that care for ED in the cardiology practice is important as well. 
Jackson et al. proposed a flowchart for cardiovascular risk assessment in men with ED and 
known cardiovascular risks factors, starting with “sexual inquiry of all men” [11]. However, 
exactly this seems to be the crux of the matter: the problem is the translation of knowledge 
about the importance of ED in cardiology into actions in daily practice. Recently, a survey 
among Dutch cardiologists showed inquiry about ED is not yet routine. Many cardiologists 
(61.5%) reported not to feel responsible for this part of patient care. Nevertheless, 41.9% 
indicated they would benefit from training regarding treatment of sexual dysfunction in 
patients with cardiovascular disease and stated the necessity of a referral directory [15]. 
Present study showed sexual counseling and attention for ED is required for ambulant 
cardiology patients. Although it may be unrealistic to expect all cardiologists to have 
the time and expertise to provide adequate sexual counseling; the results of this survey 
indicate that small adjustments can enable cardiac clinics to provide their patients with 
sufficient information. Patients indicated that consultation with a nurse and written 
information would be helpful, even more so than  consultation with the cardiologist. For 
nurses in cardiology, guidelines summarizing approaches to discuss sexuality and advises 
for follow-up are already available [27]. 
Explanation and advice about the mechanisms behind ED and its treatment options 
should be available for all men with CVD. Providing leaflets with information about ED 
may be convenient and will lower the threshold for patients to bring up the subject during 
consultation. Information for the partner should not be forgotten. Partners often have 
considerable concerns, often more so than patients [28;29]. Most of the time information 
is for the person with the cardiac disease and partners may feel their needs are pushed 
aside [30], guidelines therefore indicate the importance for partner information as well [12]. 
In patients indicating to be bothered by ED, several steps can be taken to improve erectile 
function. As stated in the guidelines, advising about lifestyle modification (i.e. reduced 
caloric intake and smoking cessation) is a rational first step because next to prevention of 
cardiovascular events, lifestyle changes may improve erectile function [10;11]. It should 
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be emphasized that a sedentary lifestyle is a potential modifiable risk factor in men with 
ED and empirical studies provide support for the beneficial role of increasing exercise 
[12;31;32].
Furthermore, a switch in antihypertensive medication may significantly ameliorate sexual 
and erectile function. If possible, prior antihypertensive therapy should be switched 
to either a third-generation β-1 blocker or an angiotensine receptor blocker [33;34]. If 
no other options are available, use of ACE inhibitors or calcium-channel blockers is not 
associated with ED; agents from these classes can be prescribed safely [35;36]. Prescription 
of a PDE5 inhibitor should be the next step. If erectile dysfunction persists after correct 
PDE5 inhibitor use, referral to an urologist should be considered for further diagnosis and 
other therapeutic options (e.g. testosterone suppletion or interacavernosal prostaglandin 
E1). In patients with other sexual dysfunction and in those in need for advice to improve 
their sexual life otherwise, referral to a sexologist is useful. 
In conclusion, next to the necessity of cardiovascular risk assessment in men with ED, 
ED is highly prevalent in ambulant cardiac patients, and information regarding ED and 
its treatment is mandatory. This information and sexual counseling can be provided in 
several ways; both consultations with the cardiologist or a (specialized) nurse, as well as 
written information would be accommodating. 
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Female sexual dysfunction (FSD) is age related and has been shown to be common 
among women with cardiovascular disease (CVD) (1-3). Sexual activity is an important 
component of quality of life in both patients with CVD and their partners, including many 
elderly patients (4). Interestingly, according to the National Health and Social Life Survey 
more women (43%) than men (31%) reported sexual problems (5). After a cardiovascular 
event, the psychological impact as well as the physiological effects of the disease and the 
medications prescribed after an event can have a major effect on patients’ sexual life. 
Furthermore, patients or partners’ anxiety of another cardiac event often lead to reduced 
sexual activity or sexual dysfunction (6) (7) (8).
Male sexual function received close scientific attention, as erectile dysfunction was shown 
to be an independent risk factor for future cardiovascular events (9;10). However, FSD 
related to CVD remains under explored.
A recent survey among Dutch cardiologist (n=414) showed that cardiologists inform 
less often about sexual function in women than in men (p<0.001)(11). Subsequently, a 
consensus document from the American Heart Association was published, encompassing 
recommendations for healthcare professionals regarding sexual counseling and 
routine assessment of sexual problems in patients with CVD and especially those after 
a cardiovascular event (12). Male and female patients are being addressed together in 
these guidelines, while studies evaluating experiences and needs of women with CVD 
regarding sexual healthcare have not yet been performed. 
We hypothesized that women with CVD have different expectations and demands than 
men regarding sexual healthcare in cardiology. Therefore, the aim of this study was to 
evaluate views of female cardiac patients with regards to sexual healthcare, in a multi-centered 
sample of women consulting the cardiologist. Results provide the necessary information to 
offer effective patient- centered care for female patients in cardiology practice.




In February 2013, a total of 625 surveys were mailed to a cross sectional cohort of adult 
female patients consulting one of the participating ‘Cardiology Centers of the Netherlands’ 
(CCN) (G.A.S, I.I.T., CCN location Amsterdam or G. J. d. G., CNN location Voorschoten) 
between January 2011 and January 2012. Furthermore 100 questionnaires were randomly 
distributed to adult female patients visiting the outpatient cardiology department of Leiden 
University Medical Center (academic hospital) or the Diaconessen Hospital Leiden (local 
general hospital) between May 2012 and January 2013. Questionnaires were distributed 
in a sealed envelope accompanied by a letter in which the nature, scope, objectives 
and contents of the questionnaire were explained and an information sheet explaining 
participation was voluntary and ensuring total anonymity. People unwilling to participate 
could mark the consent form stating their unwillingness; a question was added to obtain 
reason(s) not to participate. In the two other outpatient clinics, questionnaires were 
distributed by the secretary. Patients were invited to fill out the questionnaire at home 
and return it by mail in the provided freepost envelop. Questionnaires were processed 
by independent researchers (M.P.N and J.v.B.), and could not be traced back to individual 
patient records. The study was approved by the Committee for Medical Ethics (MEC) of 
Southwest Holland and the boards of the participating centers. The strictly anonymous 
design was the prerequisite; due to this design reminders could not been sent out to non-
respondents.
Due to the cross-sectional study design, all women over 18 years consulting a cardiologist 
in one of the participating centers were considered eligible for participation. Patients 
visiting for routine checks or medical inspection were included in the study and data from 
both sexual active and sexual inactive women were obtained.  Exclusion criteria were the 
inability to understand the Dutch or English language. 
A study flow chart is displayed in Figure 1 indicating sources and methods of selection of 
participants. 
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figure 1. Study flow diagram
Cardiovascular disease and female sexual dysfunction 99
6
survey instrument
Established, validated questionnaires about sexual function and quality of life were used 
to develop a 28-item gender-specific survey directed towards female patients with all 
possible indications for consulting a cardiologist. The survey consisted of three sections; 
in the first part demographic information was obtained, the second part was developed to 
explore prevalence of FSD, and the third part to gain insight into the needs of women with 
CVD regarding sexual health care in cardiology. Assessment of female sexual function was 
performed using the validated 6-item version of the Female Sexual Function Index (FSFI6), 
a frequently cited psychometric test for screening and diagnosis of FSD in clinical practice 
and research (13). The abbreviated version was used because it is an efficient instrument 
to disclose FSD, scoring for desire, arousal, lubrication, orgasm, satisfaction and pain (14). 
By keeping the questionnaire short, we aimed to reach a higher response rate and to 
avoid “straight line” (stereotypical) responding (15). Bother due to sexual dysfunction and 
its influence on the relationship was scored on a 0-10 scale, in which 0 meant no bother 
at all and 10 meant the most possible bother. Quality of the questionnaire was audited by 
a multidisciplinary expert panel with experience in the development of questionnaires.
data Analysis
Results were summarized by reporting responses on all surveyed items. Frequencies of 
demographic characteristics, health behaviors, chronic conditions and aspects of sexual 
function were presented. Numerical demographic values were summarized as mean (SD). 
Prevalence of FSD was based on a FSFI6 cutoff score ≤19 (14). Differences in numerical 
data between demographic groups were analyzed with independent sample t-tests. χ2 
Tests were used to assess association between categorical respondents’ characteristics 
and categorical responses. Bivariate correlations were used to correlate FSFI6- scores 
with bother-scores and linear regression analysis was used to identify predictors of an 
abnormal FSFI6 score. Statistical significance was defined as p<0.05, all tests were two-
sided. Confidence intervals were defined as 95%. Analyses were conducted using SPSS 




From the 725 women who received the questionnaire and consent form, 329 (45.4%) 
where returned. Of these respondents, 152 (46.2%) declined participation, 3 women had 
died (0.9%) and 7 (2.1%) questionnaires where returned to sender. A total of 167 women 
filled in the questionnaire, 3 were excluded because they where incomplete for more 
than 30%, 1 because the patient was under-aged, leaving 163 questionnaires for analysis 
(49.5%; see Figure 1).
Mean age of 163 respondents was 60.2 years (±13.7). For 74.8% of these women a cardiac 
diagnose was made, in the other 25.2% no cardiovascular problems were found. 
No significant age differences were seen between women without a cardiac diagnosis 
(mean age 57.4 ±13.5, see Table 1) and those with CAD (p=0.243), hypertension (p=0.11) 
or arrhythmias (p=0.49). 
However, women with heart failure, valvular disease or congenital heart disease were 
older than those without a cardiac diagnosis (mean ages 65.9±11.2, p=0.02; 70.6±11.8, 
p= 0.004 and 80.5±9.1, p=0.05 respectively). 
Of those who did not use cardiovascular medication 39.3% (n=64), 51.6% were diagnosed 
with a cardiovascular problem. Cardiovascular agents were used by 60.7% of the 
respondents; 22.1% used one, 19.6% used two and 19.0% used three or more agents 
(Table 1).
table 1. Characteristics of study sample 
Patients Characteristics n=163 a
Age, mean (range), years 60.2 (18-90)
Weight, mean (SD), kg 73.5 (±14.4)
Height, mean (SD), cm 167.0 (±10.5)
BMI mean, (SD), kg/m3 27.0 (±12.0)
Nationality n (%)
Dutch      147 (90.2)
Other western country     8 (4.9)
Non-western country  8 (4.9)
Cardiovascular agentsb, n (%)
α-blocker 3(1.8)
ACE inhibitor 23 (14.0)
ARB 29 (17.7)
β-blocker 61 (39.0)




Loop diuretic 18 (11.0)





Coumarin derivatives 6 (3.7)
Platelet Aggregation Inhibitors 35 (1.6)





Quited < 1 year ago 4 (2.4)
Quited >1-5 years ago 11 (6.7)
Quited>5-10 years ago 12 (7.3)
Quited>10-20 years ago 12 (7.3)
Quited>20 years ago 18 (11.0)
Cardiac diagnoseb  n (%) Age, mean (range), 
years
Ischemic Heart Disease 21 (12.8) 63.0 (29-84)
Hypertension 54 (32.9) 64.8 (35-88)
Arrhythmias 59 (36.0) 58.0 (18-88)
Myocardial infarction 6 (3.7) 58.0 (29-82)
Heartfailure 2 (1.2) 66.5 (66-67) 
Heart valve disease 23 (14.0) 67.2 (35-90)
Primary Myocardial Disease 2 (1.2) 63.0 (49-77)
Myxoom 2 (1.2) 52.0 (35-69)
Congenital Heart Disease 2 (1.2) 80.5 (74-87)
No cardiac diagnose 25 (15.2) 57.4 (28-77)
Abbreviations: BMI, Body mass index (m / l²); ACE, angiotensin-converting enzyme, ARB, Angiotensin 
receptor blocker
a Columns may not add to 164 due to missing value
b Multiple answers were possible, total exeeds 164
table 1. Continued
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female patients’ perception: sexual healthcare in cardiology
To the question: “If the cardiologist would ask you about sexual problems during 
consultation, how would that make you feel?” on the one hand, 15% of respondents 
(n=163; multiple answers were possible) answered “uncomfortable”, 5% “annoyed”, 
1% “offended” and 19% thought the cardiologist would not be able to help with sexual 
problems. On the other hand, 45% would not mind if the cardiologist asked about sexual 
function, 15% found it logical and almost 24% thought discussing sexual health was 
necessary for a complete consult. 
Respondents’ views about several possible options for improvements in sexual healthcare 
are displayed in Table 2. 
Of the six women who had MI, none indicated attention for sexual health was necessary, 
three indicated not to have a sexual dysfunction, the other three indicated not to believe 
the cardiologist could help them with sexual problems. Of the heart failure patients (n=2) 
one felt too old for sex (age 67) and one said her condition was insufficient. 
Women with sexual complaints
For women with self-indicated sexual dysfunction, an additional set of questions 
concerning experienced bother, treatment wish and preferred forms of treatment was 
posed, 35% of the women answered these questions.  
Respondents were asked to score discomfort/bother experienced due to sexual complaints 
on a 0 to 10 scale. Mean bother score was 3.4 (±3.0), younger age was a predictor for 
higher bother scores (β=-0.09, SE±0.04; p=0.02). Mean influence of sexual dysfunction on 
marriage or relationship was 3.1 (±2.6) on a 0 to 10 scale and this was not correlated with 
age (r=-0.03, p=0.88). 
Answers to the question: “Would you like treatment for your sexual problem(s)?” can 
be found in Table 2. Several reasons not to discuss sexual health with the cardiologist 
were mentioned; “these complaints are not related to my cardiac problem” was the most 
common (29%). “Sex is not important for me” (21%) and “I do not believe the cardiologist 
can help me with this kind of problems” (18%) were mentioned as well. Furthermore, 15% 
said to feel too old for sex (ages ranged from 60 to 74 years) and 9% answered that sexual 
function was a matter too intimate to discuss with the physician. 
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table 2. Wish for treatment of sexual complaints and preferred forms of care as can be offered in 
the cardiology practice
would you appreciate conversation with the cardiologist about 





Not applicable 82 (50.9)
would you appreciate the option of discussing sexual issues during 




Not applicable 87 (54.0)
would you like to receive written information about sexual dysfunction 




Not applicable 77 (47.8)




What would you like the cardiologist to do regarding your sexual 
complaints?
n=23c
Just listen to me 2 (8.7)
Give me some advise how to deal with it  3 (13.0)
Give me explanation about how it works   5 (21.7)
Refer me to a gynecologist      3 (13.0)
Refer me to a sexologist   2 (8.7)
Refer me to a pelvic floor physiotherapist 2 (8.7)
Give me information so I can read about it 22 (95.6)
Give me some information and let me think
about treatment options at home  
5 (21.7)
a Two respondents missed or skipped these questions 
b  Based on answers from 56 women; questions were only answers by women that indicate not to be 
satisfied with their sexual life
c  Women that answered “yes” or “maybe” to the previous question.
d No significant differences were seen between women with different cardiovascular diagnoses 
regarding or between premenopausal (n=32) and postmenopausal women (n=131).
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Specific groups and the demand for sexual healthcare 
Female sexual dysfunction scored with the Female Sexual Function Index
FSD was defined as a Female Sexual Function Index-score (FSFI6) of 19 points or less. The 
FSFI6 was only validated for women who had been sexual active in the past four weeks, 
excluding all women that were not; the female sexual function index was scored for 104 
women. 
Prevalence of FSD was 61.5% (n=64/104), prevalence of FSD increased significantly with 
age (linear-by-linear association, p<0.001). As shown in Figures 2 and 3, increasing age 
had a strong negative correlation with FSFI6 score in the sexual active population (β=-0.18 
(SE=0.04); p=<0.001). A higher age-related unstandardized coefficient was seen in women 
with hypertension (β=-0.35, SE±0.10; p=0.002), compared to normotensive women (β=-
0.17, SE±0.05; p=0.001). 
Low FSFI6 scores were not significantly associated with current and former smoking 
(p=0.436) or with BMI above 25 kg/m3 (p=0.645). However, the hypertensive women 
(n=37) had significantly lower FSFI6 scores than normotensive women (mean scores 14.6 
±7.30 versus 17.3 ±5.62; p=0.04), a trend towards association with MI was seen (mean 
scores 10.0 ±8.73 versus 16.5 ±6.22; p=0.08) (see Figure 3). 
Of those with FSD, 18% said to be very or moderately dissatisfied with their sexual life, 
21% were equally satisfied as dissatisfied, and 61% said to be moderately or very satisfied. 
Women without FSD were satisfied more often than those with FSD (93% vs. 61%; 
p<0.001), unrelated to age. Influence of FSD that patients experienced on their marriage 
or relationship was correlated to the bother scored due to FSD (r=0.46, p=0.009). And 
difference was seen between women with- and without FSD (as measured with the FSFI6-
score) regarding the wish for treatment of sexual complaints (yes or maybe) (linear-by-
linear association, p=0.011).
Sexual inactive women                                                                                                                                            
Fifty-seven women (35%) were sexual inactive in the past 12 month, these were 
significantly older than the sexually actives (mean age 68.5 ±11.6 compared to 55.8 
±12.6; p<0.001). The sexually inactive women were asked to state one or multiple reasons 
for this. The most common reason was the lack of a partner (divorced, single, widow) 
(41%). 24% answered ‘Sex is not important for me’, 29% accredited the sexual inactivity to 
physical problems and 24% said to be too tired. Thirty-five percent of the sexual inactive 
women (35%) indicated to have a sexual dysfunction, 18% of them indicated to be sexual 
inactive due this dysfunction, in 27% sexual (erectile) dysfunction of the partner was the 
reason. Differences between wishes regarding sexual healthcare in cardiology between 
sexual active and sexual inactive women can be found in Table 2. 
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figure 2. Prevalence of female sexual dysfunction by age group and percentage of FSD by diagnose
Abbreviations: CAD, coronary artery disease, Valvular HD, valvular Heart Disease; MI= myocardial 
infarction; FSD + = female sexual dysfunction present
Based on data of 104 sexual active women.
figure 3. Preferred forms of sexual healthcare and wish for treatment
Based on answers of 163 women in different categories, not all women answered. 
Totals: sexual active: n=104, sexual inactive: n=57, hypertensives: n=54, normotensives: n=106, FSD 




Using linear regression, number of cardiovascular agents was shown to be a predictor 
for lower FSFI6 scores (β= -1.47 (SE 4.31); p=0.001) per added agent, independent of age 
(Figure 4). Furthermore, the more cardiovascular agents used the more often a treatment 
wish was stated (linear-by-linear association, p=0.009).  
A significant lower mean FSFI6 score was found in women using a β-blocker (14.0 ±6.2 
versus 17.4 ±6.2; p=0.08) and in those using an ARB (12.2 ±7.9 versus 17.1 ±5.8; p=0.004). 
However, when corrected for age (β= -0.18 (SE 0.04); p<0.001) and number of agents 
used, the effects of both β-blockers and ARBs were not found predicting for FSD anymore 
(β=0.28 (SE 1.9); p=0.98 and β=-1.85 (SE 1.6); p=0.26 respectively), the number of agents the 
patient used however, remained predicting for low FSFI6 scores (β= -1.22 (SE 0.56); p=0.03). 
Nevertheless, women using β-blockers or ARBs indicated to be less satisfied with their 
sexual lives in general (linear-by-linear associations,
p= 0.019 and p=0.001 respectively) and less satisfied with their sexual relationship (linear-
by-linear associations, p= 0.019 and p=0.014 respectively). This was not the case with the 
other antihypertensive agents. Women using a β-blocker wanted treatment for sexual 
dysfunction more often than those not using a β-blocker (linear-by-linear association; 
p<0.001), this was not observed in women using ARBs.
figure 4. Female Sexual Function Index (FSFI6) score versus age and use of cardiovascular drugs.
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DISCuSSIoN
Key findings of this study were: 1) 35% of women in our sample indicated sexual dysfunction 
was prevalent and 2) 40% of them would welcome treatment for it. Only a small minority 
would appreciate consultation about sexual health with the cardiologist. Consultation 
with a nurse and the availability of written information would be valued by 20%, unrelated 
to age. The necessity for sexual healthcare in cardiology was confirmed more often in 
women with FSD as scored with the Female Sexual Function Index. Higher percentages of 
sexual dysfunction were seen among hypertensive women and, the cumulative number of 
antihypertensive agents used was found to be negatively correlated with sexual function.
To our knowledge, this was the first study evaluating the specific needs of a cross-sectional 
ambulant sample of women with CVD. The self-reported prevalence of sexual dysfunction 
was comparable to the rate found in the Observational Study Cohort of Women’s Health 
Initiative among postmenopausal women with CVD (1). Measured with the FSFI6, more 
than 60% percent of sexual active women in our sample scored to have FSD, similarly 
in a sample of 2763 women with heart disease (mean age 67 years) a prevalence rate 
of 65% was found (2). The present study showed a higher rate of FSD in hypertensive 
women, confirming data of Doumas et al, who reported a higher prevalence of FSD in 
hypertensive- (42%) compared to normotensive women (19%)(3). The association 
between β-blocker use and sexual dissatisfaction was shown in several studies among 
women as well (3;16;17). 
Antihypertensive combination therapy has been associated with higher rates of erectile 
dysfunction in men. Combination of a diuretic with a β-blocker, particularly the non-
selective ones, increased the rate of sexual dysfunction and resulted in treatment 
discontinuation in men (18;19). However, until now, this has not been studied among 
women and has to be explored in future research. 
Comparing results of this study with our previous study among men with CVD, the gender 
differences regarding sexuality are clear. Of 296 men visiting the cardiologist, 65% had 
erectile dysfunction (ED), sexual satisfaction and wish for treatment were significantly 
related to it. Compared to the women in present study, a significant higher proportion of 
men would appreciate consultation with the cardiologist (29.7% versus 5.4%) and 46% of 
men would appreciate consultation with a nurse to ask questions about sexual function, 
in contrast to 18% of women (20). In addition, whereas it is difficult to indicate if CVD has 
a direct effect on female sexual function (1;21); in men the link between ED and CVD is 
significant and has been shown and confirmed in many trials (10;22). 
This study contributes to current, scarce, knowledge about FSD in women with CVD, 
indicating women have different needs than men with regards to sexual counseling. 
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Results have to be interpreted in the light of several limitations. We tried to minimize 
potential biases by providing detailed assurance and confidentiality and by pilot testing 
and refining our questionnaire. Still the relatively low response rate may have led to 
response bias. Moreover, the sensitive nature of the topic explored may have led to non-
response bias. Especially singles, widows, and patients in poor mental or physical health 
may have decided not to participate. Epidemiologic literature showed non-respondents 
to have worse health status than the population average and to be less satisfied with 
medical care (23). Consequently, our results may be displaying an underestimation of FSD. 
Yet, distribution of demographic data in the sample and the obtained prevalence rates of 
FSD were consistent with those from prior population-based research among women with 
CVD (1;2;24). The majority of women with CVD are postmenopausal, likewise are most 
women in present study. While age is an important determinant in FSD, this age factor has 
to be taken into account while interpreting the data. 
The fact that women, in comparison to men, attributed less importance to sexual function 
in general and related to their relationship, was to be expected and was already explained 
in the sixties by Masters and Johnson (25). Women’s experience with sexual arousal 
is not focused on the physical responses, but is much more subjective and regulated 
by emotions and cognitions (26). Furthermore, aging women may devaluate their 
expectations regarding sex or its perceived importance (27). This may explain why only 
a relative small percentage of women with FSD would appreciate the various proposed 
options for improvement of sexual healthcare in cardiology. The subjective component 
of FSD makes it much more difficult to assess whether or not endothelial dysfunction in 
CVD has the same physical impact in female sexual function as it has in men. ED has been 
found to be a sentinel marker occurring years prior to cardiovascular events (28), but even 
if the same connection is found with female sexual function, the fact that FSD cannot 
objectively be measured implicates it will never be useful as marker for CVD in women.
For the cardiology practice, results of this study indicate sexual counseling does not have 
to be offered as actively in women as in men. In contrast to the recommendations made in 
the consensus document of the American Heart Association (12), our data point towards 
a passive approach with respect to sexual healthcare for women in the cardiology clinic. 
The availability of written material seems a good starting point, providing patients with 
information about sexual health in the context of CVD and lowering the threshold to 
initiate conversation about the subject. If a patient indicates sexual counseling is needed, 
the availability of a (specialized) nurse would be accommodating. This service would both 
be appreciated by the patient, and would reduce workload for the cardiologist. 
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In women with FSD using one cardiovascular agent, a switch in antihypertensive 
medication may significantly ameliorate sexual function. In several studies among males 
and in a few studies among female patients, the use of ARBs have been shown to leave 
sexual function unaffected (3;29;30) or even to improve sexual function (16;31;32). This 
however was not measured in multi-drug regimens. Our data indicated that the use of 
several antihypertensive agents together has a negative effect on female sexual function, 
independent of the combination used. This implicates that female sexual function 
would improve if the medication regiment would be emaciated. Studies regarding 
medication switches to improve sexual function in women have not yet been performed 
either. To provide recommendations for women who presenting with FSD while using 
antihypertensive agents, results of studies in men have to be extrapolated. Findings from 
observational and clinical studies pointed towards similar effects of antihypertensive 
drugs in male and female sexual function (17;32;33). Next to a switch to ARBs, if β-blocker 
use is necessary, a switch to the third-generation β-1 blocker Nebivolol may improve 
sexual function (34;35). 
In case sexual dysfunction remains after diminishing and/or switching the medication, 
referral to a gynecologist or pelvic floor physiotherapist should be considered. For those 
in need for advice to improve their sexual life unrelated to physical problems, referral to 
a sexologist is preferred. 
In conclusion, FSD is prevalent among women visiting the cardiology clinic, but in contrast 
to male sexual dysfunction (often ED) the burden appointed to it seems to be significantly 
smaller and only a minority of women indicate to appreciate conversation about sexual 
health with the cardiologist. The availability of written information about sexual function 
and/or the possibility of consultation with a specialized nurse may be good alternatives 
for patients with FSD.
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In the last three decades, the understanding of the relationship between a history 
of sexual abuse (SA) and gastrointestinal (GI) disorders has increased [1-6]. There 
is a growing awareness of the adverse health outcomes associated with SA among 
patients with GI symptoms, especially in IBS, which is a huge health-care problem. 
A history of abuse has been shown to contribute independently to the health 
status of any individual presenting with GI symptoms [6]. The prevalence 
rates of SA among patients with GI illness have been shown to range 
up to 56% in selected populations with functional GI complaints [7-11]. 
Treatment guidelines have been published and promoted to assist in conducting SA 
inquiry, as it is an essential part of the medical history [11]. However, we are unaware 
of the implementation of this knowledge in gastroenterologists’ daily practice patterns. 
We hypothesized that most Dutch gastroenterologists are aware of the possible impact of 
a SA history in their patient population, but they do not inquire about it consistently due 
to a lack of training on this subject and insufficient knowledge on treatment implications. 
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methOds
In the autumn of 2010 an online questionnaire was emailed to all the Dutch 
gastroenterologists (n=262) and fellows in training (n=140), followed by two 
reminder-emails. Eight months later, a postal mailing was sent to the non-responders. 
The 42-itemed questionnaire, designed by a urologist (H.W.E) and a gastroenterologist 
(H.H.F.), addressed pelvic-floor-related complaints and the gastroenterologists’ beliefs 
and overall impressions of pelvic floor complaints in relation to sexual functioning. We 
performed a small pilot with eight gastroenterologists to evaluate the questionnaire 
and adjusted it accordingly. The survey was accompanied by a letter explaining the 
objectives of the study. All data were collected anonymously. Demographic data included 
type of practice, medical degree (resident or gastroenterologist), gender and age. 
Data analysis was performed using SPSS release 18 (SPSS Inc., Chicago, IL, USA). 
Bivariate associations between demographic information and the type of answers 
were calculated using the Pearson chi-square procedure; comparisons of the 
percentages were made with the McNemar test and two-sided P values < 0.05 
were considered statistically significant. Some questions with more than one 
possible answer and with open answers were grouped together for analysis. In 




Of the 402 mailed questionnaires, 243 questionnaires were returned (response rate 
243/402=60%). Seventeen contained refusal notes and 43 contained a notification 
of unavailability to complete the questionnaire due to a lack of time or interest. 
Of the 183 (45.2%) filled in, 14 were incomplete. We only used questionnaires 
in which at least 90% of all applicable questions were answered. This means 
that 169 questionnaires were analyzed (42%). Overall 2.4-5.3% of the questions 
about SA and 5.3% of the sociodemographic questions were not answered. 
The majority of respondents were gastroenterologists (70%), 30% were residents 
(Table 1). Their mean age was 42.3 (range 23-64). The respondents were equally 
divided between university hospitals, teaching hospitals and district general hospitals. 
table 1.  Demographic characteristics of respondents (n=169)
Age, years (range)  n(%)







Resident gastroenterology 48 (28.4)
Unknown 9 (5.3)
Type of practice
Tertiary referral center (or university hospital) 51 (30.2)
District general teaching hospital 66 (39.1)
District general hospital 43 (25.4)
Unknown 9 (5.3)
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Asking about sexual abuse and responsibility
A small number of respondents said to always ask about SA prior to the physical 
examination; 5.0% of female and 0.6% of male patients (Table 2). In patients 
presenting with specific complaints such as chronic abdominal pain or constipation, 
gastroenterologists stated to ask about SA in 71.4% of female and 31.3% of male patients. 
Significant differences were seen between the inquiries in female vs. male patients. 
Concerning the complaints that triggered the gastroenterologists to ask about sexual 
abuse; significant differences between male- and female patients were seen as well (Table 
2). Before performing a colonoscopy, just four respondents (2.5%) asked their female 
patients about SA; while only one respondent (0.6%) asked their male patients (p=0.02). 
table 2. Sexual abuse evaluation
female patient Male patient






Yes 8 (4.9) 1 (0.6)
Do you ask each patient, referred for colonoscopy, about 
SA?
n=160 n=160
Yes 4 (2.5) 1 (0.6)
Do you ask about SA when a patient has specific 
gastrointestinal complaints?
n=161 n=160
Yes 115 (71.4) 50 (31.3)
Which complaints?b n=160 n=159
Constipation 71 (44.4) 25 (15.7)
Chronic abdominal pain 79 (49.4) 24 (15.7)
Fissura ani 31 (19.4) 13 (19.4)
Dyssynergic defecation 62 (38.8) 2 (1.3)
Fecal incontinence 37 (21.1) 34 (21.4)
a
 Totals differ because the questions were not answered consistently, some were skipped or forgotten 
 
About 7.5% considered asking about SA in female patients to be unimportant. There was a 
significant difference with male patients: 29.9% of the respondents found it unimportant 
to ask male patient about SA (p<0.01). Female physicians stated significantly less often 
that “it is not important to ask male patients about sexual abuse” (19.6%) versus 36% of 
the male doctors (p=0.03). For more comparisons between male and female physicians, 
see Table 3. 
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Do you ask each patient 
about history of sA before 




2 (2.0) 6 (10.5) 0.018* 4 (8.3) 4 (3.6) ns
♂ 
patient
1 (0.9) 0 ns 1 (2.0) 0 ns
do you ask about sexual 
abuse when a patient 









19 (33.3) ns 21 (43.8) 29 (26.1) 0.04*
do you think is it important 











Not 4 (3.9) 0 ns 1 (2.1) 3 (2.7) ns
Moderately 20 (19.6) 9 (16.1) ns 4 (8.3) 25 (22.7) 0.05
Rather 63 (61.8) 33 (58.1) ns 35(72.9) 61 (55.5) 0.06
very 14 (13.7) 13 (23.2) ns 7 (14.5) 20 (18.9) ns
do you think is it important 











Not 9 (8.8) 2 (3.5) ns 1 (2.1) 10 (9.0) ns
Moderately 41 (40.2) 14 (24.6) ns 15 (31.3) 40 (36.0) ns
Rather 42 (41.2) 31 (54.4) ns 27 (56.3) 46 (41.4) ns
very 10 (9.8) 10 (17.5) ns 5 (10.4) 27 (13.5) ns
GE, gastroenterologist; ns, not significant
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Overall, 26.4% of the gastroenterologists found it difficult to ask about SA in female 
patients and 22.9% in male patients. Thirteen percent did not know what to do if a female 
patient confirmed a history of SA, compared to 12.1% in males. Almost 10% percent of 
the respondents reported that “lack of time” represented a constraint when inquiring 
about SA.
No significant differences where found between residents and gastroenterologists 
regarding questions about SA or the barriers keeping them from asking about SA. 
To the question: “Do you think it is important to pay more attention to sexuality 
related to abdominal complaints during your training?” 61.3% said this was 
“rather important” when it concerned female patients, 46.3% found it “rather 
important” when it concerned male patients. The mean estimated prevalence rates 
of patients with a history of sexual in the respondents’ own patient populations 
were 10.6% (SD± 8.65) for female and 3.8% (SD± 3.78) for male patients. 
Using linear regression age or gender of the gastroenterologists where not of influence on 
the mean prevalence rates of sexual abuse estimated to exist in their patient populations. 
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DISCuSSIoN
This study was performed to evaluate gastroenterologists daily 
practice patterns and views regarding the care for patients with a 
history of SA. To our knowledge, this is the first report on this topic. 
Seventy percent of the respondents asked females presenting with complaints, such 
as chronic abdominal pain, constipation and fecal incontinence, about SA. An implicit 
assumption of our survey is that Dutch gastroenterologists are aware of the value that 
inquiring about SA has in assessing females with GI-complaints. However, they seem 
to be significantly less convinced when it concerns men. Thirty percent asked of the 
gastroenterologists asked their male patients about SA when presenting with specific 
complaints, such as fecal incontinence and anal fissures. In contrast, 71% did so in female 
patients with these complaints.
We assumed that asking about SA beforehand of performing colonoscopy would be 
evident in gastroenterology. Nevertheless, just 2.5% of the respondents asked their female 
patients about SA and only 0.6% asked males before performing this invasive transanal 
procedure. This in contrast to Dutch urologist of whom nearly 70% said to ask about SA 
in female patients before performing physical examination [12]. The results of this survey 
concerning gastroenterologists’ inquiry about SA before performing physical examination 
or colonoscopy are therefore disappointing.
Invasive procedures in the pelvic region can cause flashbacks, severe emotional distress 
and dissociation in patients with a history of abuse [13-16]. When this takes place, 
the patient surrenders to her or his memories and the emotional contact between 
the examiner and the patient will be disturbed. This will affect the patient-physician 
relation since communication and interaction during physical examination has been 
shown to be most important factors for patients’ perception of the examination [17;18]. 
Time constraints were cited by ten percent of the gastroenterologists as an important 
reason not to inquire about SA. In a survey among Canadian gastroenterologists, this was 
mentioned a constraint by 25% as well [19].
The argument that asking a male patient about SA is not of value in the gastroenterology 
practice was mentioned by a third of the responding gastroenterologists. 
Concerning female patients, this argument was used significantly less often (7.5%). 
This response might be due to the lack of literature regarding the effects of SA 
in males. The benefits of the disclosure and knowledge about SA history in male 
patients have not been fully studied; however, the physical and mental responses 
to SA in males are very likely to be similar or comparable to those in females. 
The other constraints the gastroenterologists reported which are keeping them from 
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asking about SA were personal discomfort with discussing this topic and a lack of 
resources for treatment or referral. These barriers can and should be resolved with 
extra training, since physicians cannot be excused of lack of involvement due to personal 
discomfort or a lack of knowledge on a subject this relevant in their daily practice. 
Furthermore, gastroenterologists underestimated the prevalence of SA in their 
populations. Several studies evaluated the prevalence of SA in gastrointestinal disease 
and these prevalence rates ranged from 6% in men and 19% in women in cross-sectional 
cohorts up to 25% in men and 56% in women in highly selected populations with 
(functional) gastrointestinal disease [7-11;20]. Nevertheless, despite the underestimation 
of the prevalence of SA in their practices, most gastroenterologists did consider SA an 
important topic and would like to receive more education and training on the subject. 
This is even more relevant because patients seldom disclose SA spontaneously. A cross-
sectional, multi-centre study in Scandinavian gynecological patients showed that 96-98% 
of women with a SA experience did not disclosed this during their latest visit to the clinic; 
1-2% stated that their doctor already knew about it and 0.6 -1.1% had spontaneously 
discussed the SA with their gynecologist during their last visit [21]. 
Present study has several imitations. A non-validated questionnaire was used in which 
cultural components were not taken into account. And, as in all questionnaire studies, 
there may be a bias in reporting. Respondents may have overestimated their own habits 
or may have responded in a more socially responsible manner. The survey and data 
analysis were performed totally anonymous to reduce this bias.
Furthermore, non-respondents may have different beliefs, attitudes and practice patterns 
than respondents which may have caused selection bias. The demographic data of the 
respondents, however, suggest a representative group and a response rate of 60% is 
rather high for a postal questionnaire [22].
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Finally, for the clinical practice the following question remains: how should 
gastroenterologists deal with patients with a history of SA? First of all, it should not 
be perceived as an obligation for gastroenterologists to ask all their patients about SA. 
Notwithstanding, the gastroenterologist needs to decide when the effects of an abuse 
history might interfere with adequate care. More training seems needed as well as easy 
to use-guidelines to providing grip for gastroenterologists when and how to consider 
a history of SA and in which situations a question about SA should always be posed. 
Secondly, one may ask each new patient to fill out a questionnaire including a question 
about SA [23], so SA can be detected in an early stage. In that respect, our self-administered 
questionnaire for pelvic-floor complaints has proved to be a reliable instrument [24]. 
In addition, training sessions could provide the skills necessary to inquire about SA in 
an appropriate and supportive manner. Furthermore, gastroenterologists should be well 
informed about treatment options for patients with sexual traumata and the different co-
morbid conditions that may exist due to the SA. In general, patients with a neglected SA 
history need to be referred for further psychological treatment. 
In future research, SA patients’ perceptions of their treatment in the gastroenterology 
practice and their opinion about phycians’questions concerning delicate matters such as 
sexuality and sexual abuse should be conducted.
For now it can be concluded that Dutch gastroenterologists underestimate the 
problem SA in their practices, and do not inquire about it routinely. However, patients 
with a history of SA are prevalent in every patient population and especially in 
those with GI complaints. Education is necessary generate more attention for the 
importance of SA in the gastroenterology practice. Training is needed to reduce 
the barriers which are withholding gastroenterologists from asking about SA and 
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The prevalence of sexual abuse (SA) in modern western societies is estimated to be 12% to 
25% for females and 8% to 10% for males [1-3]. SA has been linked to abdominal pain and 
functional gastrointestinal disorders [4;5], more healthcare utilization and exacerbated 
(pelvic) pain perception [6-8]. In community samples, patients with an abuse history have 
a 1.5 to 2 times increased risk of reporting gastrointestinal (GI) complaints compared 
to non-abused individuals [9;10]. Furthermore, SA has been linked to discomfort and 
traumatic reactions during pelvic examinations [11;12] and has been reported to make 
patients feel vulnerable when undergoing invasive endoscopic procedures [13-15]. 
Disclosure of abuse in the gastroenterological setting may allow for earlier consultation 
with mental health professionals [6].
In a recent survey among gastroenterologists, the majority stated to be aware of the 
importance of inquiring about SA. Nevertheless many indicated a lack of training in dealing 
with abuse-related problems [16]. Patients’ beliefs regarding routine direct inquiry about 
SA in gastroenterology practice have never been assessed and it is unknown whether 
colonoscopy is experienced differently by patients with a history of SA. Hypothesizing 
attention for SA in gastroenterology practice is limited; we were interested in patients’ 
beliefs and attitudes regarding care for SA. We aimed to assess if patients with a SA history 
experience colonoscopic procedures differently and to identify whether care around 
colonoscopy needs adjustment for patients with SA experience, exploring targets for the 
improvement of patient-centered care around colonoscopic procedures. 




Written informed consent was obtained from all participants. The study was approved by 
the Medical Ethical Testing Committee of Southwest Holland. 
Patients and procedure
All patients ≥ 18 years old who had undergone colonoscopy in the selected timeframe 
were included. Patients were excluded if the procedure was performed under general 
anesthesia. Patients from the LUMC with inflammatory bowel disease (IBD) were excluded 
because participation in a study addressing sexuality in IBD was offered to those patients 
in the same period. IBD-patients from the HAGA teaching hospital were not excluded.
Within 11 months after the colonoscopy took place, the selected patients (n=2348) 
received an introduction letter containing information about the study, a consent form 
and a freepost return envelope. Those returning the consent form with an affirmative 
answer received the questionnaire (in Dutch or English) within one month. The consent 
form contained an opt-out section in which reason for opting out was not asked for, as 
required by the medical ethical testing committee (MEC). One reminder letter was sent 
to non-respondents and one reminder letter was sent to respondents that agreed to 
participate but did not return a (completed) questionnaire. 
Colonoscopy 
Colonoscopies were performed according to the routine protocols of both centers. 
Each endoscopy team consisted of an endoscopist (gastroenterologist, resident in 
gastroenterology or specialized nurse endoscopist) and one or more specialized endoscopy 
nurses. Conscious sedation with intravenous midazolam and fentanyl was used in all 
patients undergoing colonoscopy. Rarely, flumazenil or naloxone were given to counteract 
the sedative action of midazolam or fentanyl, and in some patients butylscopalamine was 
given, based upon the judgment of the performing endoscopist.
Questionnaire 
The questionnaire (appendix) was developed by the researchers. It was designed 
for both men and women. An expert panel with experience with the development of 
questionnaires checked its comprehensiveness and quality. A pilot study among 5 
gastroenterologists, 3 residents in gastroenterology and 10 patients visiting one of the 
participating gastroenterology clinics was performed to assess the suitability, validity and 
comprehensiveness of the questionnaire. 
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The questionnaire included questions about sociodemographic data (age, gender, country 
of origin, way of referral and indication for colonoscopy), sexual function, micturition, 
SA history and the patient experience at colonoscopy. Furthermore, questions were 
included regarding patients’ views on conversations about sexual function and SA with 
the gastroenterologist/physician. Several questions used were from The Pelvic Floor 
Inventories Leiden (PeLFIs), which is a validated tool to assess complaints of the pelvic 
floor and about SA [17;18]. For respondents that confirmed a history of SA, additional 
questions were posed regarding desired forms of healthcare. No distinction was made 
between adult and childhood SA. Questionnaires were processed by independent 
researchers (M.P.N. and L. de V.), and could not be traced back to patient records. Data 
were strictly anonymous as prerequisite by the MEC. In order to process the data correctly 
the questionnaires were numbered and the corresponding address data were saved and 
handled separately. Because answering the questionnaire was potentially distressing 
for subjects, an independent sexologist/psychologist was available in case support was 
needed.
Statistical Analysis 
Results were summarized by reporting responses on all surveyed items. Frequencies of 
demographic characteristics and answers to the questions were all presented. Numerical 
demographic values were summarized as mean (SD). Differences in numerical data 
between demographic groups were analyzed with independent sample t-tests. χ2 Tests 
were used to assess association between categorical respondents’ characteristics and 
categorical responses. Linear regression analysis was used to identify predictors of distress 
caused by colonoscopy and to correct for these factors. Statistical significance was defined 
as p<0.05, all tests were two-sided. Confidence intervals were defined as 95%. Analyses 
were conducted using SPSS release 20 (SPSS Inc., Chicago, IL, USA), GraphPath Prism 5 was 
used to design the figures.
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From the 2348 patients who received the information letter and consent form, 1419 forms 
were returned (60.4%). Of these respondents, 610 (43.1%) declined participation and 809 
(57.0%) were willing to participate. Of the 809 patients that received the questionnaire, 
13 did not return it and 10 were incomplete for more than 30% and therefore excluded. 
One respondent was excluded because she indicated not to remember anything about 
the colonoscopy. Seventeen respondents were excluded because they underwent 
sigmoidoscopy and should not have been invited in the first place. The above led to a 
total of 768 questionnaires available for analysis (Figure 1). Mean time span between 
colonoscopy and return of the competed questionnaires was 274.0 days (±70.3). 
Mean age of participants was 61.2 years (±14.5 years), female participants were younger 
than male participants with a mean age of 59.9 (± 15.3 years) compared to 62.8 (±13.2) 
years respectively (p=0.02). There was no difference in age between patients that declined 
participation (mean age 61.4 ±15.9) and participants. Non-respondents were younger than 
participants with a mean age of 53.8 years (±16.4) (p<0.001). Of the included patients, 
43.9% were male. The majority of respondents were born in the Netherlands (88.4%, 
n=674), 3.4% was from an other western country (n=26) and 8.2% from a non-western 
country (including Turkey, Morocco, Surinam, and the Dutch Antilles, n=63) (Table 1). 
From the respondents included for analysis, 81.4% underwent colonoscopy in the general 
teaching hospital and 18.4% in the tertiary referral center (LUMC). 
Indications for colonoscopy were listed in Table 1. The most common indications were 
abdominal pain (not specified) (30.4%) and rectal blood loss (28.4%). 
Almost three quarter of respondents indicated one complaint to be the reason for 
colonoscopy (73.3%; n=563), 20.2% (n=155) indicated two complaints, 5.2% (n=40) three 
and 1.0% (n=8) indicated four different reasons for the colonoscopy. 
The majority was referred for colonoscopy by the general practitioner (48.8%). Almost 
a third (27.3%) was indicated for colonoscopy by the gastroenterologist him/herself and 
11.1% by a physician in internal medicine (otherwise), 3.7% was referred by a surgeon.  
Voiding complaints were present in 33.1% of respondents (n=254): 52.5% of them 
mentioned frequency, 27.5% urgency and 24.3% urinary incontinence. 
A quarter of the patients (25.7%) reported sexual dysfunction (n=197), this was more 
prevalent in male (34.5%) than in female patients (18.4%). 
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Age, mean (SD), years 59.9 (15.3) 62.8(13.2) 0.02
Age, ≤39 years, n(%) 41 (9.6) 25 (7.4) 0.08
Age, 40-49 years, n(%) 63 (14.7) 25 (7.4) 0.19
Age, 50-59 years, n(%) 84 (19.6) 60 (17.9) 0.07
Age, 60-69 years,, n(%) 127 (29.6) 124 (36.9) 0.04
Age, 70-79 years, n(%) 74 (17.2) 72 (21.4) 0.34
Age, 80-89 years, n(%) 38 (8.9) 29 (8.6) 0.004
Age ≥90 years, n(%) 2 (0.5) 1 (0.3) n/a
Country of origin 
n (%)                                                 






The Netherlands 378 (88.3) 296 (88.4) 0.98
Other West-European country 13 (3.0) 9 (2.7) 0.78
Morocco 2 (0.5) 2 (0.6) 0.80
Turkey 3 (0.7) 4 (1.2) 0.48
Surinam 12 (2.8) 10 (3.0) 0.89
Dutch Antilles 3 (0.7) 4 (1.2) 0.48
Elsewhere western 2 (0.5) 2 (0.6) 0.80
Elsewhere non-western 15 (3.5) 8 (2.4) 0.38
reason for colonoscopyb







Abdominal pain 150 (35.0) 81 (24.1) 0.001
Rectal blood loss 110 (25.6) 108 (32.1) 0.05
Surveillance (hereditary) colon 
carcinoma/polyposis/polypsc
111 (25.9) 97 (28.9) 0.37
Changes defecation pattern 104 (24.3) 68 (20.2) 0.18
Chronic diarrhea, constipation 
or mucus in stool
37 (8.6) 15 (4.5) 0.02
Inflammatory Bowel Disease 18 (4.2) 22 (6.5) 0.15
Pain anal region 18 (4.2) 20 (6.0) 0.27
Anemia 9 (2.1) 14 (4.2) 0.10
Otherd 38 (8.9)              31 (9.2) 0.51
n/a= not applicable.
a. Based on data from n=768 respondents of which 429 women and 336 men (due to missing 
values), columns do not necessarily add to 768 
b. Multiple answers were possible
c. Significantly more patients with the indication ‘surveillance for colonoscopy for hereditary colon 
carcinoma/ polyposis/polyps’ were seen in the tertiary center (41.3%) compared to the general 
teaching hospital (23.6%; p<0.001).
d. Under which: loss of weight, diarrhea, eating disorders etc.
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sexual abuse
SA was reported by 53 (7.0%) of the 752 respondents that answered the question ‘have 
you ever been a victim of sexual abuse?’ Sexual abuse occurred in 40 (9.5%) of females 
(n=421) and in 13 (3.9%) of males (n=331). Patients born in a non-western country 
reported more SA compared to patients born in the Netherlands or another western 
country (14.9% versus 6.3%; p=0.008). More details about the distribution of sexual abuse 
can be found in Table 2 and Figure 2.




male                          
n(%)
total sexual abuse: 
53 (7.0)
40 (9.5) 13 (3.9) 
Age
≤39 years 9 (22.5) 1 (1.5)
40-49 years 9 (22.5) 2 (2.3)
50-59 years 7 (17.5) 0
60-69 years 9 (22.5) 4 (1.6)
70-79 years 3 (7.5) 5 (3.5)
80-89 years 3 (7.5) 1 (1.6)
Age ≥90 years 0 0
Country of origin 
female 
n(%)a   
male 
n(%)a
The Netherlands 32 (80) 10 (77.0)
Other West-European country 1 (2.5) 0
Turkey 0 0
Morocco 0 0
Surinam 2 (5.0) 0
Dutch Antilles 0 2 (15.4)
Elsewhere western 1 (2.5) 0
Elsewhere non-westernc 4 (10.0) 1 (7.7)
Total Western country 33 (82.5) 10 (76.9)
Total Non-Western country d 7 (17.5) 3 (23.1)
Based on data from n=752 respondents of which 421 women and 331 men (due to missing values)
Percentage of the total respondents with sexual abuse, by gender
Total exceeds 100% because multiple answers where possible 
Namely: Brazil, Colombia, Egypt (male victim), Indonesia, Iran and Russia.
Included: Morocco, Surinam, Dutch Antilles, elsewhere non-western
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figure 2. Indication for colonoscopy in patients with sexual abuse
* p= 0.006
Based on results for 53 patients, multiple answers were possible
Thirteen of 722 respondents indicated that a physician inquired about SA (1.8%), six were 
asked by the GP (0.8%) and three by the gastroenterologist (0.4%). Of the patients that 
reported SA (n=53), 24.5% had professional help to deal with the experience and 64.1% 
said to have found a way to cope with it. More than half of patients with SA believed the 
gastroenterologist should ask about it (53.8%). Of them (n=28), 35.7% said they would 
benefit from advice about dealing with the past, this option was marked significantly 
more often in male (80.0%) than in female patients (26.0%; p=0.023). To the question ‘Do 
you think gastroenterologists need to have more training on the subject sexual health?’ 
46.7% said ‘yes’, 25.1% said ‘no’ and the remaining 21.6% answered with ‘I do not know’. 
Of patients with SA, 24 (45.3%) indicated gastroenterologists should not ask about SA 
(n=24). One of the most common reasons for this answer was: ‘I am unable to talk about 
it’. Female patients gave this answer significantly more often than male patients (29.2% 
vs. 0% respectively, p=0.05), see Table 3. 
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table 3. Should gastroenterologists ask about sexual abuse? Answered by patients with a sexual 
abuse history
‘No, the GE should not ask about SA’
 n(%) 24 (45.3) a
If not, what is the reason you do not want to talk about it?b
I am ashamed of it 6 (25.0)
I do not believe the GE can help me with this problem 7 (29.1)
I am not able to talk about it 7 (29.1)
I am afraid to tell 5 (20.8)
It is not important for me anymore 7 (29.1)
It is too intimate to discuss 6 (25.0)
‘Yes, the GE should ask about SA’
n(%)
28 (52.8) a
If yes, ‘what should the GE do after you told him about the SA?’ b
Just listen to me 7 (25.0)
Give me some advise about dealing with it 10 (35.7)
Refer me to psychologist 6 (21.4)
Refer me to a sexologist 6 (21.4)
Refer me to a pelvic floor physiotherapist 3 (10.7)
Refrain from performing a colonoscopy 2 (7.1)
Give me some information to read about it 10  (35.7)
GE= gastroenterologist, SA= sexual abuse
a. Columns do not add to 53 because one patient with SA did not answer these questions 
b. Multiple answers were possible
Patients without SA experience (n=715) were asked to answer the question: ‘Do you think 
gastroenterologists should ask their patients about sexual abuse?’ 36% said ‘Yes’ and 64% 
said ‘No’. However, of all respondents (n=768), only 23.7% believed a question about 
SA in an intake questionnaire would be peculiar (n=182). No significant difference was 
seen between patients with and without a SA history concerning this question (22.4% 
resp. 24.7%; p=0.723). Of the respondents stating that a question about SA in an intake 
questionnaire would be peculiar, the reason for this answer was mostly because they 
did not see the relationship (56.0%) or the relevance (31.1%) of SA in the context. No 
significant differences were seen between male and female respondents concerning their 
answers to the above questions. 
Victims of SA noted significantly more sexual dysfunction (64.0%) compared to those 
without SA (24.4%; p<0.001), more micturition complaints (58.8% versus 30.9%; p <0.001) 
and a combination of both complaints (37.3 versus 11.4%; p<0.001).
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Significantly more patients with SA history indicated a change in bowel habit as the reason 
for colonoscopy (p=0.006) (Figure 2). Abdominal pain was significantly correlated to sexual 
abuse in men (r=0.572, p=0.031) and to a lesser extent in women (r=0.291, p=0.052). 
More than one GI-complaint was correlated with SA (r=0.1, p=0.006), as well as age under 
60 years (r=-0.108, p=0,003).
discomfort during colonoscopy
Patients were asked to rate discomfort experienced during their last colonoscopy 
on a 10-point Likert scale in which 0 meant ‘no discomfort’ and 10 meant ‘very much 
discomfort’. Patients with a sexual abuse history rated more discomfort (mean score 4.78 
±3.47) compared to non-abused subjects (mean score 3.54 ±3.11; p=0.007) (Figure 3). 
Using linear regression, we controlled for age, gender, ethnicity, indication(s) for 
colonoscopy, and time between the colonoscopy and filling in the questionnaire. Several 
factors were found to influence the distress. Age and abdominal pain were influencing 
factors (β=-0.019 (SE=0.008); p=0.02 respectively β=0.354 (SE=0.156); p=0.024) as well as 
the number of complaints presented (β=0.738 (SE=0.276); p=0.008) and country of origin 
(Table 4). After controlling for these factor, sexual abuse was still a significant predictor for 
distress during colonoscopy (β=0.991 (SE=0.466); p=0.034). Time between participation 
in the study and colonoscopy was not of influence (β=<0.001 (SE=0.022); p=0.914), see 
Table 4.
figure 3. Distress during colonoscopy in patient with and without sexual abuse
*=significant difference
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table 4. Distress experienced during colonoscopy
sexual abuse No sexual abuse
mean (±sd) total (n) mean (±sd) total (n) p-value
total 4.8(±3.47) 50a 3.5(±3.11) 684 0.007
male 5.0(±3.82) 11 3.2(±2.93) 311 0.052
female 4.7(±3.47) 39 3.8(±3.23) 371 0.102
Age≤60 years 4.8(±3.55) 32 3.8(±3.06) 288 0.082
Age> 60years 4.7(±3.41) 18 3.4(±3.13) 396 0.071
With abdominal pain 6.0(±3.48) 20 4.0(±3.48) 204 0.009
No abdominal pain 4.0(±3.26) 30 3.4(±2.99) 480 0.289
Western country 4.6(±3.50) 40 3.5 (±3.12) 631 0.048
Non-western country 5.7(±3.34) 10 3.6(±3.03) 53 0.053
sexual complaints 5.3(±3.38) 31 3.7(±3.18) 153 0.011
Of the respondents with SA three did not fill in the distress-score
Based on answers of 734 respondents, 34 respondents did not indicate distress during colonoscopy.
Patients with SA were asked to indicate which changes around and during colonoscopy 
would have made the procedure easier for them. Of 51 patients with a sexual abuse 
history that answered this question, a quarter (25.4%, n=13) said the procedure went well, 
however 88.3% (n=45) identified one or multiple options that would make the endoscopic 
procedure less uncomfortable, these options can be found in Figure 4. 
figure 4. Possible options to diminish distress during and around colonoscopy, answers of patients 
with a history of sexual abuse
Answers to the multiple choice/open question: “The colonoscopy experience would have been 
easier/more comfortable for me if…” 
Based on answers of 51 patients with sexual abuse experience.
In the free space provided, one patient said: only start about sexual abuse if it has to do with the 
complaints, and one said ‘not declare you as depressed’. 
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DISCuSSIoN
This cohort showed a SA prevalence of 3.9% in men and 9.5% in women. Many of the patients 
which experienced SA were born in a non-western country. Importantly, a SA history was 
associated with more discomfort during the colonoscopic procedure. Abdominal pain, multiple 
gastrointestinal complaints at presentation for colonoscopy and sexual dysfunction were 
associated with SA and more discomfort during the procedure. Most sexually abused patients 
indicated that gastroenterologists should ask about it before performing colonoscopy. Several 
minor adjustments where indicated as options to diminish distress during and beforehand of 
the procedure. 
The prevalence rates of SA in our population were comparable with those obtained in a 
survey among patients visiting a general urology practice in the Netherlands [19]. In studies 
assessing SA in selected samples of patients with (functional) gastrointestinal illness from 
referral gastroenterology clinics, up to 44% of women and 11% of men reported sexual abuse 
[20-23]. However, when the same questions about sexual abuse were posed in community 
samples, the reported prevalence rates of SA with physical contact (touching and penetration) 
were comparable to the rates found in present study [24;25]. Because we were restricted 
by the MEC the specific form of abuse experience could not be asked about, therefore the 
demarcated question: ‘Have you ever been a victim of sexual abuse?’ was used. Because this 
question implicates sexual abuse wíth contact, patients with less explicit forms of abuse such 
as exposure to exhibitionists or (verbal) sexual intimidation will not have felt addressed. This 
will have led to an underestimation of sexual abuse in our sample, together with the effects of 
selection and non response bias. 
To minimize potential biases we provided detailed assurances of confidentiality, pilot tested 
and refined the instrument and used balanced keying. Still, traumatized patients may have 
elected not to participate in the study to avoid reliving painful memories and non-respondents 
may have had no affinity with the subject or may have considered their participation irrelevant 
for the study. Some patients with SA may have refused colonoscopy and therefore did not 
receive the invitation to participate in the study. The initial response rate was no higher 
than 32.7% (768/2348), but in the first mailing (2348 patients) only the letter with study 
information was sent out. Patients were requested to send back the consent form in order to 
obtain a questionnaire or opt out of the study. This step must therefore be regarded as study 
recruitment; a part of this initial sample was not eligible due to changes in address, illness, 
memory loss or death. Therefore the eligible response rate of 54.1% (768/1419 respondents) 
should be used and considered representative [26]. 
An obvious limitation regarding the interpretation of discomfort experienced during 
colonoscopy is the absence of control for confounding variables such as length of the 
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procedure and the amount of additional sedation used. Due to restrictions imposed by the 
MEC, we could not link questionnaires with patient files and therefore were unable to obtain 
these data.
Furthermore, recall bias may have occurred. The validity of retrospective reports by adults of 
their own adverse experiences in childhood has been extensively studied; so called infantile 
amnesia, the effect of mood and false or recovered memory may all influence retrospective 
recall of traumatic experiences [27;28]. In response, methods for addressing the issues 
of reporting unreliability and recall bias in retrospective reports of child sexual abuse were 
explored. The influence of recall bias was found to be small, accounting for less than 1% of 
the reporting variance [29]. Moreover, longitudinal data have to rely on retrospective recall 
for measures of experiences since the last interview as well, which will often involve reporting 
over a period of several years. And because longitudinal data are very expensive to collect, the 
discussion about methodology ended with the conclusion that retrospective reports about 
childhood abuse have a worthwhile place in research until better methods are found [30].
In spite of these limitations, this was the first study obtaining an inventory of SA in colonoscopy 
patients, identifying their needs regarding the colonoscopic procedure and comparing 
experienced discomfort during colonoscopy between patients with and without SA. Our results 
were consistent with prior research showing that female patients with a history of SA reported 
more discomfort and anxiety during gynecological examination [12;31-33]. And confirmed the 
link between sexual abuse, abdominal pain and multiple GI-complaints already found in the 
early nineties by Drossman et al. which has been verified in many studies afterwards [6;34;35]. 
The reason a history of SA results in more pain during pelvic examinations may be explained by 
a variety of neural and humoral pathways that link brain, pelvic floor and gut [36]. Alterations 
in psychopathological and cortico-limbic pain modulatory systems have been described as 
mediating mechanisms for the association between SA and gastrointestinal disorders [7]. 
In addition, anxiety and trauma, especially SA, are significantly associated with dysfunction 
of the pelvic floor [37], leading to FGID [37;38], dyspareunia [39], dysfunctional voiding [40] 
and chronic pelvic pain [41]. In patients with IBS and a history of SA significantly more pain 
was reported to aversive rectal distention (similar to colonoscopy) compared with patients 
with IBS or abuse alone. Patients with IBS and SA reported higher pain scores and greater 
anterior mid cingulate activation with rectal distention than patients with either IBS or SA [42]. 
It is therefore remarkable that, however significant, the differences in mean distress scores 
found between patients with and without SA where rather mild (3.5 versus 4.8). This could 
be due to the fact that anxiety, depression and post-traumatic stress disorders play a major 
part in both perception of pain and symptoms as well [43]. A recent study using in-person 
interviews among gastroenterologists and endoscopy nurses to obtain information regarding 
development of psychological and/or physical symptoms after gastrointestinal endoscopy, 
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fourteen of the 29 gastroenterologists (48%, 95% CI = 30.7–66.2%) reported encountering 
patients with new onset psychological symptoms lasting for more than a month after upper 
endoscopy or colonoscopy. A history of psychiatric illness was noted in 11 of 19 patients (58%) 
and a history of sexual abuse was noted in five of 19 patients (26%). Physicians reported that 
the endoscopic procedure was longer or more difficult than usual in six of 19 patients and that 
four of 19 patients had requested to prematurely terminate the procedure [44]. Our study 
specifically focused on SA in relation to distress experienced during colonoscopy. Patients with 
psychological problems, but without a SA history may have caused the diluted difference in 
discomfort between patients with and without SA. 
Given the mounting evidence of the long-term detrimental effects of SA, especially as 
regards to gastrointestinal complaints [37], routine inquiry about SA in the gastroenterology 
practice might be expected. However, only 1.8% of the responding patients reported their 
gastroenterologist asked about ‘negative sexual experiences’ or abuse during consultation. 
Accordingly, a recent study among gastroenterologists showed that 2.5% of them asked female 
patients and 0.6% asked male patients about SA before performing colonoscopy. However, the 
majority of gastroenterologists’ rated it as important to pay more attention to SA during their 
training [16]. 
From a patients’ perspective, in the present study we found that three-quarters of the patients 
would not find it peculiar if a question about SA would be asked in an intake questionnaire 
beforehand of the colonoscopy. On the contrary, a third of respondents without SA believed the 
gastroenterologist should ask about it, and of the patients with SA experience, more than half 
believed so. More inquiry about SA may result in a better understanding between physician and 
patient, which is known to be the most important aspect of the pelvic examination experience 
for women [45]. If the endoscopist is informed about patients’ traumas, compassionate and 
individualized care around and during the endoscopic procedure might diminish its impact. 
This study indicated that offering options such as use of a chaperone, deeper sedation and/or 
clear communication about the steps taken during the procedure may decrease discomfort, 
helping the patients to undergo the examination. Offering extra attention to patients with 
a history of sexual abuse may limit avoidance of transanal endoscopic procedures and may 
improve cooperation during procedures and therapy.
In conclusion, the results of this study have several implications for clinical practice. At 
least a tenth of women and up to four percent of men undergoing colonoscopy indicated 
experiencing SA. Colonoscopy was shown to be more distressing for patients with a history of 
SA. Consequently, especially in the gastroenterology practice this subject deserves attention. 
Discussing SA in medical practice seems difficult for both physician and patient. This study 
indicates that the use of a standardized intake questionnaire including questions about SA 
could be a solution to this problem.
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PArt i   CArdiOLOGy & CAre fOr sexuAL heALth
the cardiologist
Chapter 2 
Discussing sexual function in the cardiology practice
Background: In patients with cardiovascular disease, sexual dysfunction is frequently 
encountered. Erectile dysfunction shares the same modifiable risk factors as coronary 
artery disease and the fear of triggering cardiovascular events can create stress and 
anxiety impacting the sexual lives of patients and their partners. To optimize health care, 
knowledge of cardiologists’ attitude and practice patterns regarding the discussion about 
sexual function is essential. 
methods: A 31-itemed anonymous questionnaire was mailed to 980 members of the 
Netherlands Society of Cardiology (cardiologists and residents in cardiology training). 
The questionnaire addressed awareness, knowledge and practice patterns about sexual 
dysfunction in cardiac patients. 
results: 53.9%  of the cardiologists responded. Sixteen percent stated to discuss sexual 
function regularly. In the past year, an estimated mean of 2% of patients was referred for 
help with a sexual problem. The majority (70%) of cardiologists advised patients never 
or seldom about resuming sexual activity after myocardial infarction. PDE5-inhibitor use 
was assessed by 19.4% of the cardiologists. Important reasons for not discussing sexual 
function were lack of initiative of the patient (54%), time constraints (43%) and lack of 
training on dealing with SD (35%). 63% of the cardiologists stated they would be helped 
with a directory of sexual health care professionals where they can refer patients to. 
Conclusion: Sexuality is not routinely discussed in the cardiology practice. Explanations 
for the lack of attention towards sexual matters are ambiguities about responsibility and 
a lack of time, training and experience regarding the communication and treatment of 
sexual dysfunction.  
Chapter 3
what do cardiologists know about the effects of cardiovascular drugs on sexual function? 
Background: Several cardiovascular agents, such as diuretics and β-blockers, can negatively 
affect sexual function, leading to noncompliance with therapy. Others such as angiotensin 
II receptor blockers (ARBs) can improve patients’ sexual function (SF). 
For this chapter we aimed to gain insight into cardiologists’ knowledge about the effects 




methods: An anonymous questionnaire was mailed to 980 members of the Netherlands 
Society of Cardiologists (cardiologists and residents in training). 
results: Almost 54% of Dutch cardiologists responded; 414 questionnaires were analysed. 
45% of cardiologists was aware diuretics can negatively affect sexual function, 93.1% knew 
about the negative effects β-blockers can have, but only 9.2% was aware ARBs can have 
positive effects on sexual health. Almost half of respondents (48.2%) stated to change 
medication regularly in attempt to improve sexual function. Experienced cardiologists said 
to do this significantly more often than less experienced ones. 
Conclusion: Cardiologists’ knowledge about the effects of cardiovascular drugs on sexual 
health appears to be insufficient. Sexual dysfunction is not routinely taken into account 
when cardiologists prescribe drugs.
Chapter 4 
A review of the positive and negative effects of cardiovascular drugs on sexual function:
A proposed table for use in clinical practice
Several antihypertensive drugs, such as diuretics and β-blockers, can negatively affect 
sexual function, leading to diminished quality of life and often to noncompliance with 
the therapy. Other drug classes, however, such as angiotensin II receptor blockers 
(ARBs) are able to improve patients’ sexual function. Sufficient knowledge about effects 
of these widely used antihypertensive drugs will make it possible for cardiologists and 
general practitioners to preserve and even improve patients’ sexual health by switching 
to different classes of cardiac medication. Nevertheless, previous data (chapter 2) indicate 
that most cardiologists lack the knowledge about the effects cardiovascular agents can 
have on sexual function and will thus not be able to provide the necessary holistic patient 
care with regard to prescribing these drugs.
To be able to improve health care on this point, we aimed to provide a practical overview, 
for use by cardiologists as well as other health care professionals dealing with sexual 
dysfunction in their clinical practices.  Therefore, a systematic review of the literature 
was performed. The eight most widely used classes of antihypertensive drugs have been 
categorized in a clear table, marking whether they have a positive, negative or no effect 




Erectile dysfunction in the cardiology practice
Background: Erectile dysfunction (ED) is an independent risk factor for cardiovascular 
events sharing mutual risk factors with coronary artery disease. Several guidelines for 
the management of ED in cardiovascular disease have been proposed, recommending 
cardiologists to routinely inquire about erectile function. However, males’ specific needs 
and wishes regarding sexual healthcare in cardiology are unknown. We sought to identify 
male patients’ view concerning possible improvements in sexual healthcare and preferred 
forms of sexual counseling in the cardiology practice. 
methods: Cross-sectional multicentered survey study among at random selected males 
visiting a cardiologist. 
results: Of 388 respondents, 296 questionnaires were eligible for analysis. Mean age of 
respondents was 62.9 years. Overall 56% (n=165) had ED, with up to 86% in patients with 
heart failure. Mean bother experienced due to ED was 5.93 (±2.57) on a 0 to 10 scale. Most 
respondents indicated to feel comfortable discussing sexual health with the cardiologists 
(88%). Of men with ED (n=165), 46% would like to have a conversation with the cardiologist 
about possibilities to improve sexual function, 55% would be helped if questions could 
be asked during consultation with a specialized nurse and 58% would appreciate written 
information. Of all respondents (n=296) 28% ever tried a phosphodiesterase inhibitor, 4% 
received the prescription of the cardiologists.
Conclusion: ED is highly prevalent in patients with a variety of cardiovascular diagnosis 
and care for sexual function is mandatory. Patients indicated that above consultation with 
the cardiologist both consultation with a specialized nurse and written information would 
be helpful.
Chapter 6
Cardiovascular disease and female sexual dysfunction
Background: Cardiovascular disease (CVD) greatly impacts physical and psychological 
wellbeing and influence patients’ sexual life. Guidelines for sexual counseling in cardiology 
were published, but women’s needs regarding sexual health care in cardiology have 
not yet been evaluated. Aim of this chapter was to assess women’s needs and wishes 
concerning sexual health care in cardiology.
methods: Cross-sectional multicentered survey was assessed among 725 randomly 
selected women visiting a cardiologist. 
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results: Of 329 responding women, 163 questionnaires were eligible for analysis (mean 
age 60.1). 35% indicated to have sexual complaints, 5% would like treatment for it. Options 
for sexual health care in the cardiology practice were proposed, of all respondents 6% 
would appreciate consultation with the cardiologist regarding sexual function, 18% would 
value consultation with a nurse and 16% valued written information. Using the female 
sexual function index-score (FSFI), 62% of sexual active women (n=104) had female 
sexual dysfunction (FSD). Hypertensives more often than normotensives (r=0.20, p=0.04). 
β-blocker-use was correlated with sexual dissatisfaction (r=-0.23, p=0.02) and number 
of cardiovascular agents used was a predictor for lower FSFI-scores (β=1.47 (SE 4.31); 
p=0.001) per added agent and was related to treatment wish for FSD (linear-by-linear 
association, p=0.009). 
Conclusion: Sexual complaints and FSD are prevalent in women with CVD, therefore 
attention for sexual health in the cardiology practice is most apposite. However, 
consultation with a cardiologist is not necessarily required; availability of written 
information and possibility to discuss sexual issues with a nurse would be time and cost-
effective options.
PArT II    GASTroENTEroloGy & SExuAl TrAuMA
the gastroenterologist
Chapter 7
Sexual abuse history in gastrointestinal illness, how do gastroenterologists deal with it?
Background: Data show increased prevalence rates of sexual abuse among patients 
with gastrointestinal complaints. Sexual abuse causes multiple symptoms related to 
pelvic floor and stress mediated brain-gut dysfunctions. Treating patients with a history 
of sexual abuse asks for a holistic approach, using centrally targeted interventions. 
However, data about gastroenterologists practice patterns regarding care for victims of 
sexual trauma are not available. 
In this chapter we aimed to evaluate whether gastroenterologists address sexual abuse 
in their daily practice and to assess their knowledge regarding the implications of sexual 
abuse in gastrointestinal disease.  
methods: A 42-itemed anonymous questionnaire was mailed to all 402 members of 
the Dutch Society of Gastroenterology (gastroenterologists and fellows in training). The 
questionnaire addressed sexual abuse and pelvic-floor-related complaints. 
results: 183 of the 402 (45.2 %) questionnaires were returned. Overall 4.7% of the 
respondents asked their female patients regularly about sexual abuse; in males this 
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percentage was 0.6%. Before performing a colonoscopy, these percentages were even 
smaller (2.4% and 0.6% respectively). When patients presented with specific complaints, 
such as chronic abdominal pain or fecal incontinence, 68% of the gastroenterologists 
asked females about SA and 29% of the males (p<0.001). The majority of respondents 
stated it rather important to receive more training in how to inquire about sexual abuse 
and about the implications for treatment. 
Conclusion: Gastroenterologists do not routinely inquire about sexual abuse and they 
rarely ask about it before performing colonoscopy. There is a need for training to acquire 
the skills and knowledge to be able to deal with patients with a history of sexual abuse. 
The gastroenterology patient
Chapter 8
The impact of sexual abuse in patients undergoing colonoscopy
Background: Sexual abuse has been linked to strong effects on gastrointestinal health. 
Colonoscopy can provoke intense emotional reactions in patients with a sexual abuse 
history and may lead to avoidance of endoscopic procedures. 
Objective of this chapter was to determine whether care around colonoscopy needs 
adjustment for patients with sexual abuse experience, thereby exploring targets for the 
improvement of care around colonoscopic procedures. 
methods: Questionnaires were mailed to patients (n=1419) from two centers within 
11 months after colonoscopy. Differences in experience of the colonoscopy between 
patients with and without a sexual abuse history were assessed and patients’ views 
regarding physicians’ inquiry about sexual abuse and care around endoscopic procedures 
were obtained. 
results: A total of 768 questionnaires were analyzed. The prevalence of sexual abuse 
was 3.9% in male and 9.5% in female patients. Patients born in a non-western country 
reported more sexual abuse (14.9%) than those born in a western country (6.3%; 
p=0.008). Discomfort during colonoscopy was indicated on a scale from 0 to 10, mean 
distress score of patients with sexual abuse was 4.8(±3.47) compared to 3.5(±3.11) in 
patients without a sexual abuse history (p=0.007). Abdominal pain was a predictor for 
higher distress during colonoscopy (β=-0.019 (SE=0.008); p=0.02, as well as the number 
of complaints indicated as reason for colonoscopy (β=0.738 (SE=0.276); p=0.008). Of 
patients with sexual abuse experience, 53.8% believed gastroenterologists should ask 
about it, 43.4% said deeper sedation during colonoscopy would diminish the distress. 
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Conclusion: Sexual abuse is prevalent in patients presenting for colonoscopy. Patients 
with a sexual abuse history experience more distress during the procedure and indicate 







The main purpose of this thesis was to evaluate how medical specialists communicate with 
regards to sexual health and sexual dysfunctions, and to provide evidence for patients’ 
needs regarding care for sexual health in specialized medical practice.
CoMMuNICATIoN 
In 1962 Joshua Golden, one of the first sexual investigators, wrote: “The basic problem 
in managing sexual conflicts has two aspects; those problems which the patient brings, 
and those which the physician brings. […] the personal feelings of the doctor influence 
his ability to communicate with his patients about sexual matters, this involves not only 
matters of information, but the skill required in communicating effectively with patients 
about anxiety-laden topics”(1).
Since the late sixties, more and more literature pointed to the impact of sexual abuse and 
sexual dysfunction on quality of life. The first guidelines were presented in the seventies 
(2-4). 
In spite of all the attention sexual health and sexual function has received in research and 
the media in the past fifty years, this thesis shows that at this time, in 2014, physicians 
ways of dealing with sexual dysfunction or care for sexual health did not change much.
While open-mindedness, liberty of speech and straightforwardness have become 
respected Dutch values, yet taboos exist when it comes to the topics sexual abuse (5), 
sexual dysfunction and sexuality in the ill and the elderly (6;7). Chapter 2, chapter 4 and 
chapter 7 of this thesis indicated that medical specialists still have trouble discussing 
subjects related to sexuality. Even though they acknowledge their importance, various 
motives keep them from asking patients about sexual function or about traumatic sexual 
experiences. One of the main reasons is the perceived inability to deal with these matters 
once expressed, the same problem that was already pointed out by Joshua Golden in 
1962... 
SExuAl hEAlTh IN SECoND AND ThIrDlINE hEAlThCArE
PArt i
Part I of this thesis identified that communication about sexual dysfunction and sexual side 
effects of medication is not yet routine in the cardiology practice, even though guidelines 
and reviews have been showing its necessity and purpose.
z
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Care for sexual health, from cardiologists’ perspective
One does not need a lot imagination to picture a fifty year old, decent, male cardiologist 
sitting behind his desk, trying to convince a sixty year old male patient to use his beta-
blocker. The cardiologist tries to stay patient while explaining the importance of the beta-
blocker use once again, but a full waiting room awaits him. 
Is it surprising this cardiologist does not start about the effects the beta-blocker may have 
on erectile function? Probably not, because next to the lack of time, the cardiologist is not 
trained to discuss sexual function or counsel about sexual health. Moreover, the patient 
did not start about erectile dysfunction, so why would he? 
On the other side of the desk, the patient indeed did not take his beta-blocker because it 
diminishes and weakens his erections. He and his wife still enjoy their sexual relationship 
and the ability to have good erections makes him feel young and virile. The patient already 
knows that he needs to take the beta-blocker to reduce his blood pressure and the risk of 
cardiovascular events, but he feels great at the moment and the benefits of the medication 
are more on the long term and therefore intangible to him.
This example may be exaggerated but many physicians reading it may recognize the 
hesitation and natural resistance to start about this sensitive topic which may lead to 
uncomfortable conversations or takes a lot of time. Everyone that has ever visited a 
doctor may recognize the feeling that several questions are still unanswered when leaving 
the doctors’ office. In fact, you may have wished the doctor would have given you more 
reassurance or you may have felt that half of your questions remained unanswered. 
With a helicopter view it is obvious to see that the reason for this patients’ non-adherence 
with therapy is the effect of the beta-blocker on the erectile function. The consultation 
would have taken less time if the cardiologist would routinely ask about sexual function 
after prescribing a beta-blocker. Or if the patient would have been informed by the 
cardiologist, a nurse, the apothecary or an information leaflet that erectile dysfunction 
may occur with beta-blocker use. 
It is well known that adherence with antihypertensive therapy is dependent on sufficient 
information about side effects (8). It was shown that prescribing sildenafil for ED resulted 
in significant improvements in adherence rates (from 48% to 66%) with antihypertensive 
therapy (9;10). A better solution would be of course, if the physician would try to reduce 
the side effects by switching to other agents (chapter 3).
Training is needed to make the cardiologist more comfortable with raising the subject of 
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sexual health and to make them familiar with treatment and referral options (chapter 2 
and chapter 4). 
Sexual healthcare in cardiology, from cardiac patients’ perspective 
The male patient 
Chapter 5 made apparent that ED was prevalent among the vast majority of male cardiac 
patients, compared to those without a cardiac diagnose. Of those with ED, most were 
bothered by it and half would have liked to discuss possible treatment options with the 
cardiologist.
ED has been shown to be a very common problem among men with cardiovascular 
disease. Next to the fact that it might be a result of insecurity about the cardiac condition 
or induced by the antihypertensive agents used. It is therefore impossible for cardiologists 
to avoid paying attention to male sexual healthcare.
On the other side, patients need to be educated and helped to lose prejudices which keep 
them from asking questions about sexual health. It should feel natural for cardiologists 
and their male patients to discuss ED, since it can significantly impact patients’ and 
their partners’ quality of life, reduce their adherence with therapy and cause relational 
problems, while ED easily can be reduced or resolved.
The female patient 
Most of the women studied in chapter 6 of this thesis, were 60 years or older and therefore 
postmenopausal. The low response rate for the study was already an indication for the 
reservations women in this age category have towards sexuality.
The survey results however, showed a prevalence of FSD almost as high as ED in the male 
cohort. But the women clearly appointed less importance to sexual function compared to 
men in the same age category. Most women with sexual dysfunction were not interested 
in treatment for SD. 
This may be explained by the fact that aging (postmenopausal) women devaluate their 
expectations regarding sex, or do not attach great importance to the sexual side effects of 
their medication  (11). 
Another explanation may be the lack of knowledge about female sexual function. 
For men, treatment for ED was found in the form of PDE-5 inhibitors. The discovery and 
release of Viagra in 1998 has led to a steady cash flow for pharmaceutical companies. 
Advertisement for the different erection potentiating agents is abundantly present in all 
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kinds of media. This may surely have diminished the embarrassment for men to talk about 
ED. And, because knowledge about ED has been spread for promotional purposes, most 
men now know there is hope for improvement of erectile function, which may be good 
reason to wish to speak to the doctor about it. 
On the other hand, the search for female-desire drugs has been a fixation of the 
pharmaceutical industry for more than a decade as well, largely because the popularity 
of PDE-5 inhibitors have shown that gigantic sums of money can be made with a quick 
chemical solution to sexual dysfunction.
Viagra and its competitors deal with the ‘simple’ mechanism of ED, which is the most 
troubling difficulty for men. But the psychological complexity of hyposexual desire 
disorder, the most common cause for FSD, has as yet defeated industry giants.
It is also important to note that Viagra isn’t entirely without influence on the mental state 
of desire. The mechanics of the body and the mysteries of the mind are intertwined. 
When a man has an erection, his sensitized nerves and enhanced feelings of power have a 
positive feedback on his drive (12). Research has shown, that women are less cognizant of 
genital arousal, and probably for this reason, Viagra-like substances haven’t done enough 
to raise women’s ratings of desire in past experiments. For women, agents need to be 
added to more directly target the brain (13). The desire pill for women (Lybrido©), which 
has recently been in the news, combines PDE5-inhibitors with testosterone and showed 
an increase in desire and in rates of orgasm in preliminary trials (14;15). However, the 
Food and Drugs Administration (FDA) has to approve of larger randomized trials, before 
this medication has a change to reach the market. If that happens, providing a quick and 
easy solution for women to improve their sexual function, they may start wishing for more 
sexual healthcare in the cardiology practice as well. 
Until then, the recommendation for female sexual healthcare in the cardiology practice 
as can be inferred from this thesis is as follows: women with cardiovascular disease 
appreciate the availability of information and options for sexual healthcare. However, the 
initiative to start about sexual health in cardiology should be left with the female patients 
themselves (see chapter 6). 
The other recommendations for improvements of sexual healthcare in cardiology as can 
be deduced from the data in part i were summarized and presented in Figure 1.
Future studies are mandatory to assess the effects of these adjustments on patients’ 
satisfaction with the provided care and to assess improvements in quality of life.
figure 1. Proposed adjustments for the cardiology practice to improve sexual healthcare for patients 
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with cardiovascular disease 
Sexual activity is contraindicated in patients with unstable or decompensated heart disease (i.e. 
unstable angina, decompensated heart failure, uncontrolled arrhythmia or significantly symptomatic 
and/or severe valvular disease), sexual activity should be deferred until the patient is stabilized and 
optimally managed(16).  
*PDE-5 inhibitors are contraindicated in combination with use of organic nitrates 
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PArt ii
Care for sexual abuse in gastroenterology, from gastroenterologists’ perspective
In recent years, the scientific community has been paying attention to the relation 
between lifetime sexual abuse to gastrointestinal complaints. The prevalence of sexual 
abuse is higher in patients with gastrointestinal symptoms (17-20).
Chapter 7 of this thesis however, indicated that inquiring about sexual abuse is not yet 
routine in the Dutch Gastroenterology practice. 
Training and a standard question(naire) to improve care 
Our data pointed to the importance of training for residents and gastroenterologist to 
obtain the necessary knowledge about sexual abuse and its effects on gastrointestinal 
symptoms. Furthermore, a standard question about sexual abuse before performing 
endoscopy (chapter 8) would be a simple, but effective improvement of care. 
Research indicated that, even if sexual abused women do not confirm the abuse in the 
first instance, physicians’ routinely asked questions about it may evoke the idea that 
discussion about it is possible (21). Beforehand of asking about abuse it is important for 
the physician to explain that gastrointestinal symptoms can be related to experiences of 
sexual abuse in the past. This may help the patient to relate his or her history and once the 
sexual abuse is entrusted to the physician, it is much easier to place the patients’ sickness 
behavior and health-problems in the right context.
Clinical guidelines for care around colonoscopy in patients with a sexual trauma should 
become available to enable gastroenterologists to offer patient centered care and 
diminish distress for these patients as much as possible during trans anal procedures. In 
that respect questions about earlier traumatic abuse may save time, frustration, money 
and energy, instead of causing extra diagnostic procedures, unnecessary operations, 
doctor-shopping and greater health costs (22).
Special treatment needs for patients with a sexual abuse history
Next to the treatment of the physical components of the complaints of these patients, 
the gastroenterologist should be aware that referral to a mental health consultant is 
often desirable for patients with sexual abuse experience. Childhood sexual abuse can 
lead to a wide range of psychiatric illnesses, as posttraumatic stress disorder (PTSS), 
anxiety disorders, dissociative disorders, substances abuse, conversion and somatization 
disorders, (borderline) personality disorders and psychosis (23;24). Other psychiatric 
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consequences are suicidal thoughts, auto mutilation, emotional instability, aggression, 
delinquent behavior, negative self-image, feelings of guilt and despair, sexual dysfunction 
(as seen in chapter 8), anxiety attacks, sleeping disorders, distrust, relational problems 
and loneliness (25;26). 
Most victims of abuse react neutral or relieved to questions about sexual abuse, only 
in a minority it was described to increase the complaints (23). The fear that many healthcare 
providers have, that asking about abuse would lead to more disturbances, is not grounded (27).
Inquiry into abuse is important for both men and women (see the subheading ‘gender’ 
on page 172) and in every age category, not in the least in the elderly. For even decades 
after the sexual abuse, it can still hugely impact mental en physical health of its victims. 
Many elderly patients may have early experiences which may be partly dealt with or were 
successfully repressed. In later age posttraumatic complaints can exaggerate and even 
start after decennia in which the patients thought the trauma was processed (27). In Table 
1 factors suggesting a history of abuse are displayed (28).
It may be difficult to address the psychological difficulties patients have, coping with 
chronic pain and illness because that can be intimidating for the non-psychiatric physician. 
But the physician need to emphasize that improvement in psychological distress can 
increase tolerance of pain and provide better adjustment to medical illness. 
Several forms of psychotherapy are proven to be helpful (29), but because of shame 
or inability to deal with the generated emotions, the patient may be reluctant to see a 
mental health consultant. In this situation the physician must accept the patient’s wishes’ 
continue in care and suggest that the topic can always be discussed another time. In any 
case it is important the gastroenterologist maintains continuity in care, referral to a mental 
health professional should always exist next to treatment of the physical complaints (28). 
The mental health consultant can identify psychological co-morbid conditions, confirm 
sexual abuse history and decide on psychopharmacologic treatment. If needed, the mental 
health consultant can either personally initiate or implement referral for psychological 
treatment along with medical care. 
From the results described in chapter 7 and 8, several effective and easy applicable 
recommendations for adjustments in care for patients with sexual trauma in 
gastroenterology could be deduced. These recommendations are presented in the form 
of a flow charts (Figure 2, page 170). Future implementation studies should be conducted 
to evaluate whether these options are effective and if they improve treatment and 
outcomes of patients with a sexual abuse history in the gastroenterology practice.
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table 1. Factors associated with a history of abuse
Psychological issues
Difficulties in establishing trust
Difficulties perceiving a sense of control over the illness and life events
Feelings of helplessness and dependency
Feelings of vulnerability, shame and guilt
Gastrointestinal and other medical disorders
Chronic pain (including functional abdominal pain syndrome)
Severe constipation (slow transit constipation, and pelvic floor dyssynergia)
Chronic pelvic pain 
Narcotic bowel syndrome
Eating disorders (bulimia nervosa, anorexia nervosa, rumination)
Unexplained vomiting
Morbid obesity
Multiple functional GI and functional somatic conditions
Psychiatric disorders
Somatoform disorders (somatization, conversion, hypochandiasis, pain)
Dissociation disorders including multiple-personality disorder
Personality disorders (borderline personality disorder, histrionic personality disorder)
Eating disorders (bulimia nervosa, anorexia nervosa, rumination)
Anxiety disorders (post-traumatic stress disorder, obsessive-compulsive disorder)
Severe depression and panic disorder
Illness-related behaviors
Disability disproportionate to the clinical data
Attempts to validate disease and denial that psychological factors may play a role
Placement of responsibility for healthcare with physician
Avoidance of health-promoting behaviors
Marked anxiety and difficulties with procedures (rectal or vaginal examination, endoscopy)
Borderline behaviors (intense attachments, ‘splitting’ difficulty in dealing with uncertainties, 
demanding behaviour)
Unwanted outcomes
Multiple diagnostic procedures, treatments and surgeries
Substance abuse (alcohol, medications, illegal drugs)
Disability and litigation seeking
Frequent and excessive use of medical care services
Source: Drossman et al. Ann Intern Med. 1995;123(10):782-794. 
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figure 2. Proposal for the improvement of care for patients with sexual abuse in the gastroenterology 
practice 
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health care for sexual abuse in gastroenterology, from patients’ perspective
The patient-physician relation can be significantly improved if openness about sensitive 
topics such as sexual abuse can be created (30;31). Results of chapter 8 showed that most 
patients with a history of sexual abuse would appreciate the gastroenterologists asking 
about it. Gender was not of influence. In both male and female patients the prevalence 
of sexual abuse was significant. As was already explained these figures were likely an 
underestimation due to the demarked question used for the identification of sexual 
abuse, by means of which mild to moderate abuse forms such as fondling or exposure to 
exhibitionists were implicitly excluded. In addition, we presumably missed many patients 
from non-Western countries, due to cultural and linguistic barriers. 
The association of abuse and gastrointestinal disease
Chapter 8 showed that abdominal pain was related to a history of sexual abuse and with 
more distress during colonoscopy. This was a finding we expected, while multiple studies 
have indicated the association between gastrointestinal illnesses, pain and sexual abuse 
(32-34). Furthermore, epidemiological studies have suggested a link between a history of 
abuse and a diagnosis of more severe irritable bowel syndrome (IBS) (18;28;32). And, patients 
with a history of abuse have more severe illness and poorer health outcomes (32). 
Several possible mechanisms have been suggested to explain these associations (35): 
A history of sexual abuse may have a sensitizing peripheral effect that contributes to 
heightened visceral sensitivity (peripheral disordered visceral function);
Sexual abuse may have a centrally mediated effect on modulation of the conscious 
perception of visceral signals and/or altered affective or behavioral responses to afferent 
visceral signals, thus leading to more severe symptoms and adverse clinical outcome. 
One study looked at the effect of a history of abuse on visceral, rectal sensation in patients 
with IBS. It was examined whether reduced pain thresholds in patients with IBS were 
related to psychological factors and/or prior history of sexual abuse. They found that 
higher pain sensitivity in IBS patients correlated with psychological factors (that is, anxiety 
and somatization). However, sexual abuse was not found to be associated with lower pain 
thresholds (36). Support for a possible central modulating role of sexual abuse on affective 
and behavioral responses came from studies using brain imaging techniques. These 
studies have shown morphological (decreased hippocampal mass)(37;38) and functional 
(reduced activation of anterior cingulate cortex)(39) abnormalities in subjects with sexual 
abuse history. Using PET and fMRI it was shown that a history of abuse modulates the 
anterior cingulate cortex activation, a region involved in the motivational and affective 
reactions to painful stimulation (40-42). These alterations in cingulate cortex activity were 
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associated with pain reports and correlated with psychosocial distress (43).
In summary, the fact that sexual abuse leads to more illness behavior and abdominal pain 
is not only caused by psychological factors and coping strategies but as well by stress-
induced changes in the hippocampus and cortex.
Gender
in chapter 8 it was found that sexual abuse was more prevalent among female than male 
patients. This is in concordance with the literature, sexual abuse has always been more 
prevalent in women, however childhood sexual abuse of boys have come to the surface 
more often in the past years, for example in the catholic church (44). 
In our sample, no differences were seen between male and female sexual abuse victims 
regarding the distress scores and physical complaints. This may indicate that men and 
women respond to sexual abuse in a similar fashion, however, gender differences 
regarding this response has never been studied. Virtually all research studying the effects 
of sexual abuse were conducted among female patients, leaving the effects of sexual 
abuse on men a significant understudied subject. To be able to further adjust patient-
centered healthcare for sexual abuse victims in the gastroenterology practice, studies 
exploring the effects of abuse in men needs to be conducted. 
While currently all evidence about the impact of sexual abuse in gastrointestinal disease 
was collected in female patients, it is comprehensible that gastroenterologists paid more 
attention to sexual abuse in women than in men (chapter 7). 
rolE for ThE GENErAl PrACTITIoNEr IN CArE for SExuAl 
fuNCTIoN AND SExuAl ABuSE
The results found in both parts of this thesis can be extrapolated to other medical workers. 
Especially the general practitioner is important in this context. 
In the Netherlands, the general practitioner (GP) can play a crucial role in sexual 
healthcare. The GP is the gatekeeper and manager of patient’s health and receives all 
correspondence from patient consultations with the medical specialist. Furthermore, the 
GP often provides the patients with (repeated) prescriptions for medication prescribed 
by a medical specialist. Ideally, patients have a good relationship with their GP, he or 
she could be easier to approach than the medical specialist. Patients and GP should be 
familiar with one another. 
If this, rather old fashioned situation, is the case the GP would be a much better place 
for patients to talk about and receive treatment for sexual dysfunction, to ask questions 
regarding sexual health or to talk about abuse experiences. 
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Older studies among GP’s and their patients, however, showed that even in this type of 
general practice, patients find it difficult to talk about sex and sexual abuse experiences 
(45-47). And, GP’s do not usually tend to ask about sexual dysfunction or a possible story 
of abuse (48;49).
In the modern form of Dutch general practices, patients do not ‘have’ their own GP 
anymore. Patients visit a healthcare center in which several GP’s work together and mostly 
are not available during every day of the week. In this situation, the lack of continuity in 
care from the ‘personal’ GP may be another barrier for patients to bring up the topics sex 
and/or sexual abuse. Research should be conducted to identify if this new form of general 
practice changed the attention for sexual health and whether this is an extra barrier for 
patients to reveal abuse experiences.
Lastly, it needs to be noted that in recent years several sexual assault centers where 
opened in the US and in Europe to provide multidisciplinary care for men and women who 
experienced sexual abuse, for example rape. These centers enable provision of medical, 
forensic and physiological support and follow-up care (50). Since 2012 sexual assault 
centers were opened in Utrecht and in Nijmegen. Both GP’s and medical specialists should 
be aware of the availability of these centres for the referral of patients reporting recent or 
ongoing sexual abuse. In addition, while sexual abuse regrettably is such a common social 
problem, availability of only two centres for sexual assault victims is rather scarce. Centers 
should be initiated in every large city in the Netherlands.   
final remarks
It seems strange that in this modern western society where freedom is everything and 
taboos seem to have disappeared, discussing sexual matters with a physician still seems 
to be difficult. 
Sex is, next to the origin of human life, an important component for quality of life. 
Problems in sexual health, such as sexual dysfunction or sexual victimization, highly affect 
people’s lives and their relationships. It therefor deserves much more attention in medical 
healthcare. 
With the use of internet, patients have become better informed and more demanding. 
A different type of health care -patient centered health care- is becoming the standard. 
To adequately provide this patient centered healthcare, sexual health has to be given the 
necessary attention. And attention for sexual abuse has to be incorporated in (specialized) 
medical healthcare. We may still have a long way to go, but the results of this thesis may 
be a next step toward this transition.   
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Bij patiënten met cardiovasculaire ziekten en na cardiovasculaire events kunnen zowel 
de fysieke en psychische aspecten van de aandoening, als de ziekte en de bijbehorende 
medicatie grote invloed hebben op het seksuele functioneren (1). Seksualiteit is een 
belangrijke determinant voor kwaliteit van leven. Met de huidige levensverwachting is 
het behoud van de seksuele relatie, ook op hogere leeftijd belangrijk geworden (2). 
Erectiele disfunctie en cardiovasculaire ziekten hebben gezamenlijke risicofactoren 
zoals hypertensie, diabetes, metabool syndroom en arteriosclerose. Aanwezigheid 
van erectiele disfunctie (ED) is een krachtige voorspeller gebleken voor myocardinfarct 
(MI), cerebrovasculaire events en mortaliteit (3-5). Omdat peniele arteriën smaller zijn 
dan coronairen hebben mannen gemiddeld drie jaar voor het ontstaan van angineuze 
klachten al last van erectiele disfunctie (6;7). Andersom wordt bij 75% van de mannen met 
chronische stabiele coronaire ziekten erectiele disfunctie geconstateerd (8). 
Ook bij vrouwen met cardiovasculaire aandoeningen komt seksuele disfunctie veel voor (9). 
Vrouwelijke seksuele disfunctie lijkt met name gerelateerd en hypertensie en het gebruik 
van β-blokkers (10;11), tot op heden blijft dit echter een onderbelicht onderzoeksgebied. 
Daarnaast hebben veel cardiovasculaire geneesmiddelen een negatieve invloed op de 
seksuele prestaties. Naast diuretica en β-blokkers (12-14), lijkt ook digoxine de seksuele 
functie negatief te beïnvloeden (15). Aan de andere kant zijn positieve effecten aangetoond 
van angiotensine receptorblokkers en statines (16-18).
Recent werden door the American Heart Association aanbevelingen gedaan voor de 
voorlichting aan de cardiale patiënten (én hun partner) over het veilig hervatten van 
seksuele activiteiten bij cardiovasculaire aandoeningen (19). Ook werden richtlijnen en 
reviews geschreven over de diagnostiek en behandeling van ED in relatie tot cardiovasculair 
risicomanagement (20;21). 
Hoe de Nederlandse cardioloog in de dagelijkse praktijk omgaat met het onderwerp 
seksualiteit en of hij bekend is met de effecten van cardiovasculaire middelen op de 
seksuele functie was tot op heden niet bekend. Om het bovenstaande te evalueren werd 
een enquête uitgevoerd onder alle Nederlandse cardiologen en cardiologen in opleiding 
(AIOS). Daarnaast werd niet eerder gekeken naar de wensen van cardiale patiënten 
ten aanzien van seksuele gezondheid. Om deze wensen in kaart te brengen werd een 
multicenter, cross-sectioneel onderzoek werd uitgevoerd onder patiënten die een 
cardioloog consulteerden.




Vragenlijstonderzoek werd verspreid onder alle leden van de Nederlandse Vereniging 
voor Cardiologie in het najaar van 2011. Daarnaast werden tussen maart 2012 en januari 
2013 driehonderd vragenlijsten uitgedeeld aan patiënten die de polikliniek cardiologie 
van het Leids Universitair Medisch Centrum of het Diaconessenhuis Leiden bezochten en 
werden 1275 vragenlijsten verstuurd aan patiënten van Cardiologie Centra Nederland, 
locaties Voorschoten en Amsterdam Zuid. (Figuur 1). 
De vragen werden verzonden/uitgereikt in een envelop samen met een brief met 
uitleg over de studie en een toestemmingsformulier. Patiënten die de Nederlandse taal 
machtig waren en ouder waren dan 18 jaar werden geïncludeerd. In verband met de 
cross-sectionele studieopzet werden ook patiënten die voor medische keuring kwamen 
geïncludeerd, evenals patiënten bij wie geen cardiale oorzaak voor de klachten werd 
gevonden. Exclusie vond plaats van patiënten die aangaven niet te weten welke cardiale 
diagnose was gesteld. Vragenlijsten waarbij niet meer dan 30%  was ingevuld werden 
geëxcludeerd. Goedkeuring voor het uitvoeren van de patiënten enquête werd verkregen 
bij de Medisch Ethische Toetsingscommissie van het LUMC. 
figuur 1. Studie stroomdiagram
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Vragenlijsten
De vragenlijst voor cardiologen werd ontworpen door de auteurs. Een pilotstudie vond 
plaats onder 40 cardiologen en AIOS in het LUMC. Voor de evaluatie van cardiale patiënten 
werden genderspecifieke vragenlijsten ontworpen, bestaande uit drie secties. Het eerste 
deel bevatte vragen met betrekking tot de cardiale problematiek en demografische 
gegevens. In het tweede deel werd informatie vergaard over seksuele activiteit en 
seksueel functioneren, hierbij werd voor mannen gebruik gemaakt van de verkorte 
versie van de International Erectile Dysfunction Index (IIEF-5)(22;23). Voor vrouwen werd 
de gevalideerde, verkorte versie van de Female sexual function index (FSFI-6) gebruikt 
(24;25). Het derde deel behelsde de mening van patiënten betreffende het bespreekbaar 
maken van seksuele problematiek met de cardioloog en eventuele oplossingen hiervoor. 
Statistische analyse
Een score van 21 punten of minder op de IIEF-5 werd beschouwd als ED (22). De 
grenswaarde voor seksuele disfunctie bij vrouwen was een FSFI score lager dan 19 (25).
Statistische bewerking werd uitgevoerd in SPSS (versie 20, Chicago, IL, USA), waarbij 
tweezijdige p-waarden <0.05 als significant werden beschouwd. Voor de meeste 
vergelijkingen werd gebruik gemaakt van de gepaarde t-toets of de Pearsons χ2 toets. 
Bivariate correlatie werd gebruikt om FSFI-6, IIEF-5 en lastscores te correleren, lineaire 
regressie werd gebruikt voor het identificeren van voorspellers voor lage FSFI- en IIEF- 
scores. 
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rESulTATEN
Visie van de cardioloog 
tabel 1. Demografische gegevens deelnemende cardiologen (n=414) 






AIOS cardiologie 79 (19.1)
Type praktijk n(%) n=412*
Academisch centrum, 90 (21.8)
Topklisch opleidings ziekenhuis 174 (42.2)
Streek ziekenhuis 148 (35.9)
ervaringsjaren binnen de cardiologie, n(%)
0-11 maanden 18 (4.3)
1-2 jaar 30 (7.2)
3-5 jaar 80 (19.3)
6-10 jaar 106 (25.6)
11-15 jaar 49 (11.8)
15 jaar of meer 131 (31.6)
*n verschilt omdat niet alle respondenten de antwoorden op deze vragen hebben beantwoord.
SD=Standaard Deviatie
Spreken over seksuele functie (hoofdstuk 2)
Meer dan de helft (54%) van de Nederlandse cardiologen en AIOS retourneerde de 
vragenlijst (zie figuur 1). 412 vragenlijsten waren geschikt voor analyse. 2% van de 
cardiologen zei seksualiteit altijd te bespreken, 17% gaf aan dit regelmatig te doen, 49% 
zei ‘soms’, 27% zei ‘zelden’ en 3% besprak het onderwerp nooit. Het merendeel voelde 
zich ook niet verantwoordelijk voor deze taak, 42% dichtte die toe aan een ander, waarvan 
70% daarbij dacht aan de huisarts. Toch zei 39% zich verantwoordelijk te voelen voor 
het bespreken van seksuele problematiek gerelateerd aan cardiovasculaire ziekten, 20% 
zei niet te weten wie deze verantwoordelijkheid heeft of zou moeten hebben. Ervaren 
cardiologen spraken significant vaker over seksuele problematiek dan AIOS (p<0.001). De 
meerderheid zei zelden (49%) of nooit (20%) adviezen te geven over het hervatten van de 
seksuele activiteiten na een myocardinfarct of bij hartfalen. Bij mannen werd significant 
vaker dan bij vrouwen naar de seksuele functie gevraagd (p<0.001).
Chapter 11184
Belangrijke redenen om niet te beginnen over seksualiteit waren gebrek aan initiatief van 
de patiënt (54%), tijdgebrek (43%) en gebrek aan training om dit onderwerp bespreekbaar 
te maken en gebrek aan kennis over het behandelen van seksuele problematiek (35%). 
Een groot gedeelte van de respondenten (42%) zei training te willen om kennis over dit 
onderwerp te verbeteren om het gemakkelijker met patiënten bespreekbaar te maken. 
63% gaf aan geholpen te zijn met een overzicht van hulpverleners naar wie zij patiënten 
met seksuele problematiek kunnen doorverwijzen.
kennis over de effecten van antihypertensiva op de seksuele functie (hoofdstuk 3)
De cardiologen en AIOS cardiologie werd gevraagd om van de acht belangrijkste klassen 
antihypertensiva aan te geven of deze een positief, een negatief of geen effect hebben op 
de seksuele functie van de gebruiker. Het merendeel (93%) wist dat β-blokkers negatieve 
effecten kunnen hebben op de seksuele functie, 41% wist het van diuretica. Van digoxine 
was de negatieve invloed bekend bij 12% van de respondenten. 
Voor calcium antagonisten, ACE-remmers en α-blokkers is in de literatuur nooit een 
significant negatief effect op de seksuele functie aangetoond. Bijna de helft van de 
cardiologen (49%) wist dat calcium antagonisten neutraal zijn wat betreft de effecten op 
de seksuele functie, van α-blokkers wist 45% dit en 61% wist dat ACE-remmers geen effect 
hebben op de seksuele functie. 
Verscheidene studies hebben aangetoond dat angiotensine receptor blokkers positieve 
effecten hebben op het endotheel, op de doorbloeding van de geslachtsorganen en 
daarmee op de seksuele functie (26-32), 9% van de cardiologen was hiermee bekend. 
Ook aan statines worden deze positieve effecten toegeschreven (33-37), 11% van de 
responderende cardiologen was hiervan op de hoogte. Bijna de helft van de cardiologen 
(48%) zei regelmatig de medicatie te switchen om de seksuele functie van patiënten te 
verbeteren, 48% zei regelmatig te vragen naar bijwerking op het gebied van seksualiteit 
en 27% zei dit vaak te doen.
Naar het gebruik van phosfodiesteraseremmers (PDE5) wordt door 38% van de cardiologen 
en AIOS regelmatig gevraagd, 50% vraagt zelden naar het gebruik van deze middelen. 
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tabel 2. Overzicht van de effecten van de meest voorgeschreven klassen cardiovasculaire middelen 








Angiotensine Receptor Blokkers + 
Statines +
° Informatie uit gerandomiseerde trials, dubbel blinde crossover studies en prospectieve 
vragenlijststudies onder zowel mannen als vrouwen;
* Behalve voor Nebivolol, dit middel lijkt een positief effect te hebben;
** Behalve voor kaliumsparende diuretica welke geen effecten lijken te hebben op de seksuele 
functie; 
- = negatief effect, ± = geen effect, + = positief effect
visie van de cardiologische patiënt
De mannelijke patiënt (hoofdstuk 5)
296 vragenlijsten waren geschikt voor analyse (figuur 1). De gemiddelde leeftijd was 
62.9 jaar (±11.1). De meerderheid was het afgelopen jaar seksueel actief geweest (81%), 
ED werd aangeduid als de belangrijkste reden voor seksuele inactiviteit (43%). De IIEF-
5 vragenlijst is alleen gevalideerd voor seksueel actieve mannen en van hen (n=240) 
scoorde 65% minder dan 21 punten, duidend op matig tot ernstige ED. Van de mannen 
die antihypertensiva (n=202) gebruikten zei 36% een negatief effect van de medicatie 
op de erectie te bemerken. Patiënten scoorden gemiddeld een 5.9 (±2.6) op een schaal 
van 0 tot 10 voor de last die zij ervoeren van ED. Deze last was negatief gecorreleerd met 
de IIEF-5 score (r-0.63; p<0.001). 91% van de mannen zou het als vanzelfsprekend of zelfs 
als een opluchting ervaren als de cardioloog over de seksuele functie zou beginnen. 46% 
van de mannen met ED gaf aan een gesprek met de cardioloog te willen om te spreken 
over mogelijkheden voor verbetering van de erectie. Een consult met een (gespecialiseerd) 
verpleegkundige werd door 55% zinvol geacht, ook zou 58% geholpen zijn met schriftelijke 
informatie. In totaal (seksueel actieven en inactieven) gaf 50% (n=148) van het cohort aan 
een seksuele disfunctie te hebben, 42% wilde daar behandeling voor. Bijna dertig procent gaf 
aan al eens een phosphodiesteraseremmer geprobeerd te hebben (n=86). De meerderheid 
kreeg een phosphodiesteraseremmer op recept van de huisarts (65%), 8% van een vriend 
of familielid en 2% bestelde het op internet. Een kwart kreeg het recept van een medisch 
specialist, waarvan 4% van de cardioloog. 
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Leeftijd, gemiddeld (spreiding), jaren 62.9 (20-94) 60.1 (18-90)
Gewicht, gemiddeld (SD), kg 85.9 (±13.7) 73.5 (±14.4)
Lengte, gemiddeld (SD), cm 180.3 (±6.9) 167.0 (±10.5)
BMI*, gemiddeld, (SD), kg/m3 26.4 (±3.6) 27.0 (±12.0)
Nationaliteit n (%)
Nederlands 268 (91.5)            148 (90.2)
Ander westers land 10 (3.4)                 8 (4.9)
Niet-westers land 13 (4.4)  8 (4.9)
Cardiovasculaire middelen ǂ n (%)
α-receptor blokker 13 (4.4) 3(1.8)
ACE remmer 95 (32.4) 23 (14.0)
Angiotensine receptor blokker 57 (19.5) 29 (17.7)
β-receptor blokker 103 (35.2) 61 (39.0)
Calcium-antagonist 44 (15.0) 24 (14.6)
Digoxine 11 (3.8) 2 (1.2)
Loop diureticum 11 (3.8) 18 (11.0)
Thiazide diureticum 33 (11.3) 5 (3.0)
Nitraten 20 (6.8) 7 (4.3)
Statines 112 (38.2) 34 (20.7)
Anders 16  (5.4) 7 (4.3)
Cardiale diagnoseǂ n (%)
Angina pectoris 86 (29.2) 21 (12.8)
Hypertensie 90 (30.5) 54 (32.9)
Ritmestoornis 87 (29.5) 59 (36.0)
Myocard infarct 34 (11.5) 6 (3.7)
Hartfalen 10 (3.4) 2 (1.2)
Hartklepaandoening 25 (8.5) 23 (14.0)
Primaire myocard aandoeningen 5 (1.7) 2 (1.2)
Congenitale hartziekten 4 (1.4) 2 (1.2)
Geen cardiale diagnose 41 (13.9) 25 (15.2)
*BMI = m / l², ACE = angiotensine converterend enzym 
† Kolommen tellen niet altijd op tot het aangegeven totaal door ontbrekende waarden
ǂ Meerdere antwoorden mogelijk
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De vrouwelijke patiënt (hoofdstuk 6 )
163 vragenlijsten waren geschikt voor analyse. De gemiddelde leeftijd van de participerende 
vrouwen was 60.2 (±13.7) jaar. 35% gaf aan seksuele problemen te ondervinden, van hen 
zei 6% hiervoor behandeld te willen worden, 34% zou behandeling overwegen indien die 
mogelijkheid geboden zou worden. 35% was niet seksueel actief in het afgelopen jaar 
(n=57). Deze vrouwen waren gemiddeld ouder dan de seksueel actieven (64.5 ±11.6 versus 
55.8 ±12.6; p<0.001). De meest genoemde reden voor seksuele inactiviteit was het gebrek 
aan een partner (41%). Vierentwintig procent vond seks niet (meer) belangrijk. Van de 
104 seksueel actieve vrouwen werd bij 62% een seksuele disfunctie gescoord met de FSFI 
(score <19). Vrouwen met hypertensie scoorden lager dan normotensieven (gemiddelde 
scores 14.6 ±7.3 respectievelijk 17.3 ±5.6; p=0.04). Het gebruik van een β-blokker was 
gecorreleerd aan lagere scores voor tevredenheid op het gebied van de seksuele 
gezondheid en met onvrede over de relatie (p=0.019 resp. p=0.002). Het aantal gebruikte 
antihypertensiva bleek een voorspeller te zijn voor lagere FSFI scores (β= -1.47 (SE 4.31) 
per toegevoegd medicament (p=0.001). Hoe meer antihypertensiva de respondent slikte, 
hoe vaker een behandelwens voor FSD werd geuit (p=0.009), hierbij was de specifieke 
combinatie van medicatie niet van invloed. Van de vrouwen met FSD wilde 9% hier met 
de cardioloog over spreken, 23.4% zou er over willen praten met een verpleegkundige en 
19% zou schriftelijke informatie waarderen.
Van alle vrouwen stond 34% neutraal tegenover het vragen naar seksuele functie door de 
cardioloog, 35% zou het als positief of logisch ervaren. Aan de andere kant zou 16% het 
ongemakkelijk of vervelend vinden als de cardioloog naar seksuele functie zou vragen, 
14% dacht niet dat de cardioloog hen hierover advies zou kunnen geven.
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figuur 2. Percentage seksuele disfunctie bij mannen (ED) en vrouwen (disfunctie niet gespecificeerd) 
per leeftijdscategorie en per cardiale diagnose
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figuur 3. Gewenste vormen van aanbod zorg voor seksuele disfunctie in de cardiologische praktijk
Gebaseerd op de antwoorden van 296  mannen en 163 vrouwen.
Totalen: mannen jonger dan 60 jaar: n=116, mannen ouder dan 60 jaar: n=185
Vrouwen jonger dan 50 jaar: n=32, vrouwen ouder dan 50 jaar n= 131











Dit onderzoek laat zien dat er een discrepantie bestaat tussen de behoeften van cardiale 
patiënten betreffende de aandacht voor seksuele disfunctie en de geboden zorg. De 
meerderheid van de mannen met een cardiovasculaire diagnose heeft een vorm van ED 
en geeft aan daar last van te hebben. Hiervan heeft de helft een actieve behandelwens. 
Bij vrouwelijke cardiale patiënten ligt dit gecompliceerder. Ondanks het feit dat meer dan 
een derde aangeeft seksuele disfunctie te hebben, wordt er weinig behoefte aan zorg 
aangegeven. Behandeling met antihypertensiva lijkt bij vrouwen van grote invloed te zijn 
op de seksuele functie.
Verder kan aan de hand van onze resultaten gesteld kan worden dat Nederlandse 
cardiologen onvoldoende kennis hebben van de effecten die de verschillende soorten 
antihypertensiva kunnen hebben op de seksuele functie. 
Vergelijking met de literatuur
Niet eerder werd onderzocht wat de wensen van cardiale patiënten zijn op het gebied 
van seksuele gezondheidszorg. De prevalentie van ED en FSD was vergelijkbaar met 
grote internationale studies onder cardiale patiënten (8;10;38;39). De resultaten van de 
enquête onder cardiologen toont aan dat er meer training nodig is om goede seksuele 
zorg te kunnen bieden. 46% wenst meer helderheid om doelgericht te kunnen verwijzen 
(40). Ervaring in het vak bleek voor cardiologen en AIOS een belangrijke voorwaarde om 
het onderwerp seksualiteit te bespreken. Het trainen van de communicatie over seksuele 
problematiek blijkt de belangrijkste voorspeller voor het daadwerkelijk bespreken hiervan 
in de praktijk (41).
Beperkingen van het onderzoek
De belangrijkste beperking van dit onderzoek is waarschijnlijk de non-respons bias 
vanwege het gevoelige onderwerp. Daarnaast kunnen de antwoorden van de cardiologen 
onderhevig zijn geweest aan overschatting door zelfrapportage. Om deze potentiële bias 
zo klein mogelijk te houden werd volledige anonimiteit bij de verwerking en opslag van 
de data verzekerd.
Beschouwing
De resultaten van de survey onder cardiologen kunnen teleurstellend genoemd worden, in 
1981 werd cardiologen immers al aanbevolen om seksuele problematiek bespreekbaar te 
maken (42). Onze resultaten laten zien dat ervaring in het vak een belangrijke voorwaarde 
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is om dit -toch vaak als lastig ervaren onderwerp- aan te snijden. Ook een gebrek aan 
tijd werd door een belangrijk deel van de cardiologen genoemd als reden om niet over 
seksuele problematiek te beginnen. Dit probleem zou opgelost kunnen worden door 
verpleegkundigen op te leiden die angst en onzekerheid rondom seksuele activiteit met 
patiënten kunnen bespreken, en patiënten met een seksuele disfunctie naar de juiste 
hulpverlener kunnen verwijzen. 
Daarnaast is klaarblijkelijk nog veel winst te behalen daar waar het de kennis betreft van 
cardiologen over de effecten op de seksuele functie van de door hen voorgeschreven 
cardiovasculaire medicatie. De helft van de cardiologen zegt regelmatig de medicatie 
aan te passen om het seksueel functioneren van patiënten te verbeteren. Aan de hand 
van deze data kan echter gesteld worden dat kennis van de effecten op seksuele functie 
van de bekendste klassen antihypertensiva nog onvoldoende is. Richtlijnen bevelen 
cardiologen aan patienten standaard naar seksuele functie te vragen alvorens medicatie 
uit te schrijven (1;43). Onze data wijzen er echter op dat dit slechts in de minderheid van 
de gevallen gebeurt. Dit kan naast een vermindering van het seksueel functioneren –en 
dus kwaliteit van leven- ook gevaar opleveren. Zo is het gelijktijdig gebruik van nitraten 
met phosfodiesteraseremmers gecontraïndiceerd in verband met het risco op hypotensie 
(1). Onze data toonden dat dertig procent van de mannelijke cardiale patiënten een 
phosfodiesteraseremmer gebruikt of heeft gebruikt, maar dat dit middel in de overgrote 
meerderheid van de gevallen niet werd verkregen via de cardioloog. Minder dan de helft 
van de cardiologen zei naar het gebruik van phosfodiesteraseremmers te vragen. Hieruit 
kan geconcludeerd worden dat de cardioloog dus meestal niet op de hoogte is van 
phosfodiesteraseremmer gebruik van zijn patiënten en dat waarschuwingen over 
gecombineerd gebruik met nitraten dus vaak niet gegeven zullen worden.
Tenslotte blijkt uit de evaluatie van cardiologische patienten dat vrouwen significant 
minder waarde hechten aan aandacht en zorg voor seksuele disfunctie dan mannen. 
Dit verschil kan verklaard worden doordat seksuele problematiek bij mannen met CVZ 
(vaak) veroorzaakt wordt door ED. Voor ED is medicamenteuze behandeling ruimschoots 
beschikbaar, iets wat de afgelopen jaren breed onder de aandacht is gebracht in de 
media. Dit in tegenstelling tot seksuele problematiek bij vrouwen, waarvoor nauwelijks 
aandacht bestaat en therapeutische mogelijkheden minder bekend zijn (10). Daarnaast 
is vrouwelijke seksualiteit meer afhankelijk van emoties en verlangens en minder van de 
fysieke functie waardoor het moeilijker te objectiveren is (44). 
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Conclusies en aanbevelingen
Dit onderzoek geeft handvatten om seksuologische zorg binnen de cardiologie aan 
te kunnen bieden. De resultaten tonen aan dat een groot gedeelte van de mannelijke 
patiënten met CVZ last heeft van ED en graag met de cardioloog zou spreken over 
behandelmogelijkheden. Dit in tegenstelling tot vrouwelijke cardiologie patiënten van 
wie slechts een minderheid met de cardioloog over seks zou willen praten, ondanks dat 
een groot deel van hen FSD heeft. Voor vrouwen heeft een actieve benadering niet de 
voorkeur. Echter, opties die de drempel verlagen om het onderwerp aan te snijden, zoals 
een folder in de wachtkamer en de mogelijkheid met een verpleegkundige te spreken, 
zouden door zowel mannen als vrouwen gewaardeerd worden. 
Een belangrijke redenen voor de cardioloog om het onderwerp seksualiteit niet ter sprake 
te brengen is een gebrek aan tijd en training. Cardiologen geven daarbij aan dat het 
waardevol zou zijn te beschikken over een regionale lijst met hulpverleners voor efficiënte 
doorverwijzing. 
Op nascholingsbijeenkomsten en in de opleiding voor cardiologen zou meer aandacht 
besteed moeten worden aan de kennis over medicatie wat betreft de invloed op de 
seksuele functie en aan het onderwerp seksualiteit bij CVZ.
Daarnaast zouden cardiologen ontzien kunnen worden door hulp van een verpleegkundige 
die seksualiteit met patiënten kan bespreken. Ook voor de huisarts is een belangrijke 
rol weggelegd. Voor cardiovasculair belaste patiënten die zich bij huisarts of cardioloog 
melden met seksuele disfunctie zijn dezelfde leefstijl adviezen van toepassing als die 
ter voorkoming van cardiovasculaire gebeurtenissen (20;45). Een verandering van de 
medicatie kan verbetering van seksuele functie geven. Indien mogelijk dient de medicatie 
bij patiënten met klachten van seksuele disfunctie omgezet te worden naar een derde 
generatie β-1 blokker of een angiotensine receptor blokker (12;46;47). Indien dit niet 
mogelijk is kunnen ACE-remmers of calciumantagonisten veilig voorgeschreven worden 
(16;18). Voor mannen is het voorschrijven van een phosphodiesteraseremmer de 
volgende stap. Verwijzing naar een uroloog kan overwogen worden indien ED persisteert 
of als er sprake is van andere seksuele disfunctie (20). Vrouwen kunnen doorverwezen 
worden naar een gynaecoloog of bekkenbodem fysiotherapeut. Voor patiënten, bij wie 
de fysieke aspecten van seks een minder grote rol lijken te spelen, kan verwijzing naar een 
seksuoloog uitkomst bieden.
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Sinds dertig jaar is bekend dat seksueel misbruik niet alleen psychische, maar ook 
somatische gevolgen heeft (7,9,12). Op gastrointestinaal terrein hebben patiënten met 
een geschiedenis van SA 1.5 tot 2 maal groter risico op klachten, vergeleken met de 
algemene populatie (1;2).  De prevalentie van seksueel misbruik (sexual abuse, SA) in de 
Westerse maatschappij ligt bij vrouwen tussen de 12 en 33% en bij mannen tussen de 4.5% 
en 10% (3-7). SA is ook geassocieerd met hevige emotionele reacties en gevoelens van 
schaamte bij gynaecologisch en endoscopisch onderzoek, wat kan leiden tot vermijding 
en uitstel van behandeling (8-11). Patiënten melden misbruik zelden spontaan, maar tijdig 
signaleren kan overbodig medisch handelen voorkomen en maakt het mogelijk de patiënt 
de juiste zorg aan te bieden (7;12). Voor patiënten met SA in het verleden kan aandacht 
hiervoor belangrijk zijn voor de arts-patiënt relatie. Deze relatie is de belangrijkste factor 
die de ervaring van de patiënt tijdens het inwendig lichamelijk onderzoek beïnvloedt (13;14). 
Eerdere studies toonden belemmeringen aan bij gynaecologen en urologen om naar SA te 
vragen (15;16). Voor MDL-artsen was dit nog niet onderzocht. Ook is weinig bekend over 
het effect van colonoscopie op slachtoffers van SA, vergeleken met patiënten zonder een 
dergelijke voorgeschiedenis. 
Doel van dit onderzoek was om 1) inzicht te krijgen in de kennis en praktijkvoering van 
MDL-artsen betreffende de zorg aan patiënten met een verleden van SA en 2) te evalueren 
wat de impact is van het colonoscopie op patiënten met SA in het verleden en welke 
aanpassingen rondom de procedure deze impact mogelijk kunnen verminderen.




In 2010 werden alle praktiserende Nederlandse MDL-artsen (n=262) en MDL-artsen in 
opleiding (AIOS)(n=140) uitgenodigd een digitale vragenlijst in te vullen. 
In 2011 ontvingen patiënten (>18 jaar) die in de afgelopen 11 maanden colonoscopie 
hadden ondergaan in het Haga ziekenhuis of in het Leids Universitair Medisch Centrum 
(n= 2348) een informatiebrief over de studie en een toestemmingsformulier. Vragenlijsten 
(zie hieronder) werden alleen verstuurd aan patiënten die het toestemmingsformulier 
terugstuurden en bevestigden deel te willen nemen. Patiënten die colonoscopie onder 
algehele anesthesie ondergingen werden geëxcludeerd (Figuur 1). Een herinnering werd 
verstuurd naar non-respondenten en naar respondenten die aanhadden gegeven deel te 
willen nemen maar de vragenlijst niet terugstuurden. Dit observationele cross-sectionele 
onderzoek werd uitgevoerd volgens de STROBE-richtlijnen (17) en werd goedgekeurd 
door de Medisch Ethische Commissie van Zuidwest Holland.
figuur 1. Studie stroomschema
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Vragenlijsten
De vragenlijsten werden op basis van literatuuronderzoek ontworpen door de auteurs. De 
vragenlijst voor artsen werd als pilot getest onder 8 MDL-artsen en aios en de vragenlijst 
voor colonoscopie patiënten werd getest door 10 patiënten. Een gedeelte van de patiënten 
vragenlijst werd gebaseerd op de Pelvic Floor Inventories Leiden (PelFIs), een gevalideerde 
vragenlijst voor het achterhalen van bekkenbodemproblematiek en seksueel misbruik in 
het verleden (18).
De belasting van de colonoscopie werd gescoord op een schaal van 1 tot 10, waarbij 0 
stond voor ‘geen belasting’ en 10 voor ‘de meest zware belasting denkbaar’. Onderscheid 
tussen SA in de jeugd of op volwassen leeftijd werd niet gemaakt.
De vragenlijsten werden verwerkt door twee onafhankelijke onderzoekers (M.P.N en L. de 
V) en konden niet herleid worden tot gegevens van arts of patiënt. Omdat deelname aan 
de studie mogelijk als confronterend ervaren kon worden en vragen kon oproepen, waren 
een onafhankelijke psycholoog en seksuoloog beschikbaar voor consultatie. 
Colonoscopie 
Colonoscopie werd verricht onder sedatie met midazolam en fentanyl volgens de 
protocollen van de participerende centra. Ieder endoscopie team bestond uit een 
endoscopist (MDL-arts of AIOS MDL) en een of meerdere endoscopieverpleegkundigen. 
Statistische analyse
Data werden geanalyseerd met behulp van SPSS (versie 20, Chicago, IL, USA), waarbij 
tweezijdige p-waarden <0.05 als significant werden beschouwd. Numerieke demografische 
waarden werden samengevat als gemiddelden (±SD).Verschillen in numerieke data tussen 
de demografische groepen werden geanalyseerd met de ongepaarde T-toets. De Pearson 
χ2 test werd gebruikt om de associatie tussen categoriale gegevens van respondenten en 
categoriale antwoorden te vergelijken.
Armitrage’s trend test werd gebruikt voor de associatie tussen categoriale gegevens 
en antwoordmogelijkheden met een glijdende schaal. Lineaire regressie werd gebruikt 
om voorspellers voor stress tijdens colonoscopie te vinden en hiervoor te corrigeren. 
Betrouwbaarheidsintervallen werden gedefinieerd als 95%. 
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rESulTATEN
Antwoorden van de mdL-arts
tabel 1. Demografische gegevens (n=169)







MDL-arts in opleiding 48 (28.4)
Onbekend 9 (5.3)
Type praktijk, n(%)
Academisch Centrum 51 (30.2)
STZ ziekenhuis 66 (39.1)
Streek ziekenhuis 43 (25.4)
Onbekend 9 (5.3)
*Het gedeelte met demografische gegevens werd niet door alle respondenten ingevuld
Van de 243 geretourneerde vragenlijsten waren er 169 geschikt voor analyse; 60 
respondenten gaven aan niet deel te willen nemen, 14 vragenlijsten waren onvolledig 
ingevuld (zie figuur 1). Voorafgaand aan lichamelijk onderzoek gaf 5% van de MDL-artsen 
aan naar SA te vragen bij vrouwelijke patiënten, slechts 1 respondent (0.6%) meldde dit te 
doen bij mannen. Voorafgaand aan colonoscopie gaf 2.5% van de MDL-artsen aan naar SA 
te informeren bij vrouwen en slechts 1 respondent deed dit ook bij mannen. Bij patiënten 
met specifieke klachten zoals chronische buikpijn, fecale incontinentie of obstipatie zegt 
71.4% bij vrouwen naar SA te vragen en 31.3% bij mannelijke patiënten (p<0.001).
De meeste MDL-artsen onderkennen het belang van vragen naar SA: 29.9% vond het 
niet van belang bij mannelijke patiënten en 7.5% vond dit niet van belang bij vrouwelijke 
patiënten (p<0.001), 
24.6% van de MDL-artsen gaf aan het moeilijk te vinden om naar SA te vragen en 
12.5% gaf aan niet te weten hoe te handelen als SA aan het licht zou komen. 10% gaf 
aan dat tijdgebrek een reden was niet naar dit onderwerp te vragen. Tenslotte werd aan 
de MDL-artsen gevraagd een schatting te geven van de prevalentie van SA in de eigen 
patiëntenpopulatie. Voor vrouwen werd deze gemiddeld geschat op 10% en voor mannen 
op 4%.
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Leeftijd, gemiddelde (SD), jaren 59.9 (15.3) 62.8 (13.2) 0.02
≤39 jaar, n(%) 41 (9.6) 25 (7.4) 0.08
40-49 jaar, n(%) 63 (14.7) 25 (7.4) 0.19
50-59 jaar, n(%) 84 (19.6) 60 (17.9) 0.07
60-69 jaar, n(%) 127 (29.6) 124 (36.9) 0.04
70-79 jaar, n(%) 74 (17.2) 72 (21.4) 0.34
80-89 jaar n(%) 38 (8.9) 29 (8.6) 0.004
≥90 jaar n(%) 2 (0.5) 1 (0.3) n/a
Geboorteland
n (%)                                                 
Vrouw                  
n=428 a 




Nederland 378 (88.3) 296 (88.4) 0.98
Ander West-Europees land 13 (3.0) 9 (2.7) 0.78
Marokko 2 (0.5) 2 (0.6) 0.80
Turkije 3 (0.7) 4 (1.2) 0.48
Suriname 12 (2.8) 10 (3.0) 0.89
Nederlandse Antillen 3 (0.7) 4 (1.2) 0.48
Ander westers land 2 (0.5) 2 (0.6) 0.80
Ander niet-westers land 15 (3.5) 8 (2.4) 0.38
Indicatie voor colonoscopieb







Buikpijn      150 (35.0) 81 (24.1) 0.001
Rectaal bloedverlies 110 (25.6) 108 (32.1) 0.05
Controle (erfelijke) colon carcinoom/
poliposis/poliepc
111 (25.9) 97 (28.9) 0.37
Veranderd defecatiepatroon 104 (24.3) 68 (20.2)     0.18
Chronische diarree en/of obstipatie 
en/of slijm bij de ontlasting
   37 (8.6) 15 (4.5) 0.02
IBD 18 (4.2) 22 (6.5) 0.15
Pijn anale regio 18 (4.2) 20 (6.0) 0.27
Anemie 9 (2.1) 14 (4.2) 0.10
Anders   38 (8.9)  31 (9.2) 0.51
a. Gebaseerd op de gegevens van 768 respondenten waarvan 429 vrouwen en 336 mannen (in 
verband met ontbrekende waarden, 
komen de totalen niet altijd uit op 768);
b. Meerdere antwoorden mogelijk;
c. Significant meer patiënten met de indicatie ‘controle (erfelijk) coloncarcinoom/polyposis’ werden 
gezien in het academische centrum vergeleken met het topklinische ziekenhuis (23.6%; p<0.001);
n/a = niet van toepassing; ns = niet significant, IBD = Inflammatory Bowel Disease.
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Prevalentie seksueel misbruik
In totaal gaf 7% van de patiënten aan slachtoffer van SA te zijn geweest. Van de vrouwen was 
dit 10% (40/421) en van de mannen 3.9% (13/331; p=0.003). Niet-westerse immigranten 
rapporteerden meer SA dan patiënten uit een westers land (14.9% versus 6.3%; p=0.008). 
Dit komt voor vrouwen overeen met cijfers uit populatieonderzoek, bij mannen is het 
lager dan op grond van populatieonderzoek is te verwachten. 
Praten over seksueel misbruik 
Aan 1.8% van de respondenten was ooit door een arts naar SA gevraagd. Van patiënten 
met SA gaf 53.8% aan dat de MDL-arts hier wel naar zou moeten vragen (n=28). Een deel 
van de patiënten (29.2% van de vrouwen) gaf aan dat dit niet nodig was, omdat ze er “niet 
over kunnen praten” (zie Tabel 3). Van de 768 respondenten gaf 23.7% aan het vreemd te 
vinden als een vraag over SA gesteld zou worden in een intakevragenlijst voorafgaand aan 
de colonoscopie. Onbegrip over de relevantie was voor 89.1% in deze subgroep de reden 
deze vraag vreemd te vinden. 
tabel 3. Moet de MDL-arts vragen naar seksueel misbruik (SA)?
Antwoorden van patiënten die SA ervaring aangaven
Nee, de MDl-arts hoeft niet naar SA te vragen, n(%) 24 (45.3) a
zo niet, wat is de reden dat u hier niet over wilt praten?b
Ik schaam me ervoor 6 (25.0)
Ik geloof niet dat de dokter me daarmee kan helpen 7 (29.1)
Ik heb er hulp voor gehad en kan er nu mee omgaan 0 (0.0)
Ik kan er niet over praten 7 (29.1)
Ik ben bang om het te vertellen 5 (20.8)
Het is niet (meer) belangrijk voor me 7 (29.1)
Het is te intiem om te bespreken 6 (25.0)
ja, de mdL-arts moet naar sA vragen, n(%) 28 (52.8) a
Zo ja, wat zou u willen dat uw dokter zou doen nadat u het had verteld?b
Alleen naar me luisteren 7 (25.0)
Adviseren over hoe ik hiermee om moet gaan 10 (35.7)
Verwijzen naar een gynaecoloog/uroloog 0 (0.0)
Verwijzen naar een psycholoog 6 (21.4)
Verwijzen naar een seksuoloog 6 (21.4)
Verwijzen naar een bekkenbodemfysiotherapeut 3 (10.7)
Afzien van colonoscopie 2 (7.1)
Informatie verstrekken zodat ik kan lezen over de behandelmogelijkheden 10 (35.7)
a. Kolommen komen niet uit op n=53 patiënten omdat 1 patiënt met seksueel misbruik in de 
voorgeschiedenis geen antwoorden heeft gegeven op de bovenstaande vragen 
b. Meerdere antwoorden waren mogelijk
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seksueel misbruik en lichamelijke klachten
Slachtoffers van SA gaven meer seksueel disfunctioneren aan dan andere respondenten 
(64.0% versus 24.4%; p<0.001). Ook mictieklachten werden vaker gemeld door patiënten 
met misbruik in de voorgeschiedenis (58.8% versus 11.4%; p<0.001). Daarnaast noemden 
slachtoffers vaker meer dan één gastro-intestinaal probleem als reden voor colonoscopie 
(r=0.1, p=0.006) en gaven zij vaker veranderingen in het defecatiepatroon aan vergeleken 
met de andere respondenten (37.7% versus 21.3%; p=0.006). Buikpijn was gecorreleerd 
aan SA bij mannen (r=0.572, p=0.031) en in mindere mate bij vrouwen (r=0.291, p=0.052). 
Ervaren belasting van colonoscopie
Respondenten werd gevraagd op een schaal van 0 tot 10 aan te geven hoe belastend zij de 
colonoscopie ervaren hadden. De groep patiënten die seksueel misbruik had meegemaakt 
ervoer de colonoscopie als belastender  (gemiddelde score 4.78 ±3.47) dan de groep 
patiënten zonder een voorgeschiedenis van seksueel misbruik (gemiddelde score 3.54 
±3.11; p=0.007). Zie figuur 2. 
figuur 2. Ervaren belasting van de colonoscopie 
Buikpijn: Patiënten die aangaven buikpijn als klacht te hebben of die buikpijn aangaven als de 
indicatie voor de colonoscopie en patiënten die naast een andere indicatie voor colonoscopie ook 
buikpijn aan gaven. Patiënten die geen buikpijn klachten aangaven of dit niet opgaven als reden 
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Ook wanneer werd gecontroleerd voor de factoren leeftijd, geslacht, etniciteit, indicatie 
en tijd tussen de colonoscopie en het invullen van de vragenlijst bleek SA een significante 
voorspeller voor belasting van de colonoscopie (β=0.991 (SE=0.466); p=0.034). Er werd 
geen verschil gezien tussen mannen en vrouwen met SA wat betreft colonoscopie 
gerelateerde belasting (gemiddelde scores van 5.00±3.82 respectievelijk 4.72 ±3.41; 
p=0.814).
Patiënten met een verleden van SA werd gevraagd welke aanpassingen rondom en tijdens 
de colonoscopie de procedure minder belastend zouden kunnen maken. 25.4% vond dat 
de huidige procedure prima was, maar de meesten noemden één of meer opties die de 
procedure comfortabeler zou kunnen maken, zie figuur 4. 
figuur 4. Mogelijkheden voor het verminderen van de belasting van de colonoscopie a 
a. Antwoorden van 51 patiënten op de multiple choice + open vraag: ‘de colonoscopie zou 
makkelijker/comfortabeler voor me zijn geweest als…?’
b. Bij anders werd genoemd: ‘Alleen over SA beginnen als het met de klachten te maken kan hebben’ 
en ‘niet je depressief verklaren’.





Aanwezigheid van de partner
Diepere sedatie
% van patiënten met seksueel misbruik in voorgeschiedenis
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disCussie
De resultaten van deze studie tonen aan dat MDL-artsen in Nederland zich bewust zijn 
van de impact van SA in hun patiëntenpopulatie, maar dat ze niet routinematig naar SA 
vragen. Resultaten van de vragenlijst onder patiënten die colonoscopie ondergingen 
laten zien dat patiënten met een voorgeschiedenis van SA meer stress ervaren tijdens 
het onderzoek. Het merendeel van deze patiënten vindt dat de MDL-arts naar SA dient te 
vragen. Verschillende mogelijkheden werden genoemd, die de belasting voor patiënten 
met een seksueel trauma tijdens de colonoscopie zouden kunnen verminderen, met 
name diepere sedatie. Gezien het grote aantal publicaties sinds de jaren ‘80 over het 
effect van SA op gastro-intestinale klachten en buikpijn ligt het voor de hand dat de MDL-
arts routinematig naar SA vraagt. Deze studie laat zien dat dit niet het geval is, en dat een 
deel van de MDL-artsen belemmeringen ervaart om hierover met een patiënt te spreken. 
Specifieke training op dit vlak kan hierin mogelijk van waarde zijn. Aandacht voor SA is 
belangrijk, omdat stressreductie tijdens de colonoscopie mogelijk kan worden bereikt door 
de aanwezigheid van een familielid, diepere sedatie of heldere communicatie tijdens het 
onderzoek. Een standaard vraag over SA in een vragenlijst voorafgaand aan colonoscopie 
zou de drempel voor zowel de arts als de patiënt verlagen om het onderwerp ter sprake 
te brengen. Van patiënten met SA in de anamnese geeft meer dan de helft aan dit met de 
MDL-arts te willen bespreken.
Het merendeel van de MDL-artsen zegt aandacht voor SA te hebben bij vrouwelijke 
patiënten die zich presenteren met klachten zoals chronische buikpijn. Uit de antwoorden 
van de patiënten in de vragenlijst kan opgemaakt worden dat minder dan 1% ooit door de 
MDL-arts naar seksueel misbruik is gevraagd. Dit is in overeenstemming met de literatuur 
over dit onderwerp; van de Nederlandse urologen en gynaecologen bleek ook slechts een 
minderheid naar SA te vragen (7;10;19;20). De resultaten van onze studie komen daarnaast 
overeen met soortgelijk onderzoek waarbij een duidelijk verband werd aangetoond tussen 
een verleden met SA en stress, angst, en herbeleving tijdens gynaecologisch (vaginaal) 
onderzoek (13;21). De weerslag van invasief lichamelijk onderzoek bij mannen met een 
seksueel trauma werd tot op heden niet onderzocht. 
Dit onderzoek heeft beperkingen. Resultaten van vragenlijstonderzoek kunnen 
onderhevig zijn aan non-response en recall bias. Patiënten met een verleden met 
SA kunnen ervoor gekozen hebben niet deel te nemen aan de studie om pijnlijke 
herinneringen te vermijden. Ook kan selectie bias optreden omdat patiënten met SA in de 
voorgeschiedenis colonoscopie wellicht weigeren of vermijden: deze patiënten kwamen 
dan niet in de studie. Allochtonen kunnen ondervertegenwoordigd zijn vanwege onbegrip 
bij taalbarrière of door culturele barrières. Daarnaast werd de vorm en intensiteit van SA 
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niet uitgevraagd, ook om deelname voor patiënten niet te belastend te maken. Alleen 
de gerichte vraag: ‘Bent u ooit slachtoffer geweest van SA?’ werd gesteld. Ten slotte kon 
vanwege het retrospectieve en anonieme studieontwerp niet gecorrigeerd worden voor 
confounders zoals de lengte van de procedure. 
Ondanks deze beperkingen geeft deze studie duidelijk aan dat SA in de voorgeschiedenis 
een impact heeft op de dagelijkse praktijk van de MDL-arts en de belasting van 
colonoscopie voor de patiënt vergroot. Meer stress tijdens colonoscopie kan mogelijk 
verklaard worden door een verstoorde visceroperceptie via verschillende neuronaal 
en humoraal gestuurde interacties tussen het CZS, de bekkenbodem en de darmen 
(22). Veranderingen in cortico-limbische pijnmodulatiesystemen spelen een rol in de 
associatie tussen SA en gastro-intestinale klachten (23). Daarnaast zijn angst en trauma, 
in het bijzonder seksueel trauma, significant geassocieerd met bekkenbodemdisfunctie 
leidend tot functionele gastro-intestinale ziekten, dyspareunie, disfunctionele mictie en 
chronische buikpijn (14;24-26). 
Concluderend blijkt dat meer aandacht voor SA binnen de gastroenterologische 
patiëntenzorg wenselijk is. Opleiding en richtlijnen zijn nodig om meer aandacht te krijgen 
voor de invloed van SA in de MDL-praktijk. Huisartsen zouden hierin vanzelfsprekend ook 
een rol kunnen spelen bij de patiënten die zij direct doorsturen voor colonoscopie.
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___ ___ ___ ___ 
 
Indien u niet wilt deelnemen aan deze survey: 
Waarom wilt u dit niet? 
□ Geen interesse 
□ Geen tijd  
□ Niet genoeg ervaring 






Leest u iedere vraag aandachtig door. Kies dan bij elke vraag het antwoord dat het meest op 
u van toepassing is. Zet vervolgens een kruisje voor het door u gekozen antwoord. Sla geen 
vragen over. Mocht u een fout maken, zet dan een streep door het foute antwoord en een 
nieuw kruisje voor het goede antwoord. Alvast bedankt voor uw medewerking. 
 
1. Wat is u leeftijd? …………jaar 
 




3. Wat is uw functie?  
□ cardioloog  
□ cardioloog in opleiding 
 
4. Waar werkt u?       
□ Academisch ziekenhuis  
□ Algemeen topklinisch opleidingsziekenhuis 
□ Regionaal- of streekziekenhuis 
 
5. Hoe lang bent u werkzaam in uw huidige beroep? 
□ 0-11 maanden   □ 6-10 jaar  
□ 1-2 jaar    □ 11-15 jaar 
□ 3-5 jaar    □ 15 jaar of meer 
 
Vragenlijst Seksualiteit  
 
6. Hoevaak bespreekt u de seksuele gezondheid van de patiënt? 
□ Nooit   
□ Zelden 
□ Soms  
□ Regelmatig   
□ Vaak 
 
7. Op uw huidige werkplek, bij hoeveel procent van de patiënten denkt u dat seksualiteit 
veranderd is ten gevolge van hun aandoening? 
…………………….% 
 







9. In het afgelopen jaar, hoeveel procent van uw patiënten heeft u doorverwezen naar 
een arts of andere hulpverlener voor begeleiding van seksuele problemen of voor het 
beantwoorden van vragen over seksualiteit? 
……………………..% 
 
10. De cardioloog heeft de verantwoordelijkheid om seksualiteit met patiënten te 
bespreken. 
□ Helemaal mee eens   □ Mee oneens 
□ Mee eens     □ Helemaal mee oneens 
□ Weet niet 
 
11. Zo niet, wie heeft dan wel de verantwoordelijkheid?(meerdere antwoorden mogelijk) 
□ De Huisarts 
□ Revalidatie arts 




□ De patiënt moet het zelf ter sprake brengen 
□ Anders, namelijk …………………………………………………………. 
 
12. In welke mate heeft u het gevoel over voldoende kennis te beschikken om het 
onderwerp seksualiteit te bespreken? 
□ Helemaal geen kennis   □ Veel kennis 
□ Niet veel kennis    □ Extreem veel kennis 
□ Enige kennis 
 
13. Op uw huidige werkplek, hoe vaak heeft u patiënten na een myocardinfarct of 
hartfalen voorlichting gegeven met betrekking tot seksualiteit over:  
 Nooit Zelden Regelmatig Vaak 
A. Wanneer seksuele activiteiten te hervatten □ □ □ □ 
B. Het rapporteren van waarschuwingssignalen □ □ □ □ 
C. Het gebruik van nitraten bij pijn  □ □ □ □ 
D. Effecten van medicatie  □ □ □ □ 
E. Gebruik van erectiebevorderende middelen  □ □ □ □ 
 
14. Op uw huidige werkplek, hoe vaak heeft u informatie over seksualiteit verstrekt aan:  
 Nooit Zelden Regelmatig Vaak 
- Mannelijke patiënten na een hartinfarct of 
hartfalen  
□ □ □ □ 
- Vrouwelijke patiënten na een hartinfarct of 
hartfalen  
□ □ □ □ 
 
15. Kunt u aangeven bij welke klachten u specifiek naar seksuele problematiek vraagt? 
(meerdere antwoorden mogelijk) 
□ Angina pectoris klachten 
□ Claudicatio klachten 
□ Hartfalen 
□ Recent myocard infarct 
□ Recent starten met een bètablocker 






16. Vraagt u naar het gebruik van erectiepillen (Viagra, Levitra, Cialis) bij mannelijke 
patiënten op uw polikliniek? 
□ Nooit   
□ Zelden  
□ Regelmatig   
□ Vaak 
 
17.  Op uw huidige werkplek, hoe vaak heeft u informatie over seksualiteit verstrekt aan 
patiënten na een hartinfarct of hartfalen uit de volgende leeftijdscategorieën? 
 
 Nooit Zelden Regelmatig Vaak 
- 20-35 jaar □ □ □ □ 
- 36-50 jaar □ □ □ □ 
- 51-65 jaar □ □ □ □ 
- 66-75 jaar □ □ □ □ 
- 76 jaar of ouder □ □ □ □ 
 
 
18. In onderstaande lijst staan redenen aangegeven die u mogelijk weerhouden om 
seksualiteit met uw patiënten te bespreken. In welke mate bent u het met de 















Onvoldoende tijd □ □ □ □ □ 
Onvoldoende kennis □ □ □ □ □ 
Onvoldoende training □ □ □ □ □ 
Het is de taak van een ander □ □ □ □ □ 
Patiënt is er nog onvoldoende klaar voor □ □ □ □ □ 
Seksualiteit wordt niet als een probleem 
ervaren door de patiënt 
□ □ □ □ □ 
Patiënt is te ziek om seksualiteit 
bespreekbaar te maken 
□ □ □ □ □ 
Redenen gerelateerd aan cultuur en religie 
□ □ □ □ □ 
Redenen gerelateerd aan taal en etniciteit □ □ □ □ □ 
Leeftijdsverschil tussen u en de patiënt □ □ □ □ □ 























Aanwezigheid van een derde partij □ □ □ □ □ 
Seks is privé □ □ □ □ □ 
Gevoel van schaamte □ □ □ □ □ 
Bang zijn om de patiënt te beledigen □ □ □ □ □ 
Hoge leeftijd van de patiënt □ □ □ □ □ 
Geen band voelen met de patiënt □ □ □ □ □ 
Geen insteek of aanleiding hebben □ □ □ □ □ 
Ik vind het zelf ongemakkelijk □ □ □ □ □ 
De patiënt begint er zelf niet over □ □ □ □ □ 
 
19. Heeft u in uw centrum de mogelijkheid om patiënten met seksuele problemen 
door te verwijzen? 
□ Ja   
□ Nee 
□ Onbekend 
Indien ja, naar:…………………………………………………………………… 
  …………………………………………………………………… 
  …………………………………………………………………… 
 
20. Heeft u behoefte aan het vergroten van uw kennis omtrent het bespreken van 
seksualiteit met uw patiënten? 
□ Ja   
□ Nee  
 
21. Heeft u behoefte aan een lijst met vaste hulpverleners waar u patiënten naar zou 




Seksueel functioneren en cardiovasculaire medicatie 
 
Met uw huidige kennis, welke medicatie denkt u dat er invloed heeft op het seksueel 
functioneren? En wat is het effect? 
Gelieve niet op zoeken aub! 
 
22. Bètablokkers:   
□ positief 











□ geen invloed 
□ negatief 
25. ACE-remmers:  
□ positief 
□ geen invloed 
□ negatief 
26. Angiotensine II antagonisten: 
□ positief 




















31. Verandert u wel eens de medicatie van een patiënt om te trachten de seksuele functie te 
verbeteren? 
□ Nooit   
□ Zelden  


























De seksuele gezondheid is een belangrijk deel van het psychische en emotionele 
welzijn van een individu. Erectiele disfunctie, beter bekent als impotentie of 
erectie stoornissen, is een veel voorkomende medische aandoening die de 
seksuele gezondheid kan beïnvloeden. Vooral bij mannen met hart- en 





A. Geeft u uw toestemming voor het gebruik van uw antwoorden (anoniem) voor  





B. Zo niet: waarom niet? 
□ Seks is een privé aangelegenheid 
□ Ik heb er geen belang bij 





























2.    Land van herkomst: 
□ Nederland 
□ Turkije 
□ Een ander Europees land:………………………… 
□ Marokko 
□ Suriname 
□ De Nederlandse Antillen 
□ Anders:……………………………………………..… 
 
3.  Wat is uw gewicht ……………….kg 
 
4.  Wat is uw lengte………………….cm 
 
5. Rookt u?  
□ Ja  
□ Nee 
□ Gestopt, sinds: ___ - ___- _____ (graag een datum invullen) 
 
6.   Waarom bent u verwezen naar de cardioloog? 
  (meerdere antwoorden mogelijk) 
o Pijn op de borst klachten 
o Hoge bloeddruk 
o Hartkloppingen 
o Onverklaarbare benauwdheid/vermoeidheid 
o Hartinfarct 
o Hartfalen  
o Anders……………………………………….. 
 






□  Ik gebruik geen medicijnen 










8.   Indien er bij u een cardiologische diagnose is gesteld, welke is dat? 
 
□ Vernauwde kransslagaderen (angina pectoris) 
□ Hoge bloeddruk 
□ Hartritmestoornissen 
□ Hartinfarct 
□ Hartfalen  
□ Hartklep aandoening 
□ Ontsteking van het hart 
□ Hartspierziekte  
□ Aangeboren hartaandoening 
□ Weet ik niet 












Als u ‘Nee’ heeft ingevuld bij vraag C, dan kunt u de volgende vragen 














        







PER VRAAG SLECHTS ÉÉN GETAL OMCIRCELEN S.V.P 
Omcirkel het antwoord dat het best uw situatie omschrijft. 
 
 
De afgelopen 6 maanden: 
 
7. Hoe omschrijft u het vertrouwen dat u heeft over het krijgen en vasthouden van een erectie? 
Weet ik niet/niet 
geprobeerd Erg laag Matig Redelijk Tamelijk goed Erg goed 
0 1 2 3 4 5 
  
8. Als u een erectie heeft door seksuele stimulatie, hoe vaak was deze dan hard genoeg voor  





Een paar keer 
(minder dan de 
helft van de tijd) 
Soms (ongeveer 
de helft van de 
tijd) 
Meestal 
(Meer dan de 
helft van de 
tijd) 
Altijd of bijna 
altijd 
0 1 2 3 4 5 
 
9. Hoe vaak lukte het tijdens de geslachtsgemeenschap om uw erectie te behouden terwijl u     





Een paar keer 
(minder dan de 
helft van de tijd) 
Soms (ongeveer 
de helft van de 
tijd) 
Meestal 
(Meer dan de 




0 1 2 3 4 5 
 
10. Hoe moeilijk was het om de erectie tot het einde te behouden tijdens de  









0 1 2 3 4 5 
 





Een paar keer 
(minder dan de 
helft van de tijd) 
Soms (ongeveer 
de helft van de 
tijd) 
Meestal 
(Meer dan de 














12.   Als de cardioloog u tijdens een consult zou vragen naar seksuele  
problemen, wat zou u hier dan van vinden? (meerdere antwoorden mogelijk) 
 
o Ongemakkelijk 
o Het zou me irriteren 
o Beledigend (seks is een privé aangelegenheid) 
o Ik denk niet dat de cardioloog me kan helpen met deze problemen 
o Dat zou me niet uitmaken 
o Het lijkt me logisch dat de arts daar naar vraagt 
o Ik zou blij zijn dat de arts dit ter sprake brengt 
o Ik zou opgelucht zijn dat het ter sprake wordt gebracht 
o Ik denk dat het noodzakelijk is voor een compleet consult 
 
 
13. Waarom bent u niet (meer) seksueel actief? (meerdere antwoorden mogelijk) 
 
o Niet van toepassing (ik ben wel seksueel actief) 
 
o Het is niet belangrijk voor me 
o Ik ben te moe 
o Ik ben te somber 
o Vanwege gezondheidsproblemen, namelijk:………………………………… 
o Ik ben bang om een hartinfarct te krijgen  
o Mijn partner is bang dat het slecht is voor mijn hart 
o Mijn conditie is te slecht 
o Vanwege een seksueel probleem (genoemd in vraag 1 t/m 5) 
o Ik voel me te oud voor seksuele activiteiten 
o Mijn partner heeft seksuele problemen 
o Mijn partner heeft gezondheidsproblemen, namelijk:………………………… 
o Mijn partner is in slechte conditie 




14.   Heeft u het idee dat de medicatie die u van uw cardioloog krijgt uw seksuele 
leven beïnvloed? 
□ Ja, het beïnvloed positief 
□ Ja, het beïnvloed negatief 
□ Nee, het heeft geen invloed 









15. Zou u het prettig vinden als u over seksuele problemen kon spreken en  
      vragen hierover zou kunnen stellen tijdens een verpleegkundig spreekuur? 
□ Ja 
□ Nee 
□ Niet van toepassing 
 
 
16. Heeft u behoefte aan een gesprek met de cardioloog over de mogelijkheden  
      om uw seksuele leven te verbeteren? 
□ Ja 
□ Nee 
□ Niet van toepassing 
 
 
17. Zou u schriftelijke informatie willen krijgen over seksuele problemen en de  
      mogelijke oplossingen hiervoor? 
□ Ja 
□ Nee 
□ Niet van toepassing 
 
 
De volgende vragen zijn niet van toepassing als u GEEN seksuele 
klacht(en) heeft, ga dan alstublieft door naar vraag 23 op pagina 7. 
 
 
18.  Kunt u aangeven op een schaal van 0 tot 10 in hoeverre u last heeft van 
uw seksuele klacht(en)? 
  0 betekent geen last, 10 betekent veel last 
 
□ …………………….. 
□ Niet van toepassing 
 
 
19.  Kunt u aangeven op een schaal van 0 tot 10 in hoeverre uw seksuele 
probleem uw relatie/huwelijk beïnvloed?  
0 betekent geen invloed, 10 betekent veel invloed 
 
□ …………………….. 
□ Niet van toepassing 
 
 
20.  Zou u behandeld willen worden voor uw seksuele probleem/klacht? 
□ Ja  
□ Misschien 
□ Nee 




21. Als u ‘ja’ heeft geantwoord op vraag 20: 
   Wat zou u willen dat uw cardioloog zou doen met betrekking tot uw     
   seksuele klacht(en)? (Meerdere antwoorden mogelijk) 
 
o Alleen naar me luisteren 
o Advies geven over hoe ik ermee om moet gaan 
o Uitleg geven  
o Verwijzen naar een uroloog/gynaecoloog 
o Verwijzen naar een seksuoloog  
o Verwijzen naar een psycholoog 
o Verwijzen naar een bekkenbodem fysiotherapeut 
o Informatie meegeven zodat ik er zelf over kan lezen 
o Informatie meegeven en me thuis over de behandelopties laten denken 
o Anders…………………………………………………    
  
22.    Als u ‘nee’ heeft geantwoord op vraag 20: 
Waarom wilt u niet dat uw cardioloog naar seksuele klachten vraagt? 
 
□ Het is niet belangrijk voor me 
□ Het is te intiem om het over te hebben 
□ Ik voel me te oud om seks te hebben 
□ Ik geloof niet dat de dokter me kan helpen met dit probleem 
□ Ik wil geen tijd van mijn dokter vragen voor zoiets 
□ Het is een privé aangelegenheid 













□ Andere specialist 
□ Ik heb het op internet besteld 
□ Van een vriend of familielid gekregen 








25.   Heeft u ideeën of opmerkingen voor het verbeteren van de seksuele          



















































De seksuele gezondheid is een belangrijk deel van het psychische en emotionele 
welzijn van een individu. Seksuele problemen komen vaker voor bij patiënten 





A. Geeft u uw toestemming voor het gebruik van uw antwoorden 





B. Zo niet: waarom niet? 
□ Seks is een privé aangelegenheid 
□ Ik heb er geen belang bij 
□ Ik heb er geen tijd voor 

































2)  Land van herkomst: 
□ Nederland 
□ Turkije 
□ Een ander Europees land:………………………… 
□ Marokko 
□ Suriname 




3)  Wat is uw gewicht ……………….kg 
 
 
4)  Wat is uw lengte………………….cm 
 
 
5) Rookt u?  
□ Ja  
□ Nee 
□ Gestopt, sinds:  ___  - ___- ______ (graag een datum invullen) 
 
 
6)   Waarom bent u verwezen naar de cardioloog? 
  (meerdere antwoorden mogelijk) 
o Pijn op de borst klachten 
o Hoge bloeddruk 
o Hartkloppingen 
o Onverklaarbare benauwdheid/vermoeidheid 
o Hartinfarct 















8)   Indien er bij u een cardiologische diagnose is gesteld, welke is dat? 
 
□ Vernauwde kransslagaderen (angina pectoris) 
□ Hoge bloeddruk 
□ Hartritmestoornissen 
□ Hartinfarct 
□ Hartfalen  
□ Hartklep aandoening 
□ Ontsteking van het hart 
□ Hartspierziekte  
□ Aangeboren hartaandoening 
□ Weet ik niet 





INSTRUCTIE: De volgende vragen gaan over uw seksuele gevoelens en 
seksuele reacties gedurende de afgelopen 4 weken. Beantwoord deze vragen 
alstublieft zo eerlijk en duidelijk mogelijk. Uw antwoorden zullen strikt 
vertrouwelijk behandeld worden. 
 
Bij het beantwoorden van de vragen zijn de volgende definities van toepassing: 
Seksuele activiteit: dit kan zijn strelen, voorspel, masturbatie en 
geslachtsgemeenschap.  
Gemeenschap: het binnengaan van de penis in de vagina. 
Seksuele stimulatie: hieronder worden onder meer situaties verstaan als 
voorspel met een partner, zelfbevrediging (masturbatie), of fantaseren over seks. 
 
Seksuele verlangens: hieronder wordt verstaan zin hebben in seks, in willen 




















Als u ‘Nee’ heeft ingevuld bij vraag C, dan kunt u de volgende vragen 
overslaan en doorgaan naar vraag 17 op pagina 5. 
 
 
ER VRAAG SLECHTS ÉÉN GETAL OMCIRCELEN S.V.P 
Omcirkel het antwoord dat het best uw situatie omschrijft. 
  










de helft van 
de tijd) 












10. Hoe vaak had u de 






















11. Hoe vaak voelde u 
zich de afgelopen 4 
weken seksueel 
opgewonden tijdens 






















12. Hoe vaak werd u de 
afgelopen 4 weken 
vochtig tijdens 






















13. Hoe vaak heeft u de 
afgelopen 4 weken een 
orgasme (klaarkomen) 























14. Hoe vaak had u de 
afgelopen 4 weken een 
ongemakkelijk gevoel 




















































15. Hoe tevreden 
was u de 
afgelopen 4 
weken over uw 
seksuele relatie 





















16. Hoe tevreden 
was u met uw 
























17. Als de cardioloog u tijdens een consult zou vragen naar seksuele problemen,  
      wat zou u hier dan van vinden? (meerdere antwoorden mogelijk) 
 
o Ongemakkelijk 
o Het zou me irriteren 
o Beledigend (seks is een privé aangelegenheid) 
o Ik denk niet dat de cardioloog me kan helpen met deze problemen 
o Dat zou me niet uitmaken 
o Het lijkt me logisch dat de arts daar naar vraagt 
o Ik zou blij zijn dat de arts dit ter sprake brengt 
o Ik zou opgelucht zijn dat het ter sprake wordt gebracht 















            zoz 
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18. Waarom bent u niet (meer) seksueel actief? (meerdere antwoorden  
mogelijk) 
 
o Niet van toepassing (ik ben wel seksueel actief) 
 
o Het is niet belangrijk voor me 
o Ik ben te moe 
o Ik ben te somber 
o Vanwege gezondheidsproblemen, namelijk:………………………………… 
o Ik ben bang om een hartinfarct te krijgen  
o Mijn partner is bang dat het slecht is voor mijn hart 
o Mijn conditie is te slecht 
o Vanwege een seksueel probleem (genoemd in vraag 1 t/m 5) 
o Ik voel me te oud voor seksuele activiteiten 
o Mijn partner heeft seksuele problemen 
o Mijn partner heeft gezondheidsproblemen, namelijk:………………………… 
o Mijn partner is in slechte conditie 




19.  Heeft u het idee dat de medicatie die u van uw cardioloog krijgt uw seksuele  
       leven beïnvloed? 
□ Ja, het beïnvloed positief 
□ Ja, het beïnvloed negatief 
□ Nee, het heeft geen invloed 
□ Niet van toepassing 
 
 
20.  Zou u het prettig vinden als u over seksuele problemen kon spreken en  
       vragen hierover zou kunnen stellen tijdens een verpleegkundig spreekuur? 
□ Ja 
□ Nee 
□ Niet van toepassing 
 
 
21. Heeft u behoefte aan een gesprek met de cardioloog over de mogelijkheden  
      om uw seksuele leven te verbeteren? 
□ Ja 
□ Nee 








22.  Zou u schriftelijke informatie willen krijgen over seksuele problemen en de  
       mogelijke oplossingen hiervoor? 
□ Ja 
□ Nee 
□ Niet van toepassing 
 
De volgende vragen zijn niet van toepassing als u GEEN seksuele 
klacht(en) heeft, ga in dat geval alstublieft door naar vraag 28 op pagina 8. 
 
 
23.  Kunt u aangeven op een schaal van 0 tot 10 in hoeverre u last heeft van 
uw seksuele probleem. 
  0 betekent geen last, 10 betekent veel last. 
 
□ …………………….. 
□ Niet van toepassing 
 
 
24.  Kunt u aangeven op een schaal van 0 tot 10, in hoeverre uw seksuele 
probleem uw relatie/huwelijk beïnvloed?  
0 betekent geen invloed, 10 betekent veel invloed 
 
□ …………………….. 
□ Niet van toepassing 
 
 
25.  Zou u behandeld willen worden voor uw seksuele probleem/klacht? 




26.   Als u ‘ja’ heeft geantwoord op vraag 25: 
   Wat zou u willen dat uw cardioloog zou doen met betrekking tot uw     
   seksuele klacht(en)? (Meerdere antwoorden mogelijk) 
 
o Alleen naar me luisteren 
o Advies geven over hoe ik ermee om moet gaan 
o Uitleg geven  
o Verwijzen naar een uroloog/gynaecoloog 
o Verwijzen naar een seksuoloog  
o Verwijzen naar een psycholoog 
o Verwijzen naar een bekkenbodem fysiotherapeut 
o Informatie meegeven zodat ik er zelf over kan lezen 
o Informatie meegeven en me thuis over de behandelopties laten denken 
o Anders…………………………………………………  
                                zoz    
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27.   Als u ‘nee’ heeft geantwoord op vraag 25: 
   Waarom wilt u hier niet met uw cardioloog over spreken? 
 
□ Het is niet belangrijk voor me 
□ Het is te intiem om het over te hebben 
□ Ik voel me te oud om seks te hebben 
□ Ik geloof niet dat de dokter me kan helpen met dit probleem 
□ Ik wil geen tijd van mijn dokter vragen voor zoiets 
□ Het is een privé aangelegenheid 




28. Heeft u ideeën of opmerkingen voor het verbeteren van de seksuele   





































Questionnaire gastroenterologists (translated from Dutch) 
 
This questionnaire concerns patients with abdominal pain, constipation, diarrhea, alternating 
constipation/diarrhea, perianal pain and patients with blood within the stool.  
 
Female sexual function 
 




2. If so, what do you ask for? 
    Dyspareunia 
    Vaginismus 
    Lack of lubrication 
Diminished sexual desire 
Incontinence during sexual intercourse 
  Fecal 
  Urinary 
     Other: …........................................................................................... 
 




4. If so, which gastrointestinal complaints? ...................................................................  
 
5. A reason not to ask:  
I don’t find it meaningful in the gastroenterology practice 
Not enough time 
If a patient has these complaints, I am unsure about therapeutic options 
I find it difficult to address 
I have insufficient knowledge how to ask for female sexual dysfunction 
Other:.................................................................................................. 
 
6. What percentage of female patients that you see do you believe experience sexual 
dysfunction? ……………………..% 
 
Male sexual function 
 




8. If so, what do you ask for?  
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10. If so, which gastrointestinal symptoms? ....................................................................... 
 
11. A reason not to ask:  
I don’t find it meaningful in the gastroenterology practice 
Not enough time 
If a patient has these complaints, I am unsure about therapeutic options 
I find it difficult to address 
I have insufficient knowledge how to ask for female sexual dysfunction 
Other:.................................................................................................. 
 




Female sexual abuse 
 













16. If so, which gastrointestinal complaints? 
Constipation 
Chronic abdominal pain 





17. A reason not to ask is?  
I don’t find it meaningful in the gastroenterology practice 
Not enough time 
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I find it difficult to address 
I don’t know what/how to ask 
Other:.................................................................................................. 
 
18. What percentage of female patients that you see do you believe experienced sexual abuse? 
…………………………..%  
 
19. Do you think it is important to pay more attention to female sexuality relating to abdominal 







Male sexual abuse 
 























24. A reason not to ask is?  
I don’t find it meaningful in the gastroenterology practice 
Not enough time 
I find it difficult to address 




25. What percentage of male patients that you see do you believe have experienced sexual 
abuse? …………………………..%  
 
26. Do you think it is important to pay more attention to male sexuality related to abdominal 








27. What is your age? …………years 
28. What is your gender? M/V 
29.  Are you in training for gastroenterologist?  
  Yes 
No 
 
30. Where do you work?       
Academic (teaching) hospital) 
District general teaching hospital 











Vragenlijst voor patiënten die in het afgelopen jaar een 
colonoscopie hebben ondergaan 
 
Geeft u uw toestemming voor het gebruik van uw antwoorden (anoniem) 






2. Geslacht (omcirkel het juist antwoord): man/vrouw 
 
3. Invuldatum: --/--/---- 
 
4. Land van herkomst: 
□ Nederland 
□ Turkije 
□ Een ander Europees land:………………………… 
□ Marokko 
□ Suriname 
□ De Nederlandse Antillen 
□ Anders:……………………………………………..… 
 
5. Wie heeft u verwezen naar de MDL-arts om het darmonderzoek te laten 
verrichten?  
□ Huisarts 







6. Waarom werd het darmonderzoek verricht? 
 (meerdere antwoorden mogelijk) 
□ Ik had bloed bij/in mijn ontlasting 
□ Mijn ontlastingspatroon was veranderd 
□ Een controle onderzoek vanwege (erfelijke) 
darmkanker 
□ Pijn in de anale regio 








Het is bekend dat een deel van de patiënten met maag- darm klachten ook 
lijdt aan seksuele problemen en/of plasproblemen. Wij willen graag weten 
of de MDL-arts patiënten hiernaar vraagt. Vandaar dat de volgende vragen 
gaan over seksuele problematiek en plasklachten. 
 
7. Heeft of had u last van klachten op het gebied van seksualiteit in de 




8. Als u ‘ja’ heeft geantwoord op vraag 7: 
 Wat voor seksuologische klachten heeft/had u? 
   (Meerdere antwoorden mogelijk) 
□ Afgenomen verlangen naar seks 
□ Afkeer van seks 
□ Moeite om een erectie te verkrijgen of vast te 
houden (man) 
□ Vroegtijdig orgasme (man) 
□ Moeite/onmogelijkheid om een orgasme te krijgen 
□ Moeite met ‘nat’ worden (vrouw) 
□ Fysieke onmogelijkheid gemeenschap te hebben 
(vrouw) 
□ Pijn bij het vrijen (vrouw) 
□ Anders…………………………………………………… 
 
9. Zo ja, heeft u hier professionele hulp voor gehad?      
□ Ja  
□ Nee 
 
10. Heeft u dit verwerkt of opgelost?     
□ Ja   
□ Nee 
 




12. Vindt u dat uw MDL-arts u had moeten vragen naar seksuele klachten?  











13. Als u ‘ja’ heeft geantwoord op vraag 12: 
  Wat zou u willen dat u MDL-arts zou doen met betrekking tot uw     
  seksuele klacht(en)? 
   (Meerdere antwoorden mogelijk) 
 
□ Alleen naar me luisteren 
□ Advies geven over hoe ik ermee om moet gaan 
□ Uitleg geven  
□ Verwijzen naar een uroloog/gynaecoloog 
□ Verwijzen naar een seksuoloog  
□ Verwijzen naar een psycholoog 
□ Verwijzen naar een bekkenbodem fysiotherapeut 
□ Informatie meegeven zodat ik er zelf over kan lezen 
□ Informatie meegeven en me thuis over de 
behandelopties laten denken 
□ Anders………………………………………………… 
 
14. Als u ‘nee’ heeft geantwoord op vraag 12: 
  Waarom wilt u niet dat uw MDL-arts naar seksuele klachten vraagt? 
 
□ Het is niet belangrijk voor me 
□ Het is te intiem om het over te hebben 
□ Ik voel me te oud om seks te hebben 
□ Ik geloof niet dat de dokter me kan helpen met dit 
probleem 
□ Ik wil geen tijd van mijn dokter vragen voor zoiets 
□ Het is een privé aangelegenheid 
□ Er is geen relatie met de klachten 
□ Anders:………………………………………………… 
 
15. Heeft u plasklachten? (zo niet, ga naar vraag 19) 
 
















16. Als u ‘ja’ heeft geantwoord op vraag 15: 
  Wat voor plasklachten heeft u? 
   (Meerdere antwoorden mogelijk) 
 
□ Vaak moeten plassen (vaker dan 8 keer per dag of 
meer dan 2 keer per nacht) 
□ Hevige aandrang voor het plassen 
□ Urine incontinentie 
□ Problemen met het ledigen van de blaas (druppelen, 
persen, erg slappe straal) 
□ Pijn bij het plassen 
□ Bloed in de urine 
□ Anders…………………………………………………… 
 
17. Heeft u hulp gehad voor uw plasklacht(en)?   
□ Ja   
□ Nee 
 
18. Wilt u hulp voor uw plasklacht(en)? 
□ Ja   
□ Nee 
 




20. Vindt u dat uw MDL-arts had moeten vragen naar plasproblemen? 






















We weten dat een deel van de patiënten die bij de MDL-arts komt met 
buikpijn of problemen met de ontlasting, een negatieve seksuele ervaring 
(seksueel misbruik) heeft meegemaakt. Dit beïnvloedt het lichaam en de 
geest en soms zijn andere manieren van behandelen nodig om die klachten 
te verminderen. Daarnaast kan een darmonderzoek erg angstig/naar zijn 
voor patiënten die seksueel misbruik meegemaakt hebben.  
Het is onbekend hoeveel artsen hun patiënten vragen naar seksueel 
misbruik (negatieve seksuele ervaringen), maar het is erg belangrijk om te 
weten hoe artsen met dit onderwerp omgaan, zo kunnen we de zorg 
verbeteren. 
 




21. Bent u het slachtoffer geweest van een vorm van seksueel misbruik? 
  


















Als u vraag 21 met ‘Nee’ heeft beantwoord, vul dan alstublieft alleen vraag 23 
tot en met 27 in. 
 
 
Als u vraag 21 heeft beantwoord met ‘Ja’ kunt u vraag 23 t/m 27 overslaan en de 







Als u geen slachtoffer bent (geweest) van seksueel misbruik: 
 
 
23. Kunt u op een schaal van 0 tot 10 aangeven hoe u het darmonderzoek 
heeft ervaren?  
    0 betekent weinig ongemak en 10 betekent erg veel ongemak 









25. Zou u het vreemd vinden als een vraag over seksueel misbruik zou 
worden gesteld in een vragenlijst, ter voorbereiding op het onderzoek bij 
de MDL-arts? 
□ Ja 
□ Nee  
 
26.  Als u ‘Ja' heeft geantwoord op vraag 25: 
 Waarom vindt u dat dan? 
 
□ Het lijkt me niet belangrijk in dit geval 
□ Het irriteert me 
□ Het is te intiem om te bespreken 
□ Het is vervelend om over na te denken 
□ Er is geen relatie met het onderzoek en mijn klachten 
□ Anders……………………………………………………. 
 
27. Vindt u dat artsen meer training moeten krijgen over het omgaan met 
seksualiteit en misbruik problematiek? 
 
□ Ja 











Als u slachtoffer bent geweest van seksueel misbruik: 
 
 
28.  Heeft u professionele hulp gehad bij de verwerking hiervan?   
□ Ja  
□ Nee 
 
29.  Heeft u een manier gevonden om met deze ervaring(en) om te gaan?  
□ Ja  
□ Nee 
 
30.  Vindt u dat de dokter moet vragen naar seksueel misbruik? 
□ Ja  
□ Nee 
 
31. Als u ‘Nee’ heeft geantwoord op vraag 30: 
    Waarom wilt u niet dat de MDL-arts hiernaar vraagt? 
    (Meerdere antwoorden mogelijk) 
□ Het is te intiem om te bespreken 
□ Het is niet (meer) belangrijk voor me 
□ Ik kan er niet over praten 
□ Ik geloof niet dat mijn dokter me met dit probleem 
kan helpen 
□ Ik heb er hulp voor gehad en nu weet ik hoe ik 
ermee om moet gaan 
□ Ik schaam me ervoor 
□ Ik ben bang om het te vertellen  
□ Anders:……………………………………………… 
 
32. Als u ‘Ja’ heeft geantwoord op vraag 30:  
Wat zou u willen dat uw dokter deed nadat u het had verteld? 
(Meerdere antwoorden mogelijk) 
□ Alleen naar me luisteren 
□ Adviseren over hoe ik hiermee om moet gaan 
□ Als het mogelijk is, afzien van het darmonderzoek 
□ Verwijzen naar een uroloog/gynaecoloog 
□ Verwijzen naar een seksuoloog 
□ Verwijzen naar een psycholoog 
□ Verwijzen naar een bekkenbodemfysiotherapeut 
□ Informatie verstrekken zodat ik kan lezen over de 
behandelmogelijkheden 
□ Informatie geven en me thuis over de 






Als u slachtoffer bent geweest van seksueel misbruik: 
 
33. Kunt u op een schaal van 0 tot 10 aangeven hoe u het darmonderzoek 
heeft ervaren?  




34.  Zou het darmonderzoek minder onaangenaam voor u zijn geweest als  
  de arts van uw negatieve seksuele ervaring(en) in het    
    verleden had geweten? 
□ Ja   
□ Nee 
 
35.   Het darmonderzoek zou gemakkelijker/comfortabeler voor me zijn    
             geweest als: 
□ Mijn partner erbij was geweest om me te steunen 
□ Mijn dokter me extra uitleg had gegeven over wat er 
allemaal gebeurde 
□ Ze me dieper hadden gesedeerd (in slaap gebracht) 
□ Anders:………………………………………………… 
 
36.  Zou u het vreemd vinden als een vraag over seksueel misbruik zou    
 worden gesteld in een intakevragenlijst bij de MDL-arts? 
□ Ja 
□ Nee  
 
37.   Als u ‘Ja’ heeft geantwoord op vraag 37: 
  Waarom vindt u dat dan? 
 
□ Het lijkt me niet belangrijk in dit geval 
□ Het irriteert me 
□ Het is te intiem om te bespreken 
□ Het is vervelend om er over na te denken 
□ Het maakt me van streek 
□ Dan durf ik niet meer naar de arts toe 
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ACE-inhibitor   Angiotensin-Converting-Enzyme inhibitor
ARBs    Angiotensin II Receptor Blockers 
CVD    cardiovascular disease
CZS    centraal zenuwstelsel
ED    erectile dysfunction
FGID    functional gastrointestinal disorders
FSFI    Female Sexual Function Index score
FSD    female sexual dysfunction
GI    gastrointestinal/ gastrointestinaal
GP    general practitioner
IBD    Inflammatory Bowel Disease
LUMC    Leiden University Medical Center
MEC    Medical Ethics Committee
MDL    Maag Darm Lever
fMRI    Functional magnetic resonance imaging
PelFIs    Pelvic Floor Inventories Leiden
PET    Positron emission tomography
PDE5 inhibitor   phosphodiesterase type 5 inhibitor
PTSS    posttraumatische stress stoornis
SA    sexual abuse
SD    sexual dysfunction
±sd    standard deviation
SE    standard error
SF    sexual function
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DANkwoorD
Dit proefschrift had niet tot stand kunnen komen zonder de hulp van de ca. 500 cardiologen, 
200 MDL-artsen en 1400 patiënten die mee hebben gewerkt aan mijn onderzoeken door 
de -vrij expliciete- vragenlijsten in te vullen en retourneren.
Verder wil ik iedereen die mij heeft geholpen met het tot stand brengen van dit proefschrift 
heel hartelijk bedanken, door hen heb ik 2 jaar lang in een zeer prettige omgeving mogen 
werken. 
Dr. Elzevier, heel veel dank voor de deuren die je voor me hebt geopend, voor de 1001 
inspirerende ideeën, voor het geloof in mij en in mijn werk en voor de ontzettend fijne 
werksfeer. De beste baas die een PhD-kandidaat zich maar kan wensen! 
Professor Pelger, dank voor de kans, voor de letterlijke en figuurlijke ruimte die ik heb 
gekregen, voor alle hulp, de goede gesprekken en de ontzettend snelle reacties.
Professor Putter, bedankt voor al uw hulp met de statistieken in dit proefschrift, dankzij u 
ben ik statistiek en SPSS-kunde zowaar leuk gaan vinden
Al mijn (oud)collega’s van het LUMC: Rob Bevers, Willemijn Zonneveld, Bart Nieuwkamer, 
Jenneke Kramer, Madelon van der Aa, Emma Klaver, Erik Planken, Gabri van der Pluijm, 
Petra Voorham, mijn inspirerende voorganger Milou Bekker, mijn collega-onderzoekers 
Cees Hoogewoning, Esmee Krouwel (waardige opvolger), Quirijn Tummers, Mark Boonstra, 
Noor Birkhoff en Flore Grijseels; heel veel dank voor de leuke tijd en de ontzettend goede 
werksfeer op afdeling J-3-P. 
Professor Osanto en Jeanne van Steijn: bedankt voor de prettige samenwerking bij het 
osteoporose project en de ruimte die jullie me hebben gegeven om mijn eigen tijd in te 
delen.
De gehele maatschap Maag-, darm- en leverziekten van het HAGA ziekenhuis: heel 
hartelijk dank voor jullie tijd en hulp en de mogelijkheid mijn vragenlijst te versturen naar 
jullie patiëntenpopulatie.
Caroline de Jong-Mom: ontzettend veel dank voor je ondersteuning, voor het meedenken, 
het nakijken en voor je hulp met het kopiëren, vouwen, adresseren en versturen van 
de meer dan 5000 (!) vragenlijsten die nodig waren om de data voor dit proefschrift te 
vergaren.
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Leonoor Gelder-Cronheim en Hennemieke Könings-Haselhoff, dank voor alle logistieke en 
praktische hulp en het secure nakijkwerk van het definitieve manuscript.
Brenda Breugelsdijk-Terveer, bedankt voor je hulp met de patiëntengegevens.
Geachte leescommissie, ik ben u alleen zeer erkentelijk voor de tijd die u heeft genomen 
het manuscript te beoordelen.
Jan Nicolai, pap, dank voor alle kansen, onder andere door onderzoek te doen binnen jouw 
afdeling, onder jouw collega’s en jullie patiëntenpopulatie. Dank ook voor je nuchterheid, 
het voorhouden van een spiegel en voor je waardige co-auteurschap.
Nelleke Nicolai, jouw loopbaan en boeken hebben me enorm geïnspireerd. Daarnaast wil 
ik je bedankten voor het reviseren van het manuscript en voor al je goede reflecties en 
ideeën.
Mijn paranimfen, Ceciel van den Berg en Barbara Wendrich, ontzettend fijn dat jullie me 
bijstaan en steunen in dit hele proces. Het geeft een enorm goed gevoel jullie achter me 
te hebben staan. 
Sophie Knijnenburg: dank je wel voor de artistieke input, je hebt de betekenis van dit 
proefschrift perfect weten om te zetten in beelden! (en daarnaast ben je de beste 
schoonzus ooit)
De AIOS chirurgie en chirurgen van het Westfriesgasthuis dank ik voor het mooie begin 
van mijn klinische carrière, bedankt dat jullie een goede dokter van mij willen maken. 
Daphne Nicolai, mam, heel veel dank voor je hulp met de organisatie van het feest en de 
onvoorwaardelijke steun die je me altijd hebt gegeven.
Jelmer en Amarantha Nicolai: dank jullie voor het zijn van de beste broer en zus die een 
mens zich kan wensen.
Leonore Nicolai, bedankt voor het goede voorbeeld.
Willem en Sandra Knijnenburg: bedankt voor jullie interesse, steun en geduld.
De rest van mijn lieve familieleden en vrienden, ontzettend bedankt voor jullie steun 
en nimmer aflatende interesse. Ik prijs mijzelf zeer gelukkig met zo’n groep fantastische 
mensen om mij heen.
Daniël Knijnenburg, dank je wel dat je altijd voor me klaar staat. Dank voor je hulp met de 
brieven, de lay-out, het meedenken en vooral voor de mentale support. Je bent geweldig!
